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SOMMAIRE 
Le présent mémoire s’intéresse à la conception, la synthèse et l'évaluation pharmacologique d'inhibiteurs 
peptidomimétiques de PACE4, une pro-protéine convertase. Ces composés sont étudiés comme 
traitement potentiel du cancer de la prostate. Le cancer de la prostate (PCa) et les traitements actuels pour 
le PCa sont donc passés en revue. L'introduction se poursuit par une brève évaluation des thérapies ciblées 
vers le PCa qui démontre que les pro-protéines convertases sont des enzymes importantes de la voie de 
transmission. Les inhibiteurs actuels des pro-protéines convertases ont finalement été examinés. Des 
études de relation structure-activité (SAR) ont été réalisées sur un octapeptide (appelé Multi-Leu; 
séquence: Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-NH2) qui s’est révélé être un prototype d’inhibition 
de l’enzyme PACE4. Ce composé a ensuite évolué par le remplacement du résidu Arg en position C-
terminale par un résidu Amba (4-amidinobénzylamide) d’une part et par l’introduction d’une DLeu au 
lieu d’une l-Leu en position P8 d’autre part. Le nouvel inhibiteur appelé C23 (séquence: Ac-DLeu-Leu-
Leu-Leu-Arg-Val-Lys-Amba) présentait une activité améliorée vis-à-vis de l’enzyme PACE4 et de bons 
résultats in vitro dans des essais cellulaires antiprolifératifs. Le but du travail présenté dans ce document 
est l’amélioration de l’affinité enzymatique pour l’enzyme PACE4, l’accroissement de la sélectivité par 
rapport à d'autres membres de la famille, en particulier la furine, et l’augmentation de l'activité cellulaire 
des composés prototypes en modifiant les résidus aux positions P3, P1 et P1'. 
Le premier chapitre concerne les études SAR sur les résidus de P3. L'amélioration de la sélectivité et de 
la puissance de l'inhibiteur est l'objectif de ce chapitre. L’acide aminé Val en position P3 du peptide 
Multi-Leu a été remplacé par des résidus basiques pour créer des interactions supplémentaires avec un 
résidu Asp dans la poche S3. Un résidu basique β-ramifié dans cette position améliore la sélectivité pour 
PACE4 jusqu'à 40 fois (Ki = 2.7 nM). 
Le deuxième chapitre traite des modifications de la position P1 du peptide prototype C23. Malgré que 
l’inhibiteur C23 ait une affinité, une stabilité et une activité cellulaire supérieures pour l’enzyme PACE4 
par rapport à son précurseur Multi-Leu, il n’est que deux fois plus sélectif pour la convertase PACE4. La 
plus grande partie de cette perte de sélectivité est due aux interactions plus favorables du résidu Amba en 
position P1 de la furine. Par conséquent, d'autres mimétiques de l’acide aminé Arg ont été testés dans 
cette position pour retrouver la sélectivité perdue. 
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Dans le troisième chapitre, l’acide aminé en position P1' a été exploré pour discriminer les enzymes 
PACE4 et furine. L’addition de résidus naturels dans cette position, cependant, n’a amélioré ni la 
sélectivité ni l’affinité. Par ailleurs, l'évaluation cellulaire a montré que les résidus hydrophobes et 
basiques amélioraient l'activité cellulaire. En utilisant des acides aminés non naturels aux positions P1 et 
P1', l'activité antiproliférative cellulaire des inhibiteurs résultants est sensiblement améliorée. Il a été 
prouvé que cette meilleure activité cellulaire était due à la pénétration accrue des inhibiteurs résultant 
d’une hydrophobicité élevée dans la région de l'extrémité C-terminale. 
En conclusion, l'affinité et la sélectivité envers la pro-protéine convertase PACE4 des inhibiteurs ont été 
améliorées par des modifications aux positions P3 et P1. Les résidus hydrophobes en position P1' 
augmentent la perméabilité cellulaire et donc l'activité antiproliférative des cellules PCa. Dans cette 
perspective, la combinaison de ces modifications pourrait conduire à une amélioration du profil 
pharmacodynamique des composés. 
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ABSTRACT 
This thesis deals with the design, synthesis and pharmacological evaluation of peptidomimetic inhibitors 
of PACE4, a pro-protein convertase. These compounds are studied as a potential treatment for prostate 
cancer. Prostate cancer (PCa) and current treatments for PCa are therefore reviewed. The introduction 
continues with a brief evaluation of targeted therapies for PCa that demonstrates that pro-protein 
convertases are important enzymes in the secretory pathway. Current inhibitors of pro-protein convertases 
are reviewed at the final part of introduction.  
Structure-activity relationship (SAR) studies were performed on an octapeptide (called Multi-Leu; 
sequence: Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-NH2) which was found to be a prototype of inhibition 
of the enzyme PACE4. This compound then evolved by replacing the Arg residue in the C-terminal 
position with an Amba (4-amidinobenzylamide) residue on the one hand and by introducing a DLeu 
instead of a l-Leu in position P8 on the other hand. The new inhibitor called C23 (sequence: Ac-DLeu-
Leu-Leu-Leu-Arg-Val-Lys-Amba) exhibited improved activity with respect to the PACE4 enzyme and 
good in vitro results in antiproliferative cell assays. The purpose of the work presented in this document 
is to improve the enzymatic affinity for the enzyme PACE4, increase selectivity over other members of 
the family, particularly furin, and increase the cellular activity of the prototype compounds by modifying 
the residues at positions P3, P1 and P1'. 
The first chapter concerns SAR studies on P3 residues. Improving the selectivity and potency of the 
inhibitor is the goal of this chapter. The amino acid Val at the P3 position of the Multi-Leu peptide has 
been replaced by basic residues to create additional interactions with an Asp residue in the S3 pocket. A 
basic β-branched residue in this position improves the selectivity for PACE4 up to 40-fold (Ki = 2.7 nM). 
The second chapter deals with the modifications of the position P1 of the prototype peptide C23. Although 
the C23 inhibitor has higher affinity, stability, and cell activity for the PACE4 enzyme than its Multi-Leu 
precursor, it is only twice as selective for the PACE4 convertase. Most of this loss of selectivity is due to 
the more favorable interactions of the Amba residue at the P1 position of furin. Therefore, other Arg 
amino acid mimetics have been tested in this position to recover the lost selectivity. 
In the third chapter, the amino acid at position P1' was explored to discriminate between PACE4 and 
furin enzymes. The addition of natural residues in this position, however, improved neither selectivity 
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nor affinity. In addition, cell evaluation showed that hydrophobic and basic residues improved cellular 
activity. By using unnatural amino acids at the P1 and P1' positions, the cell antiproliferative activity of 
the resulting inhibitors is substantially improved. This improved cell activity has been shown to be due 
to increased penetration of inhibitors resulting from high hydrophobicity in the C-terminal region. 
In conclusion, the PACE4 affinity and selectivity of inhibitors were improved by modifications in P3 and 
P1 positions. Hydrophobic residues in P1' position enhanced the cell permeability and thus the PCa cell 
antiproliferative activity. In this perspective, combining such modifications could lead to compounds with 
improved pharmacodynamic profiles. 
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INTRODUCTION 
The roots of word “cancer” come from a Greek “karkinos”, as described by the Greek physician, 
Hippocrates (460–370 B.C). However, the earliest recorded evidence of human cancer was found in 
mummies in ancient Egypt about 1600 B.C.1 The ancient Egyptians were treating surface tumors by 
surgically removing them with similar methods that are still under practice. According to Statistic Canada, 
cancer is the first cause of death in Canada followed by cardiovascular diseases.  
In medicine, cancer is the accepted name for a group of diseases associated with abnormal growth of 
eukaryotic cells. Although many types of cancer cause the growth of solid tumors, some others such as 
blood carcinomas are not intrinsically solid tumors. Cancer could initiate in any organ and then spread to 
others by translocation of cancerous cells through the blood or lymph system. Unlike benign tumors, 
malignant cancerous tumors are associated with high risk of fatality usually after cells migrate to foreign 
tissues. Cancer cells have similarities with stem cells (non-differentiated cells) and they can begin a new 
tumor wherever they migrate, which is termed as metastasis. For instance, a breast cancer cell could 
migrate to the liver and grow a new tumor, but will still be called breast cancer.2  
In general, cancerous cells develop from normal cells with a damaged DNA. Two main groups of genes 
which are crucial in cancer development are oncogenes and tumor suppressor genes. Oncogenes are 
formed by the mutation of genes of normal cells called protooncogenes. Protooncogenes control cell 
division and growth, hence their malfunction inevitably leads to a non-controlled cell division and 
growth.2  
Eukaryotic cells have several mechanisms to repair DNA mismatches after division. Abnormal cells 
undergo a programmed cell death called apoptosis.3 Apoptosis is initiated by certain intra- and 
extracellular biochemical signals. A cascade of events and reactions then results in distinctive 
morphological changes in the cell which are terminated by cell death. On the other hand, tumor suppressor 
genes control the cell division, DNA repair and regulation of apoptosis. An impairment in tumor 
suppressor genes function can produce a cancerous cell. Many factors such as chemicals including foods, 
radiation, air pollution or even certain viruses are associated with mutations or damages of tumor 
suppressor genes or oncogenes.2  
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Historically, the first practical treatment for cancer has been the surgical removal of tumor, but even 
ancient physicians had noticed the post-surgery recurrence of tumors. With the development of surgical 
techniques, radiotherapy emerged as a complementary therapy for cancer treatment in the early 20th 
century.4 Subsequently, nitrogen mustards were discovered accidentally to serve as the first cancer 
chemotherapeutic agents. Nitrogen mustards were used as warfare during World War II.5 Since then, a 
large number of chemotherapeutic agents has been developed. Parallel to these achievements, hormone 
therapy was also established for treating gender related organs tumors such as breast, ovarian and prostate 
cancer. 
I.1. Prostate cancer 
I.1.1. Prostate anatomy 
The prostate is a walnut-sized gland, the main function of which is to secrete prostate fluid, a semen 
component (one-third of the total volume of semen). This fluid provides nutrients for sperms and 
facilitates their movement. During ejaculation, the muscles of the prostate gland squeeze this fluid into 
the urethra. The prostate gland weighs about 20 grams and is placed just beneath the bladder.  
 
Figure 1. Male urogenital anatomy with permission from Canadian Cancer Society.6 
Semen is a viscous gel at the time of ejaculation and eventually liquefies 20-30 min after ejaculation, 
enabling the sperms to swim.7 A group of structural proteins, including semenogelin I and II that are 
components of semen coagulum, disappear after liquefaction. Prostate specific antigen (PSA), a protease 
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present in the prostatic fluid, is considered to be responsible for this transformation.8 The prostatic fluid 
contains high levels of citrate anions which are electrochemically balanced by high concentrations of 
cations such as Zn2+, Ca2+, Mg2+, K+ and Na+.9 Zinc inhibits PSA proteolytic activity with tight binding 
kinetics; it is itself regulated by citrate levels in the healthy prostate.10  
I.1.2. Statistics 
Prostate cancer (PCa) is the most common cancer in men responsible for about 1 in 4 cases of male 
cancers. 11 About 15 % of Canadian men will be diagnosed with PCa during their lifetime. PCa was 
attributed as the cause of death of 4100 Canadian men in 2017 and another 21300 men were diagnosed 
with PCa tumors. Responsible for 21% of all diagnosed cancer cases in Canadian men and 10% mortality 
rate in 2017, PCa has emerged as a serious healthcare issue which necessitates development of new 
treatments and therapeutics (Figure 2). 10  
 
Figure 2. Diagnosed prostate cancer and related death cases in Canada 2017.10  
I.1.3. Prostate cancer at cellular level 
The prostate gland is comprised of a variety of cell populations: an organised epithelial lineage, a fibro-
muscular stromal network, an endothelial vasculature and immune cells.12 About 95% of all prostate 
cancer cases are adenocarcinoma which is a type of neoplasia of the epithelial tissue of glandular organs.13 
The remaining types of prostate tumors are urothelial carcinoma (also called transitional cell carcinoma), 
sarcoma, small cell carcinoma, carcinoid tumours, and squamous cell carcinoma.  
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Several in-vitro cellular models have been developed for PCa cellular investigations. The gold standard 
model contains three cell lines: DU145, LNCaP and PC3.14 All of these cell lines are derived from 
metastatic prostate cancers. The DU145 and PC3 cells are hormone independent while LNCaP cells are 
androgen responsive and express androgen receptors and PSA.14 
I.1.4. Risk factors 
The principal risk factors for prostate cancer as well as many types of cancer is age. The number of 
reported cases under the age of 40 is low and increases thereafter.15 However, the mortality rate for non-
metastasized prostate cancer decreases in senior men, due to greater risk of other competing causes of 
death.16 Genetics is the second major factor. Certain gene mutations are observed in 5-10% of people 
who have PCa. For instance, BRCA1/2 mutations have been reported as risk factor in 2% PCa cases.17 
Men with a first-degree relative diagnosed with PCa are two to three times more likely to develop the 
disease. This factor increases if patient’s relatives have diagnosed with PCa before the age of 60. Race is 
being identified as another prognostic factor for PCa survival. African Americans are at higher risk of 
diagnosis with PCa while indigenous Australians display lower rates compared to Caucasian people.18 
The lifestyle also affects the PCa incidence. Cigarette smoking might increase the risk by changing the 
hormone levels or through increased exposure to carcinogens.19 A vegan diet was associated with a lower 
risk of prostate cancer, while diets rich in animal fats were favorable for PCa, probably because of the 
usually high-bound obesity.20 
I.1.5. Symptoms and diagnosis 
Most prostate tumors are diagnosed without symptoms. However, there are some unspecific symptoms 
patients experience including: difficulty in urination, observation of blood in urine and pain in the genital 
areas. The current PCa diagnosis employs screening tests for the PSA levels. Although false positive 
results raise some concerns, the PSA test remains the front-line examination of the PCa. This test is a 
non-invasive and affordable examination which has been used routinely for several years.21 In addition, 
digital rectal examination (DRE) is used as a diagnostic tool complementary to the PSA test for 
evaluation of PCa. The DRE test evaluates the size of the prostate by examining it through the rectum 
using a gloved finger. Ultimately, these tests are not sufficient, and a prostate biopsy is often necessary 
for a confirmatory PCa diagnosis. After biopsy, the prostate tissue samples are evaluated under the 
microscope, and the aggressiveness of the tumor is recorded using the Gleason scoring system.22 The 
Gleason score indicates the malignancy of the prostate tumor by a score which represents clinical stage, 
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progression to metastatic disease, and survival chance.23 A grade 1 PCa (Gleason score (GS) 6 or lower) 
is considered as low risk prostate tumor. The cells are well differentiated (not like stem cells) and rather 
look like normal prostate cells. Tumors with GS 7 (grade 2 or 3) are moderately differentiated which 
indicates an intermediate risk. Highest risk PCa tumors are allocated to grade 4 or 5 with GS 8-10 which 
are usually metastasized, and the cells are poorly differentiated. A gradual increase in the PSA levels with 
the grade of PCa is often observed. 
Globally, randomized screening of a large population with the PSA test is used as a common practice. 
The aim of such screening is to increase the survival rate of patients by early diagnosis of the prostate 
tumor. Early diagnosis enables disease treatment before it advances to the unstoppable metastatic stages. 
However, recent findings brought some doubt about the efficacy of the PSA test on reducing the mortality 
of PCa patients.24-25 High levels of PSA could be due to other non-malignant prostate diseases which will 
result in overdiagnosis and unnecessary biopsy and further inconvenience for false-positive cases. As 
represented in Figure 3, the peaks in 1992 and 2001 are due to large national screenings which were 
associated with over-diagnosis of PCa. 
Figure 3. Age-standardized incidence rates (ASIR) for selected cancers, males, Canada, 1988–2017.10 
I.1.6. Other common prostatic conditions 
Prostatitis is a common prostatic condition which is sometimes caused by bacteria and is associated with 
inflammation and swelling of the prostate gland. Mostly, it comes with painful and difficult urination. 
Three main versions of this disease are acute bacterial prostatitis, chronic bacterial prostatitis and chronic 
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non-bacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS) amongst which the former is the most 
common.  
Benign prostatic hyperplasia or prostate enlargement is caused by an overgrowth of cells which put 
pressure on the urethra and discomforts urination. The condition is considered as benign and doesn’t 
increase the prostate cancer risk. According to Canadian Cancer Society, it is not a health issue until it 
reflects other potential symptoms. 
I.2. Current prostate cancer treatments 
 Choosing a treatment for prostate carcinoma is highly dependent on the risk level of PCa, patient age, 
preferences and overall health. The tumor can grow at different rates based on the malignancy and stage 
of cancer. For less invasive tumors, doctors may prescribe active surveillance, which means patients 
would be closely monitored periodically using diagnostic tools. For more malignant cases, the treatments 
could be initiated with more radical treatments, i.e. surgical removal of the prostate gland (prostatectomy) 
and radiation therapy. Surgery can be followed by hormone therapy then chemotherapy as second and 
third lines of treatment.  
Figure 4. Androgen deprivation therapy with permissions from American Association for Cancer 
Research.26 
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I.2.1. Hormone therapy 
Hormones are among the first approved medications for prostate and breast cancers (see section I.2.3). 
Androgen hormones such as testosterone and its active metabolite, dihydrotestosterone (DHT), are 
responsible for the male characteristics viz. muscle growth, facial hair and sexual behaviour including 
prostate cell function and growth.27 DHT has 10-fold higher affinity for the androgen receptor compared 
to testosterone, making it the main androgen hormone in the prostate gland.27 In the early stages of PCa, 
the cell proliferation and regulation (apoptosis) are usually androgen dependent. Thus, androgen 
deprivation therapy (ADT) is used as a tool for combating prostate tumors for early diagnosed patients. 
Small molecules are utilized to lower the levels of testosterone in the whole body as well as tumorous 
cells to reduce tumor growth and proliferation. ADT is effective in extending the life of patients and 
slowing down the progress of tumor but cannot cure PCa. Tumors normally adapt to androgen deprivation 
and this leads to the gradual ineffectiveness of the hormone therapy.26 Several approaches in different 
levels of androgen homeostasis have been used to achieve ADT including orchidectomy (surgical remove 
of testicles) and medications such as luteinizing hormone-releasing hormone (LHRH) agonists, anti-
androgens, estrogens and more recently gonadotrophin-releasing hormone antagonists (Figure 4).28 
LHRH Agonists. Luteinizing hormone-releasing hormone (LHRH, 1) or Gonadotropin-releasing hormone 
(GnRH) is a hormone released by the hypothalamus which trigers the secretion of follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. After initial doses of LHRH 
agonists, the testosterone levels rise slightly in a condition known as flare.29 Continuing the LHRH 
agonist treatment,  the outcome is the reduction in the number (downregulation) of LHRH receptors. This 
results in reduction of circulating FSH and LH levels, along with downregulation of LHRH receptors, 
which cause a sharp decrease in gonadal testosterone production termed as chemical castration.30 The 
structures of LHRH agonists in clinic are presented in Figure 5; leuprolide 2, goserelin 3, triptorelin 4 
and histrelin 5.31 These compounds were developed by structure activity relationship (SAR) studies of 
the gonadorelin hormone. Chemical castration is associated with the shrinkage of testicles. Most patients 
prefer medications over orchiectomy due to emotional and psychological effects of removing testicles.32 
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Figure 5. Representative chemical structures of gonadorelin and LHRH agonists that are used in 
prostate cancer treatment. 
Androgen receptor antagonists. The anti-androgen drugs block the androgen receptor (AR) to prevent 
endogenous androgens such as testosterone and dihydrotestosterone from exhibiting their biological 
effects. The AR antagonists are mainly used as co-therapy with LHRH agonists to reduce the flare effect 
(Figure 6). Steroidal anti-androgens like cyproterone acetate (10) are structurally related to testosterone 
and DHT. Cyproterone acetate is an antagonist for AR and suppresses the gonadal androgen production.33 
The main class of AR antagonists are nonsteroidal and have a substituted anilide as core of the structure. 
The earlier nonsteroidal AR antagonists such as flutamide (6) and nilutamide (7) have been replaced with 
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newer agents like bicalutamide (8) and enzalutamide (9) in clinic. The hepatotoxicity of compounds 6 
and 10, and the interstitial pneumonitis associated with nilutamide (7) were the main side effects that led 
to their replacements.34-35 
Figure 6. Representative chemical structure of anti-androgen agents. 
Androgen biosynthesis inhibitors. Patients with a castration-resistant prostate cancer (CRPC) are still able 
to produce androgens in the adrenal gland and within the tumor. They do not respond to first line LHRH 
agonists and AR antagonists. The recently approved abiraterone acetate (11) is a CYP17 cytochrome 
P450 inhibitor interfering with the biosynthesis pathway of testosterone and DHT from cholesterol.36 
Abiraterone acetate (11) is also useful in the treatment of metastatic high-risk castration-sensitive prostate 
cancer.37 
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Figure 7. Representative chemical structure of GnRH antagonists. 
GnRH antagonists. GnRH antagonists mediate their biological effects by binding to the GnRH receptors 
in the pituitary gland avoiding natural gonadorelin to activate the receptor. Unlike LHRH agonists, the 
antagonism action results in immediate suppression of LH release and consequently reduces the androgen 
release from testicles.38 Due to their immediate onset of action, GnRH antagonists are valuable 
therapeutics for PCa patients who need a quick androgen control. Acyline (12), one of the first discovered 
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GnRH antagonists, readily forms gels in aqueous solutions preventing its formulation as a drug (Figure 
7).39 The other member of this class, abarelix (13), has been discontinued due to severe histamine release 
and allergic side effects.40-41 Further inclusion of urea and carbamoyl functionalities led to the discovery 
of degarelix (14) which is currently available as the only GnRH antagonist on the market.42 Degarelix 
(14) has a long duration of action compared to former agents like acyline (12) and abarelix (13). 
I.2.2. Chemotherapy 
Chemotherapy is the practice of using chemicals to treat any disease; however, in cancer terminology, it 
is used for administration of certain cytotoxic chemicals that block the growth and division of malignant 
cells. Different classes of chemotherapeutic agents have been introduced to treat cancer but only the ones 
which are administered particularly for prostate cancer are discussed herein. 
Taxanes. Taxanes are a class of natural products originally obtained from pacific Taxus (yews) and 
discovered during a U.S. National Cancer Institute-funded screening program.43 Paclitaxel (15) and its 
semisynthetic derivatives docetaxel (16) and carbazitaxel (17), are the most common taxanes used in PCa 
chemotherapy, all sharing a taxadiene core (Figure 8). Taxanes interfere with the normal function of 
microtubules during the process of cell division; thus, they are considered as mitotic inhibitors. Several 
groups have reported total syntheses of members of the taxane family,44 but all the commercial routes 
employ semi-synthesis from yew extracts.45 
Nitrogen mustards. The first developed chemotherapeutic agents for cancer were the nitrogen mustards 
which share a bis-2-chloroethyl amine moiety and are still in clinical use. Their main function is to 
alkylate DNA twice, through intramolecular aziridinium ion intermediates and to connect covalently 
DNA strands together (inter-strand cross-link). The DNA double-strand needs to be opened up during 
cell division and as a consequence of nitrogen mustard reaction, the cell division is hampered.46 The 
common nitrogen mustard in PCa treatment is estramustine phosphate (18) which has a dual hormonal 
(estrogen) and alkylating neoplastic (nitrogen mustard) action. Phosphate 18 is a prodrug and its active 
metabolites are normustine (a.k.a. bis(2-chloroethyl)carbamic acid) and estradiol. 
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Figure 8. Representative chemical structure of taxanes and estramustine phosphate. 
Anthracyclines. Another important class of chemotherapeutics is the anthracycline antibiotics which 
share an anthraquinone skeleton. They were first isolated from Streptomyces bacterium extracts as and 
examined as antibiotics; however their potent cytotoxicity led to their employment as anti-neoplastic 
agents.47 The main function of anthracyclines is to intercalate between DNA bases and hamper cell 
division. Moreover, they are good inhibitors of topoisomerase II, a vital enzyme in DNA transcription 
and replication processes.48 Anthracyclines are involved in iron-mediated generation of free oxygen 
radicals (quinone radicals) which cause DNA alkylation and damage.49 Doxorubicin (21) and its safer 
diastereomer epirubicin (22) are widely used in PCa as well as other malignant situations (Figure 9). 
Another intercalating agent is mitoxantrone (19) which is also an anthraquinone and has a similar 
mechanism of action as the anthracyclines. 
Most of the chemotherapeutic agents including taxanes and anthracyclines are administered jointly with 
prednisone, a corticosteroid anti-inflammatory medication, to reduce the pain and increase the quality of 
life of patients.50 The other beneficial effects of prednisone in PCa are the reduction of androgen levels 
and tumor growth by downregulation of adrenal androgens, transcription factors, and cytokines.51  
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Figure 9. Representative chemical structures of anthracycline antibiotics and prednisone as a 
corticosteroid. 
I.2.3. Targeted therapy 
Cancer is a complex disease due in part to the various factors regulating human cells such as signalling, 
protein translocation, growth, division, protein synthesis, DNA replication and epigenetics. The 
undifferentiation of cancerous cells increases the possibility that each cell within the tumor has a different 
mutation compared to the adjacent cells. Tumors may thus adapt during treatment reducing the efficiency 
of medications. Cancer may vary from patient to patient and during the progression of the tumor. This 
huge level of complexity makes cancer one of the most challenging problems which humans have ever 
faced. Despite many efforts and investments, there is still no universal cure for cancer. Blocking only one 
pathway or target is usually not sufficient for curing tumors especially for more malignant ones, such that 
multiple targeted therapy has become a mainstay for treating cancer. 
In the last two decades, owing to the completion of human genome map, targeted therapy received more 
attention from cancer scientists. Targeted cancer therapy utilizes small molecules or antibodies to block 
specific proteins or genes, molecular targets, that are responsible for tumor growth, progression, and 
cancer metastasis. The advantage of targeted therapy over current chemotherapy is due to their specificity 
for cancerous cells in contrast to chemotherapeutics that kill almost every rapidly-growing cell. 
Chemotherapeutics are cytotoxic agents. Targeted medicines are usually cytostatic and slow down or stop 
cell growth and proliferation rather than killing the cancerous cells. Targeted therapy along with 
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immunotherapy (modifying immune system for combating cancer) are considered as the future of cancer 
treatment.  
Table 1.New targeted medications in clinical trials. Updated from ref. 52 
Pathways Drug targets Drugs 
Drug 
development 
stage 
AR PATHWAY 
 AR 
Enzalutamide 
Apalutamide 
 Darolutamide 
Approved 
Approved 
Phase III 
 AR cofactors 
  
Androgen synthesis 
enzymes: CYP17 
 Abiraterone Approved 
ETS transcription 
factors 
 Transmembrane protease 
serine 2 
 PARP inhibitors:  Veliparib, Talazoparib Phase II 
Growth factor 
receptors 
 EGFR Afatinib, Lapatinib, Phase II 
 MET 
 Cabozantinib, Tivantinib, 
 Onartuzumab Phase II, III 
 IGFR Cixutumumab/IMC-A12, PLX3397 Phase II 
 FGFR   Dovitinib/TKI258 Phase II 
 VEGFR  Dovitinib/TKI258, Axitinib (AG013736), 
 PLX3397 Phase II 
PI3K 
 PIK3 
BKM120, GDC0980, GSK2636771, 
 BEZ235 
Phase I. II 
 AKT1  MK2206, GDC0068 Phase II 
 mTOR Temsirolimus, Everolimus, DS-3078a Phase II 
Other kinases  SRC Dasatinib/Sprycel/ BMS-354825 Phase II 
Cell Cycle 
 CDKs  Dinaciclib Phase I 
 Aurora A kinase  MLN8237 (Alisertib) Phase II 
Protein Chaperons 
 HSP90  AT13387, STA-9090 Phase I, II 
 HSP27  OGX-427 Phase II 
Clusterin/TRPM2  OGX-011/custirsen Phase III 
Histone acetylation 
(transcriptional 
repression) 
HDAC (EZH2, CHD5, 
MLL2) 
Pracinostat SB939 
Panobinostat 
 Vorinostat 
Phase III 
DNA damage repair  PARP  PARP inhibitor Veliparib Phase II 
Angiogenesis 
 VEGFR Dovitinib/TKI258, Axitinib (AG013736 Phase II 
 Angiopoietin 1, 2  AMG 386/Trebananib 
Phase II 
Developmental 
pathways: NOTCH. 
SHH, WNT 
 gamma secretase  RO4929097 
 PTCH/SMOO Vismodegib/GDC-0449, LDE-225, 
itraconazole 
Phase II  Wnt-5a, Fzd8  OMP-54F28, Foxy-5 
The available medications for PCa on the market are limited to hormonal therapy and chemotherapy for 
depriving the androgen levels and increasing the patient survival rates. Currently, many compounds are 
under development to target pathways other than the AR pathway (Table 1). DNA damage repair is 
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impaired in 90% of PCa cases, thus, inhibition of poly(ADP-ribose) polymerase 1 (PARP1) displayed 
benefits in the treatment of patients.53 PARP inhibition is also beneficial for tumors with a mutant ETS 
gene (a protooncogene transcription factor).54 The growth factor receptors are other important targets for 
prostate cancer which activate the tumor proliferation and differentiation by initiating the growth signal 
cascades. PI3K pathway kinases and other kinases which are involved in cell proliferation and apoptosis 
signaling as well as cell cycle homeostasis, are also targeted to treat PCa.55-57 Targeting histone 
deacetylase, as DNA accessibility regulators for replication is under investigation in phase III clinical 
trials.58 Proteins need to have their unique tertiary and quaternary structures for performing their 
functions. Targeting protein chaperones which assist in folding to the correct 3D structure has been 
pursued to decelerate the protein synthesis machinery of tumors.59-60 Tumor growth requires more 
nutriments and consequently more blood vessels, leading to up-regulation of genes responsible for 
angiogenesis. Suppression of angiogenesis by inhibition of vascular endothelial growth factor receptor 
(VEGFR), and angiopoietin 1 and 2 has been found useful in patients with bone metastatic PCa.61-62 
Developmental pathways cooperating with the AR pathway are heavily involved in PCa, and mutations 
in these pathways may lead to malignancy and castration resistance PCa.63 
Among candidate therapies in clinical trials, the monoclonal antibody bevacizumab (an anti-VEGF), 
aflibercept (an anti-VEGFR), dasatinib (an inhibitor of Src), custirsen (antisense against clusterin) and 
tasquinimod (an anti-angiogenesis factor)64 are under investigation in different phases (Table 1).52 
A revolutionary step towards greater involvement of targeted therapy (called precision oncology or 
personalized cancer treatment)65 is to study the molecular alterations that occur in neoplasms. Such 
alterations include mutations responsible for tumor proliferation and are specific to the individuals. This 
study may ultimately lead to targeted treatment to combat these deleterious mutations. 
I.3. Proprotein convertases 
I.3.1. Secretory pathway 
The secretory pathway consists of the endoplasmic reticulum (ER), the Golgi apparatus organelles and 
the secretory vesicles. Considerable differences exist between the chemical environment inside (lumen) 
and outside (cytosol) of the secretory pathway. While the cytosol is reductive, the ER, Golgi apparatus 
and extracellular environment are oxidative. Therefore, certain oxidation reactions such as disulfide bond 
formation are favorable in the secretory pathway, and different types of protein are found in the lumen 
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and the cytosol. During the synthesis of proteins in a ribosome (translation), if the protein possesses a 
special 16–30 residue sequence called the signal peptide in its N-terminal region, it can be recognized by 
the signal recognition particle (SRP) on the surface of the ER. The ribosome is then connected to the ER 
and the protein is translocated into the ER through its N-terminal part. Once the protein synthesis is 
terminated, a signal peptidase enzyme removes the signal peptide and releases the protein inside the 
lumen. The translocated proteins in the secretory pathway could live all their life inside the secretory 
pathway or be moved to other places of the cell such as the membrane, or sometimes be secreted to the 
extracellular matrix. Some post translational modifications (PTM) are typically necessary for further 
translocation, activation, localization, turnover, or interactions with other proteins which are normally 
mediated by enzymes.66 These covalent modifications include protein cleavage, carboxy terminal 
amidation, disulfide bond formation, addition of fatty acids, lipids, glycosides, ubiquitin or cofactors as 
well as the addition of phosphate, sulfate, methyl, hydroxyl or acyl groups to one or several amino acid 
residues or proteins. Addition of hydrophobic groups such as palmitoyl and farnesyl are crucial for 
membrane localization. Phosphorylation is particularly important in cell signal transduction because 
certain signaling kinases could be switched on or off with single phosphorylation or dephosphorylation. 
I.3.2. The discovery of proprotein convertases 
A significant group of proteins are synthesized as protein precursors (proproteins) and further activation 
is necessary for their biological functioning. Availability of inactive proproteins in large amounts allows 
the fast release of the active protein at short notice, which is especially important for hormones, clotting 
proteins, toxins (in poisonous animals), digesting enzymes (trypsin and chymotrypsin), caspases, 
collagen, and the like. The processing of proteins by amide bond lysis is one of the most imperative 
PTMs, which is normally mediated by proteases at a specific peptide bond. The subtilisin/kexin enzymes 
are one of the primary families of proteases in the activation of proproteins. 
The discovery of proinsulin and proopiomelanocortin led to the development of what was later mentioned 
as the prohormone theory by the Steiner and Chretien groups.67-68 It was followed by the identification of 
the yeast kexin, a protease related to bacterial subtilisin that proteolytically cleaves its substrates at the 
C-terminal of paired basic residues.69 Further studies pertaining to the proteolytic activity of yeast kexin 
revealed its ability to process mammalian proopiomelanocortin, the precursor of ACTH and β-
endorphin.70 These early findings led to the discovery of furin as the first human subtilisin/kexin related 
protease, which is the most ubiquitous proprotein convertase (PC) in human tissues.71 The second enzyme 
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was called PC1 (later named PC1/3) and was found simultaneously by different groups.72-73 Other similar 
family members were discovered at the beginning of the 90s and now are known as PC2, PC4, PACE4, 
PC5/6 and PC7. They cleave their substrates at paired or single basic residues with a consensus sequence 
(R/K)-[X]0,2,4,6-(R/K)-↓-P1'-P2', where ↓ represents the cleavage site. For most PCs, Arg is preferred 
over Lys as the basic residue. Their catalytic activity is highly Ca2+-dependent, as later confirmed by the 
disclosure of the furin crystal structure in 2003.74  
The subtilisin/kexin isozyme-1 (SKI-1, also called site-1 protease) and proprotein convertase 
subtilisin/kexin type 9 (PCSK9) being the last two PC enzymes to be discovered are slightly different 
compared to the other seven members because they cleave their substrates at non-basic residues. Unlike 
other members of the family, calcium is not essential to the proteolytic activity of SKI-1 and PCSK9.75 
SKI-1 and PCSK9 are only homologous in their catalytic domain in comparison with other PCs.76-77 The 
self-activation by proteolysis is the only reaction that the PCSK9 catalyzes. After removal of its 
prodomain, PCSK9 loses its proteolytic activity. 
I.3.3. Structure of proprotein convertases 
As illustrated schematically in Figure 10, PC enzymes share some similar domains in their structures 
including the ones listed below: 
Signal peptide. A short sequence of residues in the N-terminal of PCs that is recognized by secretory 
pathway for translocation into the ER. 
Prodomain. The prodomain acts both as an intramolecular chaperone and inhibitor of enzymatic 
activity.78-79 Some prodomain residues engage in direct interactions with the active site cleft and inhibit 
the catalytic activity of PC enzymes. The variation of pH and Ca2+ during translocation from the ER to 
the trans-Golgi network (TGN) and the secretory vesicles initiates the auto-catalytic removal of the 
prodomain in PC enzymes.80  
Catalytic domain. The catalytic domain is responsible for catalyzing the cleavage of the peptide bond at 
a consensus motif with paired basic residues. The mechanism of catalytic activity in PCs as in serine 
proteases relies on the catalytic triad (three residues of Asp, Ser and His). The details of the catalytic 
mechanism are discussed in section I.4.1. 
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P-domain. The P-domain plays a crucial structural role in the strong calcium and pH dependence of 
PCs.81-82 PCs lose their catalytic activity without P-domains. A conserved RGD motif within the P-
domain has a critical role in the cellular and subcellular trafficking of PCs.83-85  
Cys-rich domain. This domain has many Cys residues and contains some extra transmembrane or 
cytoplasmic regions in some PCs (furin, PC4, PC5/6, PC7 and SKI-1).77, 83 
Figure 10. Schematic representation of sequences of human proprotein convertase family members. 
Reproduced with permission from Springer Nature publishing group.86 
The active site residues are highly conserved among PCs, except for PCSK9 and SKI-1. This high level 
of homology is reflected on the consensus sequence that they recognize in their substrates. Consequently, 
some PCs can recognize the substrates of other PCs although with lower affinity (this function is called 
redundancy). Among PCs, only crystal structures of furin have been solved untill now.74 The 
demonstrated homology models for other PCs based on furin crystal structure revealed a high degree of 
homology around the active site.87 The disparities between PCs can be made distinguishable to a greater 
extent by receding from the active site region.  
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I.3.4. Cellular and tissue distributions of PCs 
The tissue distribution of PCs varies considerably between family members. Furin is ubiquitously found 
in the whole human body and plays a vital role in embryogenesis. PC1/3 and PC2 process most of the 
prohormones such as proopiomelanocortin, proglucagon and proinsulin and are thus located mostly in 
neural system, hypothalamus and endocrinal tissues.88-89 PACE4, PC5/6, PC7 and SKI-1 are widespread 
and found in several tissues. On the other hand, PC4 is only expressed in reproductive tissues such as the 
testicles and ovaries.89 PCSK9 is largely expressed in the liver and regulates the LDL receptor recycling 
and consequently the levels of fatty acids and cholesterol.90 In most human tissues, multiple PCs are 
expressed, and process diverse substrates indicating their unique role at the cellular level. 
Figure 11. Subcellular trafficking of proprotein convertases. Reproduced with permission from 
Springer Nature publishing group.86 
The PCs are synthesized and folded similarly in the ER as described in section I.3.1 for secretory proteins. 
The differences between PCs appear when they leave the ER for the Golgi apparatus. The unique profile 
of each PC for processing their substrates is related to where they are active (TGN, secretory granules, 
cell surface, endosomes or extracellular matrix; Figure 11).86 The higher efficiency of PC1/3 and PC2 in 
acidic pH allows them to process their substrate within the secretory granules of neuroendocrine cells, 
where the pH is 5 to 6. The endosomal pathway assists the journey of transmembrane furin and PC7 from 
the TGN to the cell surface and their return into the TGN.86  
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PACE4-FL (PACE4-A) and PACE4-altCT (the malignant isoform) are two alternative spliced versions 
of PACE4. The former is either secreted or is observed at the cell surface, while the latter is predominantly 
found within the Golgi apparatus and the endosomes.91 Some other spliced versions of PACE4 are also 
produced, but they remain primarily in the ER as inactive zymogens.92 A similar pattern has been noted 
for alternative splicing of PC5/6.93 The soluble 913-residue PC5/6A is secreted into the extracellular 
matrix through endosomes, while the 1860-residue PC5/6B has a transmembrane domain. Similar to furin 
and PC7, PC5/6B is able to localize between the cell surface and the Golgi apparatus.  
I.3.5. Proprotein convertases and cancer 
A large body of evidence has confirmed the involvement of PCs in various levels of cancer such as 
carcinogenesis, tumor growth, angiogenesis and metastasis.94 The malignant overexpression of different 
PCs has been documented for several types of cancer.94 The significance of PCs is due to the processing 
of cancer-related substrates in the pathologic conditions. Numerous essential malignant proteins and 
enzymes are shown to be processed by PCs or at least they have the consensus motif for proteolytic 
cleavage by PCs. PC1/3 and PC2 are mostly present in neuroendocrinal tissues and they are entangled in 
tumors with the neuroendocrinal origin.95-96 The abnormal activity profile of both PCs is revealed to be 
important in the metastasis of colorectal cancer to the liver.97 The high expression of 7B2 protein (a 
neuroendocrine chaperone for PC1/3 and PC2) was counted as evidence of such role.98 PC1/3 and PC2 
mRNA are also largely expressed in small-cell lung carcinomas.99  
Figure 12. Influence of proproteins processed by furin in cancer development. Reproduced with 
permission from John Wiley and Sons.100 
PACE4 and furin are the most studied PCs in relation to cancer and have extensive links with various 
pathologic and malignant conditions.94 Furin is found to be overexpressed in several tumors, including 
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lung, head and neck carcinomas as well as endometrial, cervical and ovarian, breast, skin, gastro-intestinal 
tract, brain and central nervous system cancers.100 In some cases, furin tends to be a marker for 
aggressiveness of neoplasms and cancer progression.100 The proteolytic activity of furin mediates the 
processing of substrates such as Pro-ADAM(TS) and Pro-MT1-MMP, which results in increased 
aggression, migration and metastasis of tumors by release of proteases from ADAM (a disintegrin and 
metalloproteinase) and MMP (matrix-metalloproteases) families. Moreover, furin-mediated processing 
is necessary in the activation of some key growth factors and their receptors such as platelet-derived 
growth factor (PDGF), transforming growth factor beta 1 (TGF-β1), vascular endothelial growth factor-
C (VEGF-C) and insulin-like growth factor 1 receptor (IGF1R) (see Figure 12).101 The growth factors 
stimulate the tumor progression by enhancing cell proliferation, angiogenesis and anti-apoptosis effects. 
Furin also processes integrin α-subunits, E-cadherin and N-cadherin (cell adhesion molecules) that are 
instrumental in the migration of cells through lymph nodes (a.k.a. metastasis).102-105  
A growing body of reports implicate the role of PACE4 in pathologic conditions. The overexpression of 
PACE4 is associated with tumor growth and malignancy.106 Breast cancer MDA-MB-231 cells were 
observed to be less aggressive (i.e. low expression of genes involved in cell growth, invasion and 
adhesion) when PACE4 mRNA was silenced, and most cell cycles were arrested in the G0/G1 phase.107 
Administration of PACE4 inhibitors decreased the proliferation of estrogen-receptor-positive breast 
cancer cell line ZR-75-1 and tumor progression.108 PACE4 mediates the collagenase type IV activation 
through the processing of pro-MMPs in non-melanoma skin cancers.109 Consequently, the increase in 
MMP levels leads to more vulnerability of cells to carcinogens (e.g. benzopyran) and accelerated 
metastasis.109-110 PACE4 overexpression was also detected in non-small cell lung cancer and ovarian 
cancer at both tumor cell lines and patient’s tissues.111-113 PACE4 also exhibits a unique role in the 
development of prostate cancer. This will be described in more detail in the following section. 
I.3.6. Validation of PACE4 as a target in prostate cancer 
The PACE4 enzyme has been proven to play a critical role in the progression and the malignancy of 
prostate. The PACE4 mRNA in DU145 cell lines was targeted and silenced using a special biochemical 
tool (i.e. on/off switch adapter-hepatitis delta virus ribozyme).114 The resulting cell line, called 4-2, 
displayed slower proliferation. That study proposed that PACE4 has a high impact on the metastasis and 
malignancy of prostate tumor through processing of growth factors. More recently, pro-growth 
differentiation factor-15 (pro-GDF-15) was discovered as a specific substrate for PACE4.91 However, 
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further investigations are essential for discovering other cancer-related substrates of PACE4. It was also 
observed that PACE4, especially its malignant spliced version PACE4-altCT, is overexpressed in prostate 
cancer tissues compared to normal prostate tissues (Figure 13-A, E and F).91, 114 The abnormally high 
levels of PACE4 in more than 90% of prostate adenocarcinoma was projected as a biomarker for prostate 
cancer.115-116  
Figure 13. Expression of PACE4 in prostate tissue and its silencing in tumor xenograft. A) Comparison 
of PACE4 with other PCs in normal and tumorous prostate. B) Representation of LNCaP tumor 
xenografts with different PCs silenced mRNA. CD34 staining of C) non-treated (arrows show the lumen 
of micro vessels) and D) PACE4-silenced tumor. PACE4 mRNA in E) Normal, and F) tumorous prostate 
tissues (purple indicates the presence of PACE4 mRNA). Figure adapted with permissions from 
Elsevier.114, 117 
The xenografted model that is defined by transplanting human tumor cells under skin or inside the organ 
of a nude mouse (a genetically modified mouse with an inhibited immune system) is widely used as in 
vivo tumor model. LNCaP xenografted tumors normally exhibit a dark red color due to the pervasive 
presence of vessels, but the color was pink in PACE4 mRNA silenced tumors, indicating less 
neovascularization (Figure 13-B).117 The density of the micro vessels was reduced by 80% by PACE4-
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silencing in tumors (Figure 13-C and D), which indicated the impact of PACE4 on vascularization of 
prostate tumors.117 Furthermore, the tumor growth was inhibited only by silencing PACE4 mRNA and 
neither furin nor PC7 mediated tumor growth (Figure 13-B). PACE4 knocked-down tumor cells were 
observed to be arrested in G0/G1 state of the cell cycle.117  
Figure 14. Mechanism of proteolysis catalyzed by serine proteases 
I.4. Inhibition of proprotein convertases 
I.4.1. Proprotein convertases are serine proteases 
Proteases are hydrolase enzymes that catalyze the hydrolysis of the peptide bonds in their substrates. 
Proteases are categorized based on their catalytic mechanisms and the key amino acid residues involved 
in proteolysis. The seven major groups of proteases include serine, cysteine, threonine, aspartate, 
glutamate proteases as well as metalloproteases and asparagine peptide lyases.  
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Serine proteases have been classified in three clans: SA (chymotrypsin-like), SB (subtilisin-like) and SC 
(α/β-hydrolase fold). Their catalytic Ser, His and Asp residues are firmly conserved with a special 
geometry despite the differences in clans.118 The other classification is based on the genetic codon of 
catalytic Ser being either TCN or AGY.119 Proprotein convertases, as they are related to subtilisin, are 
classified in the clan SB of serine proteases.  
The mechanism of peptide bond hydrolysis in serine proteases is illustrated in Figure 14. The reaction is 
initiated with a proton transfer between Ser and Asp residues, which is mediated by a His residue. The 
resulting alkoxide is now nucleophilic enough to attack the carbonyl of the amide bond. The tetrahedral 
intermediate is stabilized by the interaction with the oxyanion hole residue, which is usually an Asn in 
PCs (only in PC2 is an Asp). Another proton transfer releases the amine part of the substrate and leaves 
the enzyme to be acylated at Ser. Finally, the hydrolysis of the acyl-enzyme produces the acid part of the 
substrate and the enzyme returns to the initial state to continue the catalytic cycle. 
The substrates of proteases have a special nomenclature. Starting from the fragile peptide bond towards 
the N-terminus, the residues are named …, P1, P2, P3 and towards the C-terminus as P1', P2', P3', ... The 
interrelated sub-pocket that each residue occupies in the enzyme is indicated with …, S3, S2, S1, S1', S2', 
S3', …  
I.4.2. Peptide inhibitors of proprotein convertases 
The initial inhibitors of PCs were synthesized based on the consensus sequence of their substrates. The 
first PC inhibitor, Dec-RVKR-Cmk 22 (where Dec and Cmk stand for decanoyl and chloromethylketone, 
respectively) is a non-specific irreversible inhibitor of proprotein convertases.120-121 The crystal structure 
of 22 in the active site of mouse furin shows the chloromethylketone moiety covalently attached to the 
catalytic Ser and His residues (Figure 15).74 The Arg residues occupy the P1 and P4 having the most 
important non-covalent interactions (an Ala, two Asp and a Pro in S1 subsite; two Asp and a Tyr in S4 
subsite). A Lys residue interacts with an Asp and an Asn in S2 subsite of enzyme and P3-Val backbone 
introduce a β-sheet-like interaction with the backbone of a Gly residue. These interactions are 
significantly similar among seven members of the PC family, namely PC1/3, PC2, PC4, PACE4, PC5/6, 
PC7 and furin. Despite the wide use of compound 22 as a biochemical tool in inhibiting PC activity, its 
extended cytotoxicity, due to its alkylating nature, prevents it from being a viable molecule for drug 
discovery purposes.122  
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Figure 15. The relaxed-eyes stereo views of crystal structure of mouse furin. a) The 3D structure of furin 
with inhibitor 22 in the active site shown as ribbon b) The solid surface representation of furin with 
inhibitor represented as ball-and-sticks c) The stick model of active site residues interacting with inhibitor 
22. Reproduced with permission from Springer Nature publishing group.74 
Meanwhile, a fluorometric assay was developed for determining the inhibitory constant (Ki) of PC 
inhibitors using RXKR-AMC (where X usually is S, T or V and AMC stands for 7-amino-4-
methylcoumarin) as substrate (Figure 16).121 PC enzymes cleave this fluorogenic substrate’s amide bond 
between Arg and AMC, and the free AMC emits fluorescence (λEM, 460 nm; λEX., 370 nm). A competitive 
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inhibitor interferes with the hydrolysis reaction and competes with the substrate to occupy the active site 
of the enzyme. The concentration of the inhibitor that disables the processing of RXKR-AMC substrate 
by enzyme defines the inhibitor’s affinity. The concentration that shows half of the maximum activity of 
the inhibitor is called IC50. The IC50 is used to calculate the Ki using either the Cheng-Prusoff or Morison 
equations. When E0 < Ki (initial concentration of enzyme), Cheng-Prusoff equation provides a good 
approximation for Ki.
123 Once E0 ≥ Ki, tight binding kinetics is involved and Morison equations is 
recommended for Ki calculation.
124 
Figure 16. Fluorometric assay for determination of inhibitory constant 
The Dec-Arg-Val-Lys-ArgCH2-Ala-Val-Gly-NH2 23 (furin Ki = 3.4 nM, ArgCH2 is the reduced amide 
bond, Table 2) is identified as the first reversible peptide inhibitor for furin with tight binding kinetics.125 
Short multi-arginine peptides are also non-specific potent inhibitors of PCs.126 For example, compound 
25 is a very potent inhibitor of PCs and  together with 22 have been used as non-specific PC inhibitors in 
biochemical investigations. Other multi-basic cell penetrating peptides such as [W5R4C] and [W4R4] 
were observed to be micromolar inhibitors of PCs.127 The furin inhibitors are the most studied among 
proprotein convertase inhibitors, with a focus on the role of furin in the processing of viral envelope 
glycoproteins (e.g. hemagglutinin in influenza virus, HBeAg precursor in hepatitis B virus and gp160 in 
HIV), bacterial toxins (e.g. in anthrax) and cancer-related proteins.128-132 For instance peptide 38 (DTyr‐
KERSKR‐Tic‐VQKD, where Tic is  (S)-N-Fmoc-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) that 
subsequently evolved to the nanomolar PC inhibitor 39, is synthesized based on the hemagglutinin 
protein.122, 127 
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Table 2. The Ki (nM) of known peptide inhibitors of proprotein convertases. 
Inhibitor structure Furin PACE4 PC1/3 PC5/6 PC7 Source 
Dec-RVKR-Cmk (22) 1 3.6 - 0.12 0.12 Synthetic 
Dec-RVK-ArgCH2-AVG-NH2 (23) 3.4 - - - - Synthetic 
Hexa D-Arginine (D-Arg)6 (24) 106 580 13200 206 1875 synthetic 126, 133  
Nona D-Arginine (D-Arg)9 (25) 1 - - 19 81 synthetic 133-135  
Complete hpro-furin (26) 1.7 0.4 - - 150 hPro-furin80 
Complete hpro-PC2 (27) > 1000 > 1000 - - 131 hpro-PC280 
Complete hpro-PC1/3 (28) 1.4 1.1 - - 25 hpro-PC1/380 
Complete hpro-PACE4 (29) 5.3 2 - - 117 hpro-PACE480 
Complete hpro-PC4 (30) 9 7 - - - hpro-PC480 
Complete hpro-PC5/6 (31) 2.9 1.3 - - 16 hpro-PC5/680 
Complete hpro-PC7 (32) 12.4 0.34 - - 1.3 hpro-PC7 
64SDDDRVTWAEQQYEKERSKR83 (33) - - 600 - - pro-PC1/3 136  
50RRSRRSALHITKRLSDDDRVTWAEQQYEKERSKR83 (34) 4800 - 700 - - pro-PC1/3 136  
25-107hPro-furin (35) 107 - - - - pro-furin  
DSHAKRHHGYKRKFHEKHHSHRGYRSNYLYDN (36) 1980 - - - 2400 His- rich salivary peptides137 
235VLGALLRVKRLE246 (37) 246 - 9 317 940 pro-SAAS138 
DTyr‐KERSKR‐Tic‐VQKD (38) 790 - 1400 - - synthetic 139  
TPRARRRKKRT-NH2 (39) 23 162 - 232 142 influenza H5N1 hemagglutinin131 
8-Amino-octanoyl-RARRRKKRT-NH2 (40) 8 3 - 3 430 influenza H5N1 hemagglutinin122 
Ac-LLRVKR-NH2 (41) 1400  3.2   synthetic140 
Monocyclic KRCKKSIPPICF-NH2 (42) 0.49 - - - - sunflower trypsin inhibitor 1141 
The complete prodomains of proprotein convertases inhibit PCs with inhibitory constants in the nM range 
(Table 2, compounds 26–32).80 However, the peptide derived from pro-furin and pro-PC1/3 were shown 
to be less active compared to full prodomains (Table 2, compounds 33–35).136 His-rich salivary peptides 
(e.g. 36) also inhibit furin and PC7 in the µM range.137 Pro-SAAS is another secretory protein precursor 
that needs PC processing for maturation. A peptide segment of pro-SAAS (37) is shown to inhibit PC1/3 
with good selectivity over other PCs.138 A positional scanning conducted over 52 million hexapeptides 
resulted in compound 41, which was 28-fold selective for PC1/3 over furin.140 Peptide 42, an engineered 
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monocyclic peptide derivative of sunflower trypsin inhibitor-1 (SFTI-1) was found to be a potent furin 
inhibitor (Ki = 0.49 nM) with tight binding kinetics.141 
Bioengineered proteins have been used to inhibit PCs. The most well-known example is α1-antitrypsin 
Portland (α1-PDX) and its analogues as a serpin (an endogenous protease inhibitor protein) variant that 
inhibits furin (Ki = 600 nM) and other PCs. The engineering was performed by the replacement of a native 
AIPM motif by a PC recognizable motif (RIPR).142-143 However, its application remained limited only to 
the biochemical investigations. Other protein inhibitors including eglin c, turkey ovomucoid third domain 
and α2-macroglobulin mutants inhibit furin proteolytic activity.144-148  
The PC2 active site has some differences compared to other PCs, which renders the synthesis of its 
specific inhibitors easier. Peptide fragments of 7B2 CT protein are also potent and specific inhibitors of 
PC2.149 The smallest CT derived peptide with specific PC2 inhibition abilities is the CT 1-18 which its 
sequence is SVNPYLQGQRLDNVVAKK-NH2 (PC2 Ki = 23 nM).
150 
I.4.3. Small molecule and peptidomimetic inhibitors of proprotein convertases 
Due to the dependence of PCs on Ca2+, some calcium chelating agents have been proposed as inhibitors 
of PCs. Their low affinity and the involvement of Ca2+ over a wide range of biochemical reactions in the 
human body are obstacles for further development of this class of inhibitors.151-152 The diterpene 
compounds extracted from the Andrographis paniculata plant were found to be micromolar inhibitors of 
PC1 and PC7.153  
Despite all efforts to find non-peptide-based PC inhibitors, only compounds with the 2,5-
dideoxystreptamine scaffold exhibited nanomolar potency in the inhibition of PCs.154 The multi-
guanylated compound 43 inhibits furin with Ki = 6 nM (Figure 17).
154 However, further cellular analysis 
indicated that compound 43 has moderate cytotoxicity and low interaction with intracellular furin.155 
Optimization of this compound resulted in compounds 44 (furin Ki = 12 nM) and 45 (furin Ki = 400 nM) 
with higher capacity for treatment of pathogenic bacterial infections (e.g. Pseudomonas aeruginosa or 
Bacillus anthracis) despite their lower potency for furin. More recently, crystallographic studies of 
compound 43 in furin active sites indicated that the high affinity for furin is the result of the interactions 
of two molecules of 43 in the catalytic cleft.156 One molecule interacts directly with the S4 pocket and 
interferes with the catalytic triad, while the other molecule is bound loosely at a remote location near the 
active site.156  
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Figure 17. Structure of 2,5-dideoxystreptamine scaffold and its derivatives as potent furin inhibitors. 
Becker et al. built libraries of peptidomimetic based on the RVKR motif and early findings on compound 
23 (Table 2).157 By screening arginine mimetics in P1, they found that 4-amidinobenzyl amine (Amba) 
can replace Arg advantageously at that position. Thus, compound 46, which is the best furin inhibitor in 
that study (furin Ki = 0.81 nM), has phenylacetyl (phac) and Amba residues at positions P5 and P1 
respectively (Figure 18). This peptide analogue was a starting point for further exploration beyond the 
P4 residue which yielded guanidine 47.158 The presence of a basic P5 residue (3-guanidinomethyl-
phenylacteyl) in 47 increased the affinity for furin by a magnitude of two (Ki = 0.008 nM, Figure 18). A 
crystal structure of protonated 47 in physiological pH bound to furin showed that the additional positive 
charge interacted with negative charges of the furin active site located in the S4 subsite and an alternative 
S5 subsite.159 The P5 residue interacts unexpectedly with a region only 4 Å apart from the S4 subsite. 
Further modifications of P3-Val with natural amino acids did not improve affinity, but the inclusion of 
tert-leucine (Tle) in this position and 4-guanidinomethyl-phenylacetyl in P5 led to compound 48 (furin 
Ki = 0.005 nM), the most potent inhibitor of furin discovered to date.
160 In a more recent study, the same 
group found that the modification of P2-Arg with Lys residue was associated with reduction in acute 
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toxicity on mice and thus improved the therapeutic index, but with a diminished furin affinity compared 
to 48.161  
Figure 18. Representative chemical structure and affinity of peptidomimetic furin inhibitors 
Other crystal structures of furin with and without ligand 47 and molecular dynamic studies demonstrated 
that the shape of the enzyme changes as the inhibitor approaches the active site cleft (Figure 19).162 Free 
furin has a stable off-state conformation which transits to an on-state active conformation ready to accept 
the inhibitor. Once the inhibitor approaches the active cleft, the newly formed interactions introduce a 
favorable negative ΔGbind. The new on-state inhibitor bound conformation is more stable than the off-
state inhibitor-free conformation. A common feature of proteases including PCs is that peptide ligands 
adopt a β-sheet conformation (usually an antiparallel β-sheet) stabilized by residues in the active site 
(typically a Gly is involved).163 The formation of this β-sheet-like interaction with Gly255 of furin along 
with deep S1 subsite interactions are found to be responsible for the spatial proximity of the catalytic 
serine in the catalytically active conformation (on-state) of furin.162 The other important factors in the 
conformation of furin were chelation of two Ca2+ ions, which were shown to be instrumental in the 
structural integrity of furin.162 
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Figure 19. Schematic representation of inhibitor-induced conformation alteration in furin crystal 
structures. Figure reproduced from Dahms et al.162 
I.4.4. Inhibitors of PACE4 
Designing specific competitive inhibitors for PCs is challenging and laborious due to the high levels of 
homogeneity between the PC family in the S1–S4 subsites.164 However, some differences appear beyond 
the S5 subsite as disclosed by the new crystallographic studies of some furin inhibitors.165  
Figure 20. a) The inhibition of PACE4 and furin by PC prodomains and b) the active site interacting 
residues. Reproduced with permission from the American Chemical Society.166 
As discussed in section I.4.2 (Table 2), PC prodomains 26-32 are potent (nM range) inhibitors of PCs. 
While most prodomains inhibit PACE4 and furin in a similar range of concentrations, a PACE4 
preference was noticed for PC7 prodomain 32 (Figure 20-a).166 This was a starting point for further 
research on PC7 prodomain-derived peptides endowed with PACE4 specificity. Comparison of P7-P1 
residues in the PC7 prodomain primary cleavage site with prodomains from other PCs revealed that two 
Leu at positions P6 and P7 are a unique feature of the PC7 prodomain. (Figure 20-b).166 
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In parallel, Positional Scanning-Synthetic Peptide Combinatorial Libraries (PS-SPCL) of 6-mer peptides 
having the RVKR consensus sequence at positions P4–P1 resulted in the strong and selective inhibitor 
Ac-LLRVKR-NH2 (furin Ki = 900 nM and PACE4 Ki = 49 nM),
166 a peptide whose sequence is very 
similar to that of the PC7 prodomain-derived peptide (LLRRAKR). Sequential addition of Leu residues 
to the N-terminal of RVKR was associated with an in increase in selectivity. The peptides with three and 
four Leu showed the best potency and selectivity. However, the octapeptide displayed better 
antiproliferative activity on prostate cancer cell lines and thus, was chosen for further investigation and 
SAR analysis. This octapeptide, which was named Multi-Leu (ML) peptide, was 20 times more selective 
for PACE4 over furin (furin Ki = 430 nM and PACE4 Ki = 22 nM; Figure 21).
166 
Figure 21. Optimizing the number of Leu residues in the tail of the RVKR warhead leading to the 
discovery of Multi-Leu peptide. Reproduced with permission from the American Chemical Society.166 
In the MTT antiproliferative assay, the metabolic activity of cells is evaluated based on the ability of 
mitochondrial oxidoreductases to reduce yellow MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to purple formazan (Figure 22). Treatment of cells with different 
concentrations of PACE4 inhibitors affects their metabolic activity (response). The related dose-response 
curves are used to determine the IC50 (the concentration that shows half of maximal inhibitory effect) of 
the corresponding inhibitors. The cellular antiproliferative activity (IC50) of ML peptide on DU145 and 
LNCaP prostate cancer cells was calculated to be 100 µM and 180 µM respectively (Figure 23). 
Figure 22. Conversion of MTT to formazan in mitochondria of metabolically active cells 
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Because the sequence of the ML peptide contains only natural residues, it can be easily cleaved by human 
plasma proteases. Therefore, SAR studies were performed on this lead peptide using peptidomimetic 
strategies to improve its short half-life (t1/2). These efforts led to the discovery of compound C23 with 
enhanced affinity for PACE4 and improved cellular activity (Figure 24).167-168 Compound C23 is armed 
with 4-amidinobenzylamide (Amba) in P1 and DLeu in P8. Inclusion of these two unnatural residues 
increased the half-life from a few minutes in ML to 1.7 h in C23.169 As for furin inhibitors, Amba 
displayed stronger interactions in P1 compared to Arg, which led to higher PACE4 affinity of C23 
compared to the ML peptide (Ki = 4. 9 nM, Figure 24). The antiproliferative activity of C23 was also 
improved (DU145 IC50 = 25 µM and LNCaP IC50 = 45 µM; Figure 23 and 24). 
 
Figure 23. Dose-response curves in MTT assay for ML and C23 compounds on prostate cancer cell 
lines. Reproduced with permission from Levesque et al.170 
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Figure 24. Chemical structures, enzymatic and cellular potencies of ML and C23.  
Studies focused on the ML peptide indicated that the penetration of this peptide into the cell is essential 
for cellular antiproliferative activity.166 N-terminal extension of ML or C23 peptides with polyethylene 
glycol (PEG) chains of various lengths reduced the cell permeability of the resulting inhibitors. The lower 
cell permeability of PEGylated inhibitors was identified as the reason for attenuated cellular activity.166, 
168 The cell permeability of PACE4 inhibitors was assessed by treating the DU145 cells with FITC 
(fluorescein isothiocyanate) labeled peptides followed by counting the number of cells that emit 
fluorescence using a FACS machine (fluorescence activated cell sorter). More recently, PACE4-altCT, 
an alternatively spliced version of PACE4, has been identified as the enzyme responsible for the 
appearance of malignant metabolites in pathologic conditions.91 This spliced version is located inside the 
TGN endosomes and thus the cell penetration of the inhibitor is necessary to reach it. PACE4 mediates 
its effects on PCa by processing pro-GDF-15 to GDF15, which is an important factor for cell growth.91 
GDF15 also protects cancer cells against radiation-therapy and is involved in tumor neovascularization.91 
By inhibiting PACE4, C23 was shown to inhibit the processing of pro-GDF-15 to its mature protein as 
well as some other undiscovered substrates.91 
Both C23 and ML peptides have four leucines in P5–P8 positions. A systematic scan of these positions 
of C23 compound with all the natural residues, except Cys, revealed that these residues should be 
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essentially hydrophobic171 and that inhibitors must therefore be amphipathic to be active in cellulo. Cell 
permeability is the primary issue in this regard. 
Figure 25. Tumor progression following 2 mg/kg/day treatment with C23 compound. Reproduced with 
permission from Levesque et al.170 
N-terminal lipidation of ML or C23 preserves or improves the antiproliferative activity. However, the 
acute toxicity of lapidated inhibitors on healthy CD1 mice was significantly higher than non-lipidated 
compounds.168 
Figure 26. The dose-dependent effect of PACE4 inhibition by C23 on cell proliferation, cell quiescence, 
apoptosis and pro-GDF-15 processing in vivo. Reproduced with permission from American Association 
for Cancer Research.91 
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With improved stability in human plasma and increased cellular activity, C23 was tested in vivo using a 
LNCaP xenografted tumor mice model. When administered systematically in 2 mg/kg/day doses, C23 
inhibited the tumor growth by 60% compared to non-treated controls over a period of 18 days of treatment 
(Figure 25).170 The PSA levels during the period of treatment followed the same pattern with 47% 
reduction for treated animals at the completion of the experiment (170 ± 40 ng/mL for control and 90 
ng/mL for C23 treated animals).170 The analysis of the tumors revealed that the number of cells 
progressing through cell cycle were significantly reduced (20%) after administration of C23 (cell 
quiescence at Go/G1 state).170 The rate of apoptotic cells within control tumor raised from 2.4% to 6% in 
treated tumors, which indicated a 250% increase. In addition, the angiogenesis and micro-vascularization 
was considerably reduced in tumor tissues (40%).170 In another study, a 28 days intraperitoneal 
administration of LNCaP xenografted tumors with 2 and 4 mg/kg/day doses of C23 was shown to affect 
cell proliferation, cell quiescence and apoptosis markers in a dose-dependent manner (Figure 26-a to 26-
c).91 The levels of GDF-15, a PACE4 metabolite, was also reduced after 28 days of treatment with C23 
(Figure 26-d), which provided evidence of PACE4-mediated pharmacodynamics of C23.91 
The ML peptide and C23 was radiolabeled with 64Cu by addition of NOTA (1,4,7-triazacyclononane-
triacetic acid, a bifunctional chelating group, Figure 27) in its N-terminus to investigate its in vivo 
uptake.172 Positron emission tomography (PET) scanning of 64Cu/NOTA-DLeu-LLLRVK-Amba and 
64Cu/NOTA-LLLLRVKR-NH2 showed a rapid uptake of the peptides by LNCaP xenografted tumor 
suggesting a significant tissue penetration of PACE4 inhibitors.170, 173 The uptake of inhibitors by tumor 
was shown to follow a PACE4-dependent mechanism. Although C23 and its radiolabeled version were 
rapidly eliminated from the plasma, the study confirmed efficient distribution and significant tumor 
uptake of these PACE4 inhibitors.170 
Figure 27. General structure of NOTA-labeled peptides 
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I.5. Thesis objectives  
Despite the advantages of C23 as an inhibitor of PACE4 for the treatment of PCa, there is still room for 
improvement in selectivity, cellular activity and stability. The primary drawback of the C23 compound 
is its fairly low PACE4 selectivity. As represented in I.4.4 section, the PACE4 affinity of C23 compared 
to ML peptide was improved by more than 4-fold (PACE4 Ki = 22 nM and 4.9 nM for ML and C23, 
respectively). Unfortunately, at the same time, the PACE4 selectivity was reduced from 20-fold for ML 
to only 2-fold for C23. Furin inhibition is a concern because it is ubiquitously expressed in all human 
tissues. Consequently, its inhibition may potentiate side effects in off-target tissues.100 As a result, the 
quest of PACE4 inhibitors devoid of residual furin inhibition is still on. 
Based on PC mRNA silencing studies (section I.3.6), PACE4 is indeed the key PC in proliferation and 
homeostasis of prostate tumor. By inhibiting PACE4, C23 was shown to block the processing of pro-
GDF-15 to its mature protein.91 
Further SAR investigation of C23 and ML are addressed in the following chapters. The primary objective 
of the current thesis is to improve the selectivity and affinity of PACE4 inhibitors over furin. This goal is 
pursued by modifications in the P3, P1 and P1' positions of the ML and C23 compounds.  
In the P3 position, basic residues were investigated for replacement of Val to establish new interactions 
with Asp160 of PACE4. Asp160 was identified as the only different residue in the active site region of 
PACE4 compared to furin. The results of this study were published in ChemMedChem as a 
communication and are presented in the first chapter of the current thesis. 
Despite similarities of the S1 subsites in PACE4 and furin, Amba-bearing inhibitors such as C23 typically 
display low selectivity for PACE4. This is due to the higher affinity of Amba for furin’s S1 subsite 
compared to PACE4’s. Therefore, previously not-tested Arg mimetics were evaluated in the P1 position 
of C23 pursuing selectivity. This study, published in the Journal of Medicinal Chemistry as a full article, 
is presented in the second chapter. 
Exploiting the P1' position of PACE4 inhibitors for selectivity, surprisingly, resulted in an improvement 
of other aspects as well. Thus, screening of natural residues at this position further led to the rational 
design of some unnatural residues providing more PCa cellular penetration and antiproliferative activity. 
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The results of this investigation are published in the Journal of Medicinal Chemistry as a full article and 
are presented in the third chapter. 
Overall, different strategies including optimization of P3 (Chapter 1), P1 (Chapter 2) and P1’ positions 
(Chapter 3) are exploited to enhance the selectivity and antiproliferative activity profile of PACE4 
inhibitors. The current thesis offers new conceptual knowledge and leads for developing next generation 
PACE4 inhibitors as candidates for targeted therapy of prostate cancer. 
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CHAPTER 1 : RATIONAL DESIGN OF A HIGHLY POTENT AND SELECTIVE PEPTIDE 
INHIBITOR OF PACE4 BY SALT BRIDGE INTERACTION WITH D160 AT POSITION P3 
The current chapter was published in ChemMedChem 2017, 12, 1169 – 1172 (DOI: 
10.1002/cmdc.201700300) with the following title, authors and affiliations; 
Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge 
Interaction with D160 at Position P3 
 
Vahid Dianati,[a] Azar Shamloo,[b] Anna Kwiatkowska,[c] Roxane Desjardins,[c] Armand Soldera,[b] 
Robert Day,*[c] and Yves L. Dory*[a] 
[a] Institut de Pharmacologie de Sherbrooke, IPS, Département de Chimie, Faculté des Sciences, 
Université de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, Québec J1H 5N4 (Canada) 
E-mail: Yves.Dory@usherbrooke.ca 
[b] Département de Chimie, Centre Québécois sur les Matériaux Fonctionnels, Université de 
Sherbrooke, Sherbrooke, Québec J1K 2R1 (Canada) 
[c] Institut de Pharmacologie de Sherbrooke, Département de Chirurgie/Urologie, Université de 
Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, Québec, J1H 5N4 (Canada) 
E-mail: Robert.Day@USherbrooke.ca 
1.1. Author contributions 
This work was done in the Institut de Pharmacologie de Sherbrooke under the supervision of Pr. Robert 
Day and Pr. Yves L. Dory in collaboration with Pr. Armand Soldera’s lab at the Département de Chimie, 
Centre Québécois sur les Matériaux Fonctionnels in Université de Sherbrooke. The original research 
article was published by Vahid Dianati, Azar Shamloo, Anna Kwiatkowska, Roxane Desjardins, Armand 
Soldera, Robert Day, and Yves L. Dory in ChemMedChem 2017, 12, 1169 – 1172. Vahid Dianati and 
Yves L. Dory designed the compounds. Vahid Dianati synthesized all the compounds and performed the 
kinetic assays. Roxane Desjardins purified the recombinant enzymes for kinetic assays. Azar Shamloo 
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did the MD simulations under supervision of Armand Soldera. Anna Kwiatkowska contributed in 
performing the kinetic assays. Vahid Dianati, Robert Day and Yves L. Dory analyzed the data. Vahid 
Dianati wrote the manuscript with revisions from Anna Kwiatkowska, Robert Day and Yves L. Dory. 
1.2. Abstract 
PACE4, a member of the proprotein convertases (PCs) family of serine proteases, is a validated target for 
the treatment of prostate cancer. Our group has developed a potent and selective PACE4 inhibitor: Ac-
LLLLRVKR-NH2. In seeking for modifications to increase the selectivity of this ligand toward PACE4, 
we replaced one of its P3-Val methyl groups with a basic group capable of forming a salt bridge with 
D160 of PACE4. The resulting inhibitor is eight times more potent than the P3 Val parent inhibitor and 
two times more selective over furin, because the equivalent salt bridge with furin E257 is not optimal. 
Moreover, the β-branched nature of the new P3 residue favors the extended β-sheet conformation usually 
associated with substrates of proteases. This work provides new insight for better understanding of β-
sheet backbone–backbone interactions between serine proteases and their peptidic ligands. 
1.3. Introduction 
Binding of peptide ligands to their complementary enzyme or receptor is controlled by two important 
factors from internal and external origins; namely, their conformation and their binding interactions with 
the target. Thus, in the best scenario, their active conformation corresponds to their intrinsic most stable 
shape. Moreover, these ligands ideally develop as many noncovalent interactions as possible with the 
target biomolecule to ensure tighter binding. Here we show that proper substitution of a single key residue 
of a protease inhibitor can be leveraged to impact both factors in a concerted manner. 
β-Strands are ubiquitous secondary structures. They have been identified as important features in 
antimicrobial peptides and natural ligands for biomolecular hosts like proteolytic enzymes, major 
histocompatibility complex (MHC) proteins and transferases.163 It is well known that proteases 
universally bind to their substrates in extended β-strand conformation.174 The β-sheet backbone hydrogen 
bonding pattern (mostly antiparallel) is crucial for peptide-based ligands to bind. In drug design targeting 
proteases, drug resistance is a serious issue. The active site geometry must be conserved to maintain the 
catalytic activity, so enhancing the backbone interactions, while stabilizing the active conformation, is a 
logical way to alleviate the effect of mutations.175 
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Statistic176 and thermodynamic177-178 studies clearly established that β-sheets prefer β-branched residues 
(Val, Ile, and Thr) in their structure rather than other residues. The greater steric clashes between the local 
backbone and the side chain of β-branched residues, favors β-sheets over all other conformations.179-180 
Moreover, β-sheet hydrogen bonds are shielded from interfering water molecules.181 Consequently, Val 
and Ile are privileged residues in peptidic inhibitors of proteolytic enzymes.182-184 
Side chain to side chain interactions, including those between charged residues,185-186 cation–π 
interactions,187 π–π interactions188 and covalent bonds like disulfide bonds189 have been employed to 
stabilize artificial β-sheet models. Recently, Gellman’s group used a series of charged bearing β-branched 
amino acids making intramolecular salt bridges in their artificial β-sheets. These amino acids proved to 
be better β-sheet inducers and stabilizers than natural residues.190 Here, we take advantage of this β-sheet 
propensity by incorporating such related residues in our peptide protease complexes. 
Proprotein convertases (PCs) belong to the family of substilin–kexin serine proteases, which recognize 
their substrates through pairing with basic residues (R-P3-R/K-R-↓-P1’).86, 164 They proteolytically 
activate a range of proproteins, including hormones, receptors, growth factors, zymogens, etc. The seven 
members of proprotein convertases including PC1/3, PC2, PC4, PC5/6, PC7, furin and PACE4 have many 
resemblances in their active sites. 86, 164  We have shown that PACE4 is a promising target in prostate117 
and ovarian cancer.191 Optimization of binding selectivity is a major path toward drug candidates to 
alleviate potential side effects. Additionally, in vivo use necessitates the elaboration of stable compounds. 
Our research group has developed a PACE4 peptide inhibitor with the Ac-LLLLRVKR-NH2 sequence
166, 
170 which named the Multi-Leu (ML) after its four leucine residues. The hydrophobic tetra-Leu tail makes 
the RVKR tetrapeptide warhead an amphipathic cell penetrating peptide and increases the selectivity 
toward PACE4 (20-fold). We also reported the P1 Arg modification of ML with 4-amidinobenzylamide 
(Amba), which resulted in an inhibitor with improved activity and better stability in vivo.167-168 
A P3 modification of a peptidomimetic furin inhibitor (Phac-RVK-Amba, where Phac stands for 
phenylacetyl) has been investigated by replacing Val with many other natural and modified amino 
acids.192 That study suggested to us that β-branched residues176-178 might be used to stabilize the β-sheet 
conformation of inhibitors, while concomitantly adding interactions with furin and its homologous 
PACE4 enzymes, with suit-able β-substituents. 
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Figure 28. Structure of modified amino acids to be inserted at P3 of ML. 
1.4. Results and discussions 
According to a homology model of PACE487 developed from the crystal structure of furin (1P8J),74 
from all amino acids within the S1-S4 sub-pockets, there is just a single difference between the two 
enzymes: Asp160 in PACE4 replaces Glu257 of furin in S3. We designed β-branched basic amino acids 
1–4 (Figure 28) to replace Val at position P3 of ML, to bind Asp160 of PACE4, while stabilizing its β-
sheet conformation (Figure 29). 
 
Figure 29. Structure and binding affinities of peptide inhibitors 5–16 for PACE4 and furin and their 
selectivity profile toward PACE4. All experiments were repeated at least twice, and data are shown as Ki 
± SD. [a] 2-amino-4- guanidinobutyryl. [b] 2,3-diaminobutyryl. [c] 2-amino-3-guanidinopropionyl. [d] 
2,3-diaminopropionyl. [e] 2S,3S-diaminobutyryl. [f] 2S,3R-diaminobutyryl. [g] 2S-amino-3S-
guanidinobutyryl. 
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The binding affinities and selectivities (toward PACE4) of all the PACE4 inhibitors synthesized in the 
present work are summarized in Figure 29. Initial results from Val (5) substitution by Ala (6) suggest 
that β-branching is indeed important. We then endeavored to optimize the side chain length and the basic 
functional group. A series of ML P3 substituted analogues was prepared from commercial linear basic 
residues (7–13) using solid-phase peptide synthesis (SPPS). Inhibitors 7–10 showed almost the same 
trend for PACE4 inhibition. Since 12 and 13, gave the best results, it was then clear that the ideal chain 
length for the β-branched analogues was 0 (n = 0 in Figure 28). We then logically prepared the 
corresponding inhibitors 14–16 from synthetic β-branched residues 20a and 20b (Scheme 1). 
Scheme 1. Synthesis of Fmoc-protected residues 20a and 20b.  
Thus, Boc-Thr-OH 17a and Boc-allo-Thr-OH 17b were protected as the Boc-hydrazides 18a and 18b. 
The β-hydroxy groups were converted into azides 19a or 19b through tosylation and subsequent 
azidation, with inversion of configuration at the β position. The Boc and hydrazide protecting groups 
were removed with TFA and NBS, respectively. Fmoc groups were installed on the resulting amino acids 
to yield the protected amino acids 20a or 20b, ready for Fmoc-SPPS (Scheme 2). After eight cycles of 
deprotection and coupling with the adequate residues, the terminal amine was deprotected then acetylated. 
The resin bound peptide azides 21a and 21b were reduced to their corresponding amines 22a and 22b. 
The amine 22a was converted into the guanidine derivative 23, directly onto the resin. The cleavage and 
global deprotection of 22a, 22b and 23 gave the peptide inhibitors 14, 15 and 16, respectively. 
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Scheme 2. Synthesis of peptide inhibitors 14–16 with modified residues. 
The data reported in Figure 29 show that, among the new inhibitors with straight chains (7–13), 12 is as 
potent as ML 5. This suggests that the salt bridge between the guanidinium ion of Agp (2-amino-3-
guanidinopropionyl) in 12 and the carboxylate of Asp160 in PACE4 is in fact almost as effective as the 
β-sheet inducing effect of Val in 5. The salt bridge is not as strong with a simple ammonium ion as in 13. 
Methyl groups were then introduced at the β-position of Dap (2,3-diaminopropionyl) in 13 to transform 
it into a β-sheet inducer like Val in ML 5. It appeared that only one isomer, S-i-Dab (2S,3S-
diaminobutyryl), produced the expected additive effect. The corresponding inhibitor 14 is now more 
potent than 5, whereas its stereoisomer 15 is even less active than its parent 13. The inhibitors 14 and 15 
were docked into a model of PACE4 to compare their geometry with 5 (Figure 30). To satisfy the salt 
bridge structural requirements, the methyl group has to orient toward (for 3-S isomer) or away (for 3-R 
isomer) from the β-sheet hydrogen bond. The orientation of the β-methyl and β-ammonium groups of S-
i-Dab (14) is the same as the Val methyl substituents in the crystal structure of furin.74, 159 We assume 
that only this orientation is prone to induce the β-sheet conformation of the inhibitor ligand. This is 
supported by the χ1 value of S-i-Dab (-37 o) corresponding precisely to an antiparallel β-sheet.193 
Whereas, in inhibitor 15, the salt bridge between the ammonium group of R-i-Dab and D160 forces the 
residue to adopt a χ1 value (-160o) normally found in parallel β-sheets. This phenomenon is obviously 
fighting the natural antiparallel mode of binding of inhibitors of PACE4. Consequently, the PACE4-15 
complex is probably less stable than the stereoisomeric complex between PACE4 and 14. 
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Figure 30. Docking of inhibitors 14 and 15 in PACE4. S-i-Dab from 14 (left) and R-i-Dab from 15 (right) 
in the S3 pocket of a PACE4 homology model. 
On top of the beneficial β-sheet stabilization in peptide 14, it is also likely that the isopropyl group 
orientation could affect the solvation profile of β-sheet hydrogen bonds, by screening them from external 
water molecules. Such shield effect is absent in inhibitor 15. 
Because inhibitor 14 has the correct stereochemistry for optimal binding, its equivalent guanylated 
analogue 16 was investigated. Some degree of synergy appears to be at work in its mode of inhibition, 
because it is eight times more potent for PACE4 than ML 5, while two times more selective (20-fold vs. 
40-fold, respectively). 
To gather additional support for our hypothesis that β-branching of P3 residue might affect the 
conformation of peptide inhibitors; we recorded the CD spectra of inhibitors 5 and 6. We were expecting 
to witness different conformational behaviors. Unfortunately, both octapeptides displayed identical 
random coil spectral patterns. We then turned our attention to molecular dynamics (MD) simulations on 
a PACE4 homology model in coordination with the two tetrapeptides Ac-RVKR-NH2 and Ac-RAKR-
NH2 as ligands. Because the P3 side chains in these two model peptides are solvent exposed and have no 
interactions with the target enzyme, effect of β-branching on conformation could be investigated 
independently. The Ramachandran plot parameters, Φ and Ψ as descriptors of conformations, were 
analyzed for the P3 residue during the simulation (Figure 31a). The two tetrapeptides adapt different 
conformations described by the ∠N-H···O hydrogen bond angles (α1 and α2) between the P3 residue and 
Gly158 backbones (Figures 30 and 31b). During the MD simulations, the values of these angles for the 
Val residue remain consistently larger (average α1 of 149o and α2 of 159 o) than for the Ala residue 
(average α1 of 115o and α2 of 130o). Because the ideal α1 and α2 angles for an antiparallel β-sheet, are 
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160o ± 10o,194 the Val residue, in the model tetrapeptide, mostly adopts an antiparallel β-sheet con-
formation. Whereas the Ala equivalent in P3 is mainly in the poly-Pro II (PPII) helix region, which is 
often observed in β-turn residues. 
Figure 31.MD simulation (1 ns) of Ac-RVKR-NH2 and Ac-RAKR-NH2 docked in a PACE4 homology 
model. a) Ramachandran plots for the P3 residues. The F and Y angles for Val correspond to an 
antiparallel β-sheet, whereas those for Ala correspond to a PPII helix. b) Variations of the hydrogen bond 
angles a1 and a2 (∠N-H···O) between Gly158 of PACE4 and the P3 residues of the inhibitor backbones. 
These computational data add credibility to the idea that β-branched residues like Val, S-i-Dab (as in 14) 
and S-i-Agb (as in 16) are β-sheet inducers when located at position P3 of PACE4 (as well as furin) 
inhibitors structurally related to 5. 
1.5. Conclusion 
In summary, we introduced a new basic β-branched amino acid (S-i-Agb in 16) to the P3 position of the 
PACE4 inhibitor, ML 5, leading to the discovery of a peptidic inhibitor with improved potency and 
selectivity over furin. We propose that this improvement is the result of three additive effects at the same 
P3 position: 1) additional stabilizing electrostatic interactions with Asp160; 2) stabilizing hydrophobic 
interaction between the β-methyl substituent (having the correct configuration as in Figure 30, left) and 
the Gly158-Pro159 region of PACE4, and 3) increase in β-sheet propensity resulting from β-branching. 
To the best of our knowledge, the correlation that might exist between β-sheet propensity of inhibitor 
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residues and protease inhibition has not been studied. We suggest that β-sheet propensity improvement, 
coupled with other side chain stabilizing interactions, could be considered as a principle to target other 
proteases as well. 
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1.7. Supporting information 
1.7.1. Chemistry 
All solvents and reagents were obtained from commercial suppliers and were used without further 
purification. All commercial amino acid derivatives and coupling reagents were purchased from Matrix 
Innovation, Inc. (Montreal, QC, Canada) and ChemImpex International (Wood Dale, IL, USA). TentaGel 
S RAM resin (loading: 0.22 mmol/g) was purchased from Rapp Polymer (Tübingen, Germany). HPLCs 
were carried out on an Agilent Technologies 1100 system equipped with a diode array detector (λ = 210, 
214, 230, and 254 nm) and an Agilent Eclipse XDB C18 column (5 μm, 4.6 × 250 mm). SELDI-TOF 
mass spectrometry (ProteinChip, Bio-Rad Laboratories Inc., Hercules, CA, USA) or ESI-TOF mass 
spectrometry and HRMS (TripleTOF 5600, ABSciex; Foster City, CA, USA) used to confirm the identity 
of pure products. The 1H and 13C NMR spectra performed on an either Bruker Spectrospin 300 or Bruker 
Ascend 400 NMR instruments. The following abbreviations were used to describe spin multiplicity: s, 
singlet; d, doublet; t, triplet; quin, quintet; dd, doublet of doublets; and m, multiplet. The concentrations 
for [α]D20 are reported in g.cm-1. 
Peptide Synthesis. All the peptides were synthesized with standard Fmoc-SPPS on Tentagel S-RAM 
using 3eq amino acids, 3eq of HATU as coupling reagent and 9eq of DIPEA as base for coupling and 
20% piperidine/DMF for Fmoc deprotection. N-terminal acetylation of all the inhibitors was done with 
CH2Cl2/acetic anhydride/DIPEA (17:1:1) for 30 min. Peptides were cleaved and deprotected (side chains) 
with a cocktail of TFA/TIS/H2O (38:1:1), stirred for 2H at RT, precipitated by cold ether, washed one 
more time with ether, and lyophilized. The lyophilized peptides were purified on preparative HPLC with 
a gradient of CH3CN/H2O. The fractions were analyzed with a gradient of 10 to 70% of CH3CN and H2O 
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containing 0.1% TFA. The fractions with ˃95% purity were pooled and used for kinetic studies. All 
inhibitors were obtained as TFA salts after lyophilization. The retention time and high-resolution mass 
of all inhibitors is are reported in Table S1. 
Table S1. The HPLC retention time and high-resolution mass of peptide inhibitors with Ac-LLLLRXKR-
NH2 
Inhibitor X 
Exact Mass 
Retention time 
Calculated for Found 
6 Ala [M+2]2+ 512.3611 512.3614 26.73[a] 
7 Lys [M+3]3+ 360.9291 360.9288 16.11[b] 
8 Arg [M+3]3+ 370.2645 370.2645 16.28[b] 
9 Orn [M+3]3+ 356.2572 356.2570 16.19[b] 
10 Agb [M+3]3+ 365.5926 365.5927 16.49[b] 
11 Dab [M+3]3+ 351.5853 351.5853 16.23[b] 
12 Agp [M+3]3+ 360.9207 360.9228 16.29[b] 
13 Dap [M+3]3+ 346.9135 346.9136 25.92[a] 
14 S-i-Dab [M+3]3+ 351.5853 351.5852 25.47[a] 
15 R-i-Dab [M+2]2+ 526.8744 526.8749 25.45[a] 
16 S-i-Agb [M+2]2+ 547.8853 547.8848 26.69[a] 
[a] 50 min and [b] 20 min gradient of 10 to 70% of CH3CN and H2O containing 0.1% TFA 
49 
 
 
Scheme S1. Synthesis of compounds 14, 15 and16 
Reduction of azide group on resin. The resin bound peptide was washed with THF and then a fresh 
solution of 0.2 M SnCl2, 0.8 M PhSH and 1M of DIEPA in THF (12 mL per g resin) was added
195 and 
then stirred for 48h. After SELDI-TOF MS indicated the completion of reaction, resin was washed with 
DMF 3x, MeOH 3x and CH2Cl2 3x. 
Guanylation on resin. A series of reagents was examined for on resin guanylation (Table S2). The best 
results were obtained with N,N′-Di-Boc-S-methylisothiourea and HgCl2 reagents. The resin was treated 
with a solution of 9eq of TEA and 1.5eq of N,N′-Di-Boc-S-methylisothiourea in DMF. It was shaken for 
5 min then 3eq HgCl2 were added and shaking was continued for 2h The completion of reaction was 
monitored with ninhydrin and SELDI-TOF MS then it was washed with 3*DMF, 3*MeOH and 
3*CH2Cl2.  
 
 
 
 
 
50 
 
Table S2. The guanylation conditions 
Conditions Conversion Product 
, DMF, 24h196 
0% N. R. 
, DMF, 24h197 
0% N. R. 
, TEA, HgCl2, 2h 
100% I & II 
, TEA and after 5min HgCl2 ,2h
198 
100% II 
, TEA and after 5min HgCl2 ,2h 
100% II 
 
The overall yields for peptide inhibitors 14, 15, 16 were 35%, 32% and 24% respectively. The yields are 
calculated based on 0.22 g/mol loading of Tentagel S-RAM resin (0.5g). 
Synthesis of unnatural amino acids. The Fmoc-Agb(Boc)2-OH and Fmoc-Agp(Boc)2-OH were 
synthesized from Fmoc-Dab-OH and Fmoc-Dap-OH respectively by a method from literatures and the 
spectroscopical data are identical with the reported one.199 The rest of compounds were synthesized as 
follows.  
Boc-Thr-NHNHBoc (18a):  
 
 
 
To an ice cooled solution of Boc-Thr-OH (18.1 g, 82.6 mmol) and tert-butyl carbazate (11.46 g, 86.7 
mmol) in dry CH2Cl2 (200 mL), 2,6-lutidine (21.8 mL, 165.2 mmol) was added. After 5 min, COMU 
(37.1 g, 86.7 mmol) was added and the resulting mixture was stirred for 18 h at room temperature. The 
solvent was evaporated under vacuum and the residue dissolved in EtOAc, washed several times with 
Sat. NaHCO3 (until the aqueous phase was colorless) then with water, 0.5 N HCl and brine, dried over 
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MgSO4 and concentrated. The crude product was purified by flash chromatography (CH2Cl2/acetone from 
90:10 to 70:30) to yield a colorless solid (19.67 g, 71%).  
[α]D20= −38.1 (c=0.0013 in CHCl3) 
1H NMR (400 MHz, CDCl3): δ (ppm): 1.20 (d, J = 6.15 Hz, 3H), 1.43 (br. s., 9H), 1.44 (s, 9H), 3.96 (br. 
s., 1H), 4.21 (d, J = 5.98 Hz, 1H), 4.30 (d, J = 6.32Hz, 1H), 5.70 (d, J = 7.52Hz, 1H), 7.00 (br. s., 1H), 
8.64 (br. s., 1H). 13C NMR (100 MHz, CDCl3): δ (ppm): 171.3, 156.2, 155.6, 81.9, 80.4, 77.2, 67.3, 28.2, 
28.1, 18.2. HRMS (ESI-TOF): m/z found 334.1969 [M+H]+ (calcd. for C14H28N3O6, 334.1973). 
Boc-allo-Thr-NHNHBoc (18b):  
White solid. 77% yield 
[α]D20= −9.0(c=0.0020 in CHCl3) 
1H NMR (400 MHz, CDCl3) δ (ppm):  1.31 (d, J = 6.32Hz, 3H), 1.44 (s, 9 H), 1.46 (s, 9 H), 3.92 (d, J = 
5.12Hz, 1H), 4.01 - 4.11 (m, 1H),5.54 (d, J = 7.69 Hz, 1H), 6.75 (br. s., 1H), 8.44 (br. s., 1H); 13C NMR 
(100 MHz, CDCl3) δ (ppm): 171.6, 155.9, 155.7, 82.2, 80.6, 77.2, 69.2, 28.3, 28.1, 19.6; HRMS (ESI-
TOF): m/z found 334.1970 [M+H]+ (calcd. for C14H28N3O6, 334.1973). 
tert-Butyl 2-((2S,3S)-3-azido-2-((tert-butoxycarbonyl)amino)butanoyl)hydrazine-1-carboxylate 
19a:  
 
Tosyl chloride (10.29 g, 54 mmol) was added over 30 min to a solution of alcohol 18a (13.9 g, 41.6 
mmol) in 25 mL pyridine at 0°C. After 24h, stirring pyridine was removed by air and remaining oil was 
dissolved in EtOAc and washed 5 times with 0.2 N HCl and brine, dried over MgSO4 and concentrated 
in vacuum to give a white solid, which was dissolved in 150 mL DMF. NaN3 (8,84 g, 136 mmol) was 
added and heated for 18 h at 45 °C. After completion of the reaction, water was added and extracted with 
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Hex/Ether 1:1 three times. The combined organic layers were washed with water and brine, dried over 
MgSO4 and concentrated. The crude product was purified by flash chromatography (Hex/EtOAc 70:30) 
to a white solid (8.2 g, 55% two steps). 
[α]D20= +15.7 (c=0.0017 in CHCl3) 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.38 (d, J = 6.82 Hz, 3H), 1.45 (br. s., 9H), 1.46 (s, 9H), 3.83 (br. 
s., 1H), 4.41 (dd, J = 8.1, 5.3 Hz, 1H), 5.57 (d, J = 8.1 Hz, 1H), 6.82 (br. s., 1H), 8.71 (br. s., 1H). 13C 
NMR (75 MHz, CDCl3) δ (ppm): 168.9, 155.6, 154.0, 81.9, 80.9, 58.1, 56.0, 28.2, 28.1, 14.9. HRMS 
(ESI-TOF): m/z found 359.2035 [M+H]+ (calcd. for C14H27N6O5, 359.2037). 
tert-Butyl 2-((2S,3R)-3-azido-2-((tert-butoxycarbonyl)amino)butanoyl)hydrazine-1-carboxylate 
19b: 
White solid. 62% yield 
[α]D20= +11.1 (c=0.002 in CHCl3) 
1H NMR (400 MHz, CDCl3) δ (ppm): 1.32 (d, J = 6.49 Hz, 3H), 1.45 (s, 9H), 1.45 (s, 9H), 4.14 (m, 1H), 
4.32 (m, 1H), 5.52 (br. s., 1H), 6.91 (br. s., 1H), 8.71 (br. s., 1H). 13C NMR (100 MHz, CDCl3) δ (ppm): 
169.1, 155.9, 155.0, 81.7, 80.7, 58.4, 56.4, 28.1, 28.0, 15.9. HRMS (ESI-TOF): m/z found 359.2032 
[M+H]+ (calcd. for C14H27N6O5, 359.2037). 
(2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-azidobutanoic acid 20a:  
 
Azide 19a (10.5 g, 31.5mmol) was dissolved in 60 mL CH2Cl2 at 0°C and 60 mL of TFA was added to 
this slowly. After 2h the solution was evaporated to dryness and triturated with ether. The residue was 
dissolved in 150 mL water and cooled to 0°C. Then a solution of (10.68 g, 60 mmol) NBS in 150 mL 
THF has been added during 30min to this until the solution was remained its yellow color. When UPLC-
MS showed complete conversion, THF was removed under reduced pressure. Thereafter reaction mixture 
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was cooled again in an ice bath and basified slowly with Na2CO3 to pH=8 (it turns red because of Br2) 
and a solution of Fmoc-OSu (9.6 g, 28.3 mmol) in 80 mL THF was added dropwise. Two third of solvent 
was removed after 18h stirring at room temperature and then pH was adjusted to 3 with conc. HCl and 
extracted with CH2Cl2 three times, dried over MgSO4 and concentrated in vacuum. The residue was 
purified by flash chromatography (CH2Cl2/MeOH/AcOH 98:1:1) to a colorless solid (6.57 g, 57%, three 
steps). 
[α]D20=+41.1 (c=0.00085 in CHCl3) 
1H NMR (300 MHz, CD3OD) δ (ppm): 1.32 (d, J = 6.82 Hz, 3H), 3.92 (quin, J = 6.22 Hz, 1H), 4.20 - 
4.29 (m, 1H), 4.33-4.45 (overlapped m, 3H), 7.28 - 7.35 (m, 2H), 7.36 -7.43 (m, 2H), 7.68 (d, J = 7.26 
Hz, 2H), 7.80 (d, J = 7.48 Hz, 2H). 13C NMR (75 MHz, CD3OD) δ (ppm): 172.7, 158.7, 145.3, 142.7, 
128.9, 128.3, 126.4, 121.0, 68.3, 59.3, 59.2, 48.5, 15.4. HRMS (ESI-TOF): m/z found 367.1393 [M+H]+ 
(calcd. for C19H19N4O4, 367.1401). 
(2S,3R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-azidobutanoic acid 20b: 
White solid. 49% yield 
[α]D20=+8.2 (c=0.0011 in CHCl3) 
1H NMR (400 MHz, CD3OD) δ (ppm): 1.31 (d, J = 6.30 Hz, 5H), 4.17 - 4.23 (m, 1H), 4.24 - 4.30 (m, 
1H), 4.33 (d, J = 3.07 Hz, 1H), 4.41 (m, 2H), 7.29 - 7.36 (m, 2H), 7.38 - 7.44 (m, 2H), 7.71 (t, J = 7.43 
Hz, 2H), 7.82 (d, J = 7.52 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ (ppm):  172.5, 156.8, 143.4, 141.3, 
127.7, 127.1, 125.0, 120.0, 67.5, 58.1, 57.7, 47.0, 14.1. HRMS (ESI-TOF): m/z found 367.1394 [M+H]+ 
(calcd. for C19H19N4O4, 367.1401). 
1.7.2. Biology 
For the enzyme kinetics, the human enzymes furin, and PACE4 expressed in Drosophila Schneider 2 cells 
and purified as previously described.80 Enzyme inhibition assays carried out in 100 mM Hepes pH 7.5, 1 
mM CaCl2, 1 mM β- mercaptoethanol, and 1.8 mg/mL BSA for furin, while assaying for PACE4 were 
performed in 20 mM Bis-Tis pH 6.5, 1 mM CaCl2, and 1.8 mg/mL BSA. All assays were performed with 
the 100 μM of substrate pyroGlu-Arg-ValLys-Arg-methyl-coumaryl-7-amide (Bachem, Switzerland) at 
37 °C for 60 min, and real-time fluorescence measurement accomplished using a Gemini EM 96-well 
54 
 
spectrofluorometer (Molecular Devices, Sunnyvale, CA, USA) (λEX., 370 nm; λEM., 460 nm; Cut Off, 435 
nm). Inhibitors (as TFA salts) were added to the wells based on a decreasing concentration. Kinetics 
assays were analyzed using SoftMaxPro5, and Ki values were determined from IC50 using Cheng and 
Prusoff’s equation200 and for those inhibitors who have concentrations equal or less than enzyme in the 
experiment, the Ki were calculated according to the Morrison equation for kinetics of reversible tight-
binding inhibitors.201 
1.7.3. MD Simulation 
The protein-ligand complexes which prepared with Schrodinger package Protein Preparation Wizard,202 
were stated in a sphere of SPC water molecules of radius 100 Å, about 70 000 atoms. We used Gromacs 
4.6.6203-208 for MD simulations of system. For the ligands and proteins the Amber GS force field209was 
used. The first MD simulations step was heating the solvent to 300 K over a period of 20 ps and cooling 
to 100 K over a period of 5 ps, keeping the solute fixed. Then over 25 ps the system was gradually heated 
to 300 K. The simulation was endured for 1050 ps (total time) under constant temperature (body 
temperature, 310 K) and pressure (NPT), applying periodic boundary conditions. Every 10-time steps 
energy data, every 0.5 ps solute coordinates, and every 5 ps solvent coordinates were stored. An 
equilibrated state with respect to the total potential energy and temperature in the system was reached 
after 100 ps. The distance, angles and ramachandran parameters were calculated using gmx distance, 
angle and rama commands, respectively. 
Figure S1: Equilibration of temperature in system and pressure (NPT) during 100 ps 
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CHAPTER 2 : IMPROVING THE SELECTIVITY OF PACE4 INHIBITORS THROUGH 
MODIFICATIONS OF THE P1 RESIDUE 
The current chapter is published ns as a full article in the J. Med. Chem., 2018, 61 (24), pp 11250–11260 
(DOI: 10.1021/acs.jmedchem.8b01381) with the following title, authors and affiliations. 
Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue 
Vahid Dianati,† Pauline Navals, † Frédéric Couture,‡ Roxane Desjardins,‡ Anthony Dame,‡ Anna 
Kwiatkowska,‡ Robert Day‡* and Yves L. Dory†* 
† Institut de Pharmacologie de Sherbrooke, IPS, Département de Chimie, Faculté des Sciences, 
Université de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, Québec J1H 5N4 (Canada) 
E-mail: Yves.Dory@usherbrooke.ca 
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Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, Québec, J1H 5N4 (Canada) 
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2.1. Author contributions 
This work was done in the Institut de Pharmacologie de Sherbrooke of Université de Sherbrooke under 
supervision of Pr. Robert Day and Pr. Yves L. Dory. The original research article by Vahid Dianati, 
Pauline Navals, Frédéric Couture, Roxane Desjardins, Anthony Dame, Anna Kwiatkowska, Robert Day, 
and Yves L. Dory was published in Journal of Medicinal Chemistry. Vahid Dianati, Robert Day and Yves 
L. Dory designed the compounds. Vahid Dianati synthesized all the peptides except compound 8 and its 
Arg mimetic which was synthesized by Pauline Navals. Roxane Desjardins purified the recombinant 
enzymes for kinetic assays. The kinetic assays and cellular assays were performed by Frédéric Couture, 
Roxane Desjardins, Anna Kwiatkowska and Anthony Dame. Vahid Dianati, Robert Day and Yves L. 
Dory analyzed the data. Vahid Dianati wrote the manuscript with notes from Pauline Navals, Frédéric 
Couture and Anna Kwiatkowska, and revisions from Robert Day and Yves L. Dory. 
56 
 
2.2. Abstract 
Paired basic amino acid cleaving enzyme 4 (PACE4), a serine endoprotease of the proprotein convertases 
family, has been recognized as a promising target for prostate cancer. We first reported a selective and 
potent peptide-based inhibitor for PACE4, named the multi-leu peptide (Ac-LLLLRVKR-NH2 
sequence), which was then modified into a more potent and stable compound named C23 with the 
structure; Ac-DLeu-LLLRVK-Amba (Amba: 4-amidinobenzylamide). Despite improvements in both in 
vitro and in vivo profiles of C23, its selectivity for PACE4 was significantly reduced. We examined other 
Arg-mimetics instead of Amba to regain the lost selectivity. Our results indicated that the replacement of 
Amba with 5-(aminomethyl)picolinimidamide significantly increased the affinity for PACE4 and 
restored selectivity. Our results also provide a better insight on how structural differences between S1 
pockets of PACE4 and furin could be employed in the rational design of selective inhibitors. 
2.3. Introduction 
There is substantial evidence that proprotein convertases (PCs) are broadly involved in the malignancy 
of tumors and angiogenesis.210 This family of serine endoproteases consists of seven members namely 
PC1/3, PC2, furin, PACE4, PC4, PC5/6 and PC7, which process their substrates at the consensus motif 
of R-X-R/K-R-↓-X, X being any amino acid residue.86 The role of PCs in malignancies is through the 
activation proteolysis of oncogenic precursor proteins. Among these substrates, growth factors and their 
receptors (e.g, transforming growth factor-β and insulin-like growth factor-1 receptor family members) 
are crucial for cell growth. Other PC substrates, such as proteases from ADAM (a disintegrin and 
metalloproteinase) and Matrix-metalloprotease families, as well as adhesion molecules (e.g. E-cadherin) 
are crucial for cell adhesion and metastasis.106 Additionally, the list of substrates includes other regulatory 
proteins, along with bacterial and viral toxins.211 
The cellular overexpression of PCs provides a clue for their role in tumorigenesis, as observed in many 
malignant cell types.94 This is the case for PACE4 which is overexpressed in prostate cancer (PCa) and 
related cell lines.108, 111-112, 114, 117 mRNA silencing studies demonstrated that inhibition of PACE4 had 
effects on tumorigenesis and neovascularization PCa cell line and animal models.170 More recently, pro-
growth differentiation factor-15 (pro-GDF-15) was identified as a PACE4 specific substrate in PCa 
involved in the proliferative phenotype. A PACE4 isoform, known as PACE4-altCT is overexpressed in 
PCa cell lines has been found to be responsible for sustained tumor progression.91 It is clear that PACE4 
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inhibition could open a new therapeutic strategy for PCa either as mono or co-therapy, thus justifying our 
increased efforts to develop clinically relevant PACE4 inhibitors. 
In a previous study, we showed that the lipophilic tail composed of four leucine residues attached to the 
N-terminus of the RVKR tetrapeptide, was critical to increase the selectivity of PACE4 inhibitors. Thus, 
our octapeptide, named Multi-Leu peptide (compound 1), inhibits PACE4 and furin with Ki = 22 and 430 
nM, respectively (Figure 32).166 The replacement of P1-Arg with 4-amidinobenzylamide (Amba) and 
P8-Leu with its D isomer resulted in our current lead, named C23 (compound 2; Figure 32), with 
improved PACE4 affinity (Ki = 4.9 nM). Whereas the Multi-Leu peptide 1 was rapidly metabolized when 
tested in vivo, C23 was much more stable and consequently displayed prominent pharmacological 
efficiency (IC50 = 25 and 45 µM for DU145 and LNCaP PCa cells, respectively) with rapid uptake by 
xenografted tumors, and a human plasma half-life of 1.7 h.168, 170 However, Amba develops stronger 
interactions with furin S1 pocket compared Arg C-terminal residue in compound 1 resulting in a 
significant reduction in selectivity (only 2-fold) for PACE4 over furin. The furin preference for P1-Amba 
is even more visible with the tetrapeptide Ac-RVK-Amba. This simple ligand is twice as selective toward 
furin, emphasizing on the undeniable role and necessity of the four leucine-tail for PACE4 selectivity.157 
Figure 32. Structure of control PACE4 inhibitors 
In another study, we successfully improved the selectivity of the multi-Leu peptide by introducing β-
branched basic residues in the P3 position. This led to a 40-fold selective inhibitor.212 However, further 
studies determined that this type of compound, harboring four consecutive basic residues, was devoid of 
PCa cells antiproliferative activity, suggesting a lack of cell penetration to reach the PACE4-altCT 
intracellular target. Trials to improve the selectivity of C23 by manipulating its P5-P8 portion met with 
limited success (3-fold selectivity in favor of PACE4). All these data reveal that the Amba residue 
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constitutes a barrier for achieving more selective compounds.171 This work relates our efforts to find 
alternative residues that could successfully replace Amba at the P1 position. 
Homology models of PACE4 suggest that the S1 pocket, which accommodates the P1 residue of the 
inhibitors, is constructed from two remote regions (primary structure): the first one described as a β-sheet 
then loop motif runs from S305 to G319 and the second one, a loop−helix−loop, encompasses residues 
S345 to I364. These two parts of the cleft are clamped together by means of several interactions including 
a Ca2+ cation involved in salt bridges with D310, D353, D358, and E381 (Figure 33).87 The guanidinium 
ion of the P1 residue (Ac-RVKR-NH2) is strongly held inside the S1 pocket by means of ionic forces with 
aspartates 310 and 358, as well as ion−dipole interactions with the carbonyl groups of P308 and A344. 
These interactions are identical within all PCs.87 However, despite the high degree of homology in and 
around the S1 pocket, differences exist, as observed in the matching sequences 300HDSCN and 352GDYCS 
of furin and PACE4, respectively (see Figure 33). One hypothesis is that these disparities, that concern 
three residues only, alter the shape of the S1 pocket in furin and PACE4 and can be held responsible of 
the observed selectivity differences between compounds 1 and 2.  
Figure 33. The stereo representation of PACE4 P1–P4 active site with the Ac-RVKR-NH2 (orange) 
inhibitor. The Ca2+ cation (green sphere), located deep inside the S1 subsite, is essential for its stability. 
Generally, refining the selectivity is more laborious than enhancing the potency,213 and given the high 
degree of homology between furin and PACE4, discrimination between these two enzymes is 
challenging. Although C23 is highly potent to block tumor progression of xenograft PCa animal models, 
inhibition of the most ubiquitous member of the PC family, furin, could potentially lead to unforeseen 
side effects and drawbacks. In the present study, new residues are rationally designed, then introduced in 
the P1 position, based on available structural data and structure activity relationship (SAR) studies 
conducted on both PACE4 and furin. The main goal of our investigations is to determine the structural 
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factors (P1 position) that might discriminate between PACE4 and furin, in order to create potent and 
selective PACE4 inhibitors. 
2.4. Results and discussions 
2.4.1. Design and binding affinities 
Two groups of mimetics were designed (and biologically tested: PACE4 and furin Ki, DU145 and LNCaP 
cell lines IC50) for the P1 residue of PACE4 inhibitors (Figure 34): (a) an aliphatic series in which 
inhibitors 3−6 possess a guanidine group like Arg itself; and (b) an aromatic series whose members 7−13 
bear an amidine function like Amba. Compound 3 is an epimer of 1 at position P8. Both compounds have 
similar Ki values, but 3 is more selective (PACE4 Ki = 24 nM, 32 times selective for PACE4). The D 
residue at position P8 imparts metabolic stability and this is likely the reason why 3 is endowed with an 
improved ability to inhibit PCa cells proliferation. Accordingly, all newly synthesized inhibitors 
discussed in this work have a DLeu residue at position P8, like compounds 2 and 3.167 The first two 
derivatives 4 and 5 were rigidified analogs of 3, from which the terminal amide had been removed 
(agmatine). The alkene 4 proved to be much better than the alkyne 5.168 The improved affinity of 4 (Ki = 
13 nM), compared to compound 3, however was associated with substantial reduction of selectivity (3-
fold for PACE4). Conversion of the C-terminus amide to an alcohol moiety in 6 resulted in a poor and 
non-selective inhibitor of PACE4. These observations are, however, consistent with the poor inhibition 
of peptide alcohols reported for other serine proteases.214-215  
Together with the Amba derivative 2, the compounds 7 and 8 were used to carry out a preliminary SAR 
study of the aromatic amidine. Contrary to the Arg analogs 3−6, the side chain of Amba is more rigid and 
it is also bulkier.87, 159 It is anticipated that the amidine group will be held in the S1 pocket by the enzyme 
residues interfering with the equivalent guanidine of Arg (Figure 33 and 36). As can be observed, P308 
and A344 carbonyls, and D310 and D358 carboxylates bind tightly to the two external NH2 parts of the 
guanidinium ion. Additionally, D310 develops an extra interaction with the arginine delta-NH, so any 
designed mimics ideally need an equivalent hydrogen bond donor. Obviously, this latter interaction 
cannot exist in an amidinium ion.  
First, the analogues 7 and 8 were designed to assess the width and length of the S1 pocket. Further 
extension of Amba with one methylene unit, producing inhibitor 7, not only did not offer any 
improvement in selectivity, but also reduced the binding affinity (PACE4 Ki = 17 nM). The tetra-
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fluorinated Amba derivative 8 has very little affinity toward PACE4 and furin. There are two possible 
explanations for this negative result: either the S1 pocket is too narrow to accommodate the four fluorine 
atoms or the positive charge is absent because the calculated pKa of the tetrafluoro-benzamidine is as low 
as 6.9.216  
According to plans, O and NH substituents were introduced at the ortho position of the amidine, inside a 
fused 5-membred ring as in 9 and 10 respectively, then as free phenol 11 and aniline 12. Finally, the 
pyridine 13 was designed as a more direct mimetic of 2, because it could fill up the same space in the S1 
pocket. The inhibitor candidates 9–13 were synthesized then tested biologically. The bicyclic systems 9 
and 10 proved essentially inactive; whereas, the Ki values of the corresponding open systems, 11 and 12, 
are in the same range as those of Multi-Leu 1 and its diastereomer 3, albeit with lower selectivities. 
Compound 13 is indeed a strong and selective inhibitor (Ki = 2.6 nM, PACE4). The P1 residue of 
compound 10 has been recently used in P1 of furin inhibitors with no success.161 
Figure 34. Structure of P1 arginine mimetics used for PACE4 inhibitors with general structure of Ac-
DLeu-Leu-Leu-Leu-Arg-Val-Lys-NHR apart from 1. a with Leu at position P8 instead of DLeu. The 
inhibition of PACE4 and furin are represented as Ki ± standard deviation, and antiproliferative activity 
on PCa cell lines as IC50 ± SEM. Data adapted from Ref.
166 (bData adapted from Ref.168; cNot calculable, 
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indicates that the curve did not converged to 50% with doses up to 150 µm; dNot determined, because of 
solubility/precipitation problems. 
In order to provide a rational for the various Ki values, that are linked to the mode of binding of the P1 
side chains, density functional theory (DFT) calculations were run (Figure 35). These calculations were 
intended to disclose the minimum energy conformations of Amba derivatives and other relevant 
properties. The pKa figures of the amidinium ions and ortho functional groups were also estimated. It was 
first confirmed that the rigid Amba (side chain in Figure 35b) is indeed a good mimic of Arg (Figure 
35a). For these two P1 residues, the distances between the Cα and the central cation C atoms are 6.24 Å 
and 5.78 Å for Arg and Amba respectively (Figure 36). Amba, being slightly shorter, can fit in the S1 
cavity without much distortion. This does not hold true for the longer Amba analog 7, as demonstrated 
by its lower affinity (17 nM). In terms of charges, both guanidine and amidine are also similar since they 
exist as guanidinium and amidinium cations at physiological pH. By incorporating these functional 
groups in rings through addition of O and NH atoms, the resulting bicyclic systems (Figure 35c,d) are 
fully aromatic. Consequently, their N atoms are no longer basic (pKa: 1.0-3.5) and do become positively 
charged at physiological pH. As for compound 8 (mostly neutral at pH 7.4), which suffered the same 
drawback, the affinities of analogs 9 and 10 are drastically diminished. Upon breaking the N-O and the 
N-N bonds, the amidine moiety becomes strongly basic (Figure 35e,f) and the corresponding 
peptidomimetics 11 and 12 recover some inhibitory activity, the aniline 12 being much stronger than the 
phenol 11 (Figure 34). Calculations show that at physiological pH (7.4), the phenolate anion is the 
predominant species. Since a negative charge in that region of the inhibitor may lead to unfavorable 
interactions with the carboxylate of D310 (Figures 36), this may easily account for the lower affinity of 
inhibitor 11 for both furin and PACE4. In addition, the introduction of the aniline and phenol groups 
increases steric hindrance in the deep S1 subsite and may explain why both 11 and 12 are less potent than 
2. 
Despite its additional NH2 group, the aniline (Figure 35f) is geometrically very close to its parent amidine 
devoid of substituents (Figure 35b). For both cases, the amidinium plane is rotated relative to the 
aromatic ring by ~ 35°. Surprisingly, this torsion angle is smaller in the case of the aniline, because of its 
ortho position that induces the formation of an intramolecular hydrogen bond N−H∙∙∙N. However, for 
obvious steric reasons, the aniline-substituted amidine is prevented from reaching a fully flat geometry, 
contrarily to the simpler amidine that can, at a cost of 2.8 kcal/mol according to DFT calculations. The 
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Ki values (PACE4) for the corresponding inhibitors 2 and 12 are 4.9 and 14 nM, respectively (Figure 
34).  
Figure 35. Energy-minimized (DFT) side chain conformers of arginine (a) and arginine mimetics (b,e−g) 
and estimated pKa values of relevant functional groups. Torsion angles between amidine and aromatic 
planes are shown (θ). 
The best compound of the whole series is the pyridine 13, in terms of affinity for PACE4 (2.6 nM) as 
well as selectivity (8 for compound 13 compared to only 2 for compound 2). This overall beneficial effect 
does not arise from a better electronic complementarity with D310, because the pyridine nucleus is so 
electron-deficient that it is not basic at all (pKa: -1.6, Figure 35g) and remains neutral at all pHs. 
Nevertheless, the lone pair of the pyridine is ideally positioned in yet another intramolecular hydrogen 
bond N∙∙∙H−N with the neighboring amidinium partner. As a result, the terminal side chain of 13 is very 
flat indeed, its torsion angle θ is as small as 7°, a significant gain of 30° by comparison with isosteric 
peptide mimic 2 (see Figure 35b and 35g). Induced-fit docking models (Figure 36) suggest that the 
pyridine N atom makes no additional interaction with PACE4, in which case its sole purpose is to freeze 
the amidinium side chain in its flat conformation. From all these results, it can be inferred that a planar 
conformation of the P1 residue might fit better in PACE4 S1 pocket compared to furin. 
 
63 
 
Figure 36. Superimposed induced fit docking pose of Ac-RVKX corresponding to the P5−P1 region of 
compounds 1 (orange) and 13 (green) in the PACE4 homology model active site. 87 Enzyme’s side chain 
C atoms colored the same as corresponding ligand for clarity. H, N and O atoms are in white, blue and 
red color, respectively. The H bonds represented as yellow dashes. 
2.4.2. Cell-based assays 
In order to evaluate the cell antiproliferative activity, all the inhibitors were tested against PCa cell lines 
(DU145 and LNCaP) using an MTT proliferation assay (Figure 34). In terms of cell-based efficacy, 
neither compounds 4 nor 5 showed significant advantage over compound 3 despite their differences in 
PACE4 affinity and selectivity. However, the poor affinity of inhibitor 6 for PACE4 entirely translated 
into antiproliferative activity, and no effect was observed on both cell lines for this inhibitor in 
concentrations below 150 µM further depicting the relationship between the anti-proliferative response 
and PACE4 inhibition.  
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Figure 37. Cell permeability comparison of FITC-labeled analogues of compounds 2 and 13. 
Inhibitors 9 and 10, precipitated during the assay and, thus, their IC50 values were not measurable. 
Analogues 7, 8, 11 and 12 which are less potent PACE4 inhibitors compared to the parent compound 2, 
displayed inferior antiproliferative activity (Figure 34). Conversely, inhibitor 13 (IC50 = 130 and 140 µM 
for DU145 and LNCaP cells, respectively) displayed lower antiproliferative activity than control 
compound 2 (IC50 = 25 and 45 µM for DU145 and LNCaP cells, respectively). Knowing the requirements 
of PACE4 inhibition to reach the intracellular PACE4 for efficient antiproliferative activity, the cell 
permeability of 13 was tested using a N-terminally FITC labelled version (compound 15).91, 166, 173 
However, the results depicted no considerable difference in the permeability compared to control FITC-
labeled analogue 14 corresponding to inhibitor 2 (Figure 37).  
Overall, compound 13 with the best affinity for PACE4 and reasonable selectivity among the P1 modified 
inhibitors provided reasonable antiproliferative activity in PCa cell lines. The Ampa could be an 
appropriate P1 residue for further development of more selective PACE4 inhibitors.  
2.4.3. Chemistry 
All the peptides 5 and 7−13 were synthesized using a combination of solid and solution phase peptide 
synthesis as reported earlier for compound 2.168 Briefly, the fully protected P8−P2 peptide was 
synthesized with conventional Fmoc-tBu strategy on a 2-chlorotrytylchloride resin. After coupling of the 
last amino acid and removal of the Fmoc protective group, the peptide was acetylated and then cleaved 
from the resin under mild acidic conditions. The P1 residue amines were then coupled with the protected 
peptide in solution. The fragment coupling procedure used to connect the heptapeptide to arginine 
mimetic synthons may obviously lead to some degree of epimerization at the P2 position, the lysine 
residue. However, the final products were proven to be pure by 1H NMR spectroscopy after reverse-phase 
(RP) preparative high-performance liquid chromatography (HPLC). Compound 6 was prepared in a 
different manner using a literature’s method for the synthesis of C-terminal alcohol peptides.217 In the 
final step, the side chains of all the peptides, were deprotected using TFA cocktails. The FITC-labeling 
of compound 15 was carried out as previously reported for compound 14.168 
The alkyne 18, P1 residue of compound 5, was obtained from two consecutive Mitsunobu reactions on 
2-butyne-1,4-diol 16 and a final phthalimide deprotection (Scheme 3). For the P1 residues of 9 and 10, 
compound 19 was converted to a dinitrile 20. The regioselective formation of 5-membered ring, was 
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followed by reduction of remaining nitrile moiety to yield compounds 21 and 22. The inhibitor 11 was 
then prepared by catalytic hydrogenation of inhibitor 9.  
Scheme 3. Synthesis of P1 arginine mimetics for inhibitors 5, 9 and 10. Reagents and conditions: (a) 
phthalimide, DIAD, PPh3, THF, 0 
oC to rt, 16 h; (b) N,N'-Di-Boc-guanidine, DIAD, PPh3, THF, 0 
oC to 
rt, 16 h; (c) N2H4.H2O, CHCl3/MeOH, 4 h; (d) Pd(PPh3)4, Zn(CN)2, DMF, 80 
oC, 6 h; (e) AcNHOH, 
K2CO3, DMF, 12 h; (f) BH3-THF 1 M in THF, 0 
oC to rt, 6 h; (g) N2H4.H2O, n-BuOH, reflux, 16 h. 
The synthetic pathways of four other P1 residues are outlined in Scheme 4. Compound 25 was obtained 
by condensation of 4-formylbenzonitrile 23 with nitromethane prior to consecutive reduction of the 
double bond and nitro group and then Boc protection of the resulting amine giving compound 25. The 
nitrile group of this compound was then converted to an amidine and the Boc protection was removed to 
afford compound 26.218 Nitromethane was also employed in a SNAr2 reaction to prepare 28 from 
pentafluoro-benzonitrile 27. The nitro product 28 was transformed to the Arg mimetic 29 by conversion 
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of nitrile to amidine. The final step of the conversion to 29 included a catalytic reduction which the 
nitromethyl moiety was reduced to the aminomethyl as well. The benzylic alcohol 31 was prepared by 
oxidation of the methyl substituent in the starting material 30. The alcohol 31 was transformed to the 
corresponding tosylate, and then azide, which was finally converted to the Boc-protected amine 32 via a 
Staudinger reaction. The nitrile of 32 was transformed into an amidine as before (25 to 26), during which 
process the nitro group was also reduced to an aniline (step f in Scheme 4). Cleavage of the Boc group 
yielded the amine 33. The bromide in 34 was replaced by a nitrile, then its ester was reduced to the 
benzylic alcohol 35. Mitsunobu reaction on 35, using phthalimide as nucleophile, followed by hydrazine 
opening of the resulting phthalimide led to the corresponding amine, that was immediately protected as 
its t-butyl carbamate 36. From there, the same three-step procedure used to prepare 26 from 25, and 29 
from 28, was applied to 36 to obtain the amine 37. 
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Scheme 4. Synthesis of P1 arginine mimetics for inhibitors 7, 8, 12 and 13. Reagents and conditions: (a) 
MeNO2, NaOH, MeOH/H2O, <10-15 
oC, 15 min then 5 M HCl; (b) Bu3SnH, CH2Cl2, rt, 16 h; (c) Zn, 
HCl(aq), 65 oC, 1h; (d) (Boc)2O, K2CO3, THF/H2O, 16 h; (e) NH2OH.HCl, DIPEA, MeOH, 60 
oC, 16 h; 
(f) Ac2O, DIPEA, THF then 10% Pd/C, AcOH/MeOH, 35 atm H2, 12 h; (g) Conc. HCl(aq), MeOH, 0 
oC 
to rt, 1 h; (h) MeNO2, TMG, -35 
oC, 5 min; (i) H5IO6, CrO3, MeCN, 3 h; (j) i-BuOCOCl, NMM, THF, 0 
oC, 2 min then NaBH4 in MeOH, 30 min; (k) TsCl, Et3N, DMAP, MeCN, 1 h; (l) NaN3, NaI, DMF, 1 h; 
(m) PPh3, H2O, THF, 16 h then K2CO3, (Boc)2O, 16 h; (n) Pd(PPh3)4, Zn(CN)2, DMF, 100 
oC, 16 h; (o) 
NaBH4, LiCl, MeOH, 2 h; (p) phthalimide, DIAD, PPh3, THF, 0 
oC to rt, 16 h; (q) N2H4.H2O, 
CHCl3/MeOH, 3 h;  
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2.5. Conclusion 
In conclusion, we developed new inhibitors for PACE4 through SAR studies of the P1 residue. Our results 
emphasize structural differences in the S1 pocket that can be used to discriminate between furin and 
PACE4. This could open a novel avenue for achieving higher selectivity. Inhibitor 13 is the most potent 
and selective inhibitor in the series and displayed Ki = 2.6 nM which is 2-fold more potent and 4-fold 
more selective than C23 (compound 2). Although the P1-Ampa in 13 introduces the same stabilizing Van 
der Waals contacts as Amba in 2, the former is held rigidly (intramolecular H bond) in a flat conformation, 
suggesting that its gain in affinity for PACE4 might precisely results from this rigidifying process. Despite 
similarities in structures and cell permeabilities, surprisingly, compound 13 exhibited lower efficiency in 
PCa cell antiproliferative assay compared to 2. Further studies may provide the knowledge to explain this 
impairment, however, this significant improvement at the P1 position can now be used in combination 
with other modifications at other positions. 
2.6. Experimental 
2.6.1. Chemistry 
All chemical reagents and solvents were obtained from commercial resources and used without further 
purification. Fmoc-protected amino acids and coupling reagents, were purchased from ChemPep (Miami, 
FL, USA) or Chem-Impex International (Wood Dale, IL, USA), and 2-chlorotrityl-chloride resin from 
Rapp Polymer (Tübingen, Germany). Other reagents were purchased from Sigma Aldrich (St. Louis, MO, 
USA). Manual Fmoc/tBu strategy was utilized for peptide synthesis. Analytical reverse phase HPLC was 
performed on an Agilent Technologies 1100 system equipped with a diode array detector (λ = 210, 214, 
230, and 254 nm). Preparative HPLC were accomplished on a Waters preparative HPLC machine 
[Autosampler 2707, Quaternary gradient module 2535, UV detector 2489 (λ = 214 and 230 nm), fraction 
collector WFCIII] equipped with an ACE5 C18 column (250 × 21.2 mm, 5 μm spherical particle size). 
Analytical HPLC was carried out using C18 columns, either Agilent Eclipse XDB (5 mm, 4.6 μm, 250 
mm) or a Phenomenex Jupiter (5 mm, 4.6 μm, 250 mm). A gradient of H2O/MeCN containing 0.1% TFA 
was used as eluent for both analytical and preparative HPLC. The identity of the pure products was 
confirmed using an ESI-HRMS system (TripleTOF 5600, ABSciex; Foster City, CA, USA). For synthesis 
check a Water H Class Acquity UPLC coupled with an SQ Detector 2 and a PDA eλ detector paired with 
an Acquity UPLC CSH C18 column (1.7 μm×2.1 mm×50 mm) was used  with a linear gradient from 5 
to 95% of MeCN containing 0.1% formic acid in 0.1% aqueous formic acid was used for 1.3 min and a 
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flow rate of 0.8 mL/min. NMR experiment were carried out on either AV300 Bruker (300 MHz for 1H 
and 75 MHz for 13C), Avance III hd 400 Bruker (400 MHz for 1H , 377 MHz for 19F and 100 MHz for 
13C) or Agilent Varian (600 MHz for 1H). Complete decoupling of protons was applied in 13C NMR 
experiments. The new compounds were additionally characterized with IR spectroscopy (Alpha-Platinum 
ATR Bruker, diamond crystal). The purity of biologically tested compounds 5−13 and 15 were confirmed 
to be more than 95% using RP analytical HPLC and 1H NMR (13). The compounds were characterized 
by HRMS. 
Peptide synthesis general procedures. Compounds 5 and 7−10, 12 and 13 were provided as follows: 
Fmoc-Lys(Boc)-OH (1.2 equiv) was attached to a 2-chlorotrityl chloride resin in the presence of N,N-
diisopropylethylamine (DIPEA) (4 equiv) in dimethylformamide (DMF) for 3 h. The resin was washed 
using a sequence of DCM (3×), a cycle of MeOH/DCM (3×) and DCM (5×). The peptide chain was 
elongated by standard Fmoc-SPPS. The Fmoc group was removed with 20% piperidine in DMF. The 
Fmoc-protected amino acids were coupled using 5 equiv of protected amino acids, 5 equiv of HATU, and 
15 equiv of DIPEA in DMF for 45 min. The last residue was acetylated by a solution of 
Ac2O/DIPEA/DCM (5:10:85) for 30 min. Each protected peptide was released from the resin with a 
solution of 20% hexafluoro-2-propanol (HFIP) in DCM. The solvents were evaporated in vacuo, and the 
residue was lyophilized in tert-BuOH/H2O (50:50). DIPEA (7.5 equiv) was added to an ice-cooled 
solution (0 °C) of protected peptide, arginine mimetic (2.5 equiv), benzotriazol-1-yl-oxytripyrrolidino-
phosphonium hexafluorophosphatehexafluorophosphate (2.7 equiv), and 6-chloro-1-
hydroxybenzotriazole (7.5 equiv) in DMF, and the reaction was stirred overnight at room temperature. 
The solvent was removed with an air stream to afford the crude protected peptide. The final deprotection 
of side chains was achieved by a solution of H2O/TIPS/TFA (2.5:2.5:95) for 2 h. Purification with RP 
preparative HPLC (gradients of H2O/MeCN containing 0.1% TFA) resulted in pure peptides as their TFA 
salts after lyophilization.  
Compound 6. Fmoc-Arg(Pbf)-ol (0.63 g, 0.99 mmol)219 was added to a 2% solution of DBU in DMF 
(7.0 mL) and agitated with 2-chlorotrytylchloride resin (0.3 g, 0.33 mmol) for 7 h. Fmoc-Lys(Boc)-OH 
(0.93 g, 1.98 mmol) was coupled to the free alcohol using DIPEA (0.15 mL, 0.99 mmol) and DMAP 
(0.01 g, 0.11 mmol). Then, the peptide was synthesized via deprotection/coupling cycles on the resin as 
previously mentioned in the general procedure for peptide synthesis. After final acetylation, the protected 
peptide was obtained by treating the resin with a 25% solution of HFIP in DCM (5.0 mL). Solvents were 
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removed, and the O−N acyl migration was performed by stirring a solution of the resulting crude product 
in 20% piperidine in DMF (4.0 mL) for 1 h. Global deprotection was carried out as mentioned in the 
general procedure for peptide synthesis. The crude peptide was purified by preparative HPLC as 
described in the general procedure. 
Compound 11. The peptide inhibitor 9 (0.05 g, 0.05 mmol) was dissolved in MeOH/H2O (50:50, 4.0 
mL). 10% Pd/C (50 mg) was added and the slurry was stirred under H2 (1 atm) for 16 h. After the 
completion of reaction (monitored by UPLC-MS), the reaction mixture was filtered through a pad of 
diatomaceous earth. The pad was washed with distilled water and the filtrate evaporated to dryness with 
a stream of air. The residue was purified by reversed phase preparative HPLC as described in general 
procedure. 
Compound 13. 1H NMR (600 MHz, D2O): δ (ppm) 8.64 (d, J = 1.8 Hz, 1H), 8.01 (d, J = 7.9 Hz, 1H), 
7.94 (dd, J = 7.9, 1.8 Hz, 1H), 4.55 (AB d, J = 15.6 Hz, 1H), 4.49 (AB d, J = 15.6 Hz, 1H), 4.32−4.16 (m, 
6H), 4.04 (d, J = 7.9 Hz, 1H), 3.14 (m, 2H), 2.96 (quin, J = 6.1 Hz, 2H), 2.01 (m, 1H), 1.97 (s, 3H), 
1.86−1.70 (m, 4H), 1.70−1.49 (m, 16H), 1.45 (m, 1H), 1.37 (m, 1H), 0.92−0.80 (m, 30H). 
N-(4-Phthalimido-but-2-ynyl)-N',N''-1,3-bis(tert-butyloxycarbonyl)guanidine (17). 
4-N-Phthalimido-but-2-yn-1-ol was obtained as a colorless solid in 52% yield using a reported procedure 
with all obtained spectra agreed with the literature.220 1H NMR (400 MHz, CDCl3) δ (ppm): 7.88 (dd, J 
= 5.4, 3.0 Hz, 2H), 7.75 (dd, J = 5.4, 3.0 Hz, 2H), 4.49 (s, 2H), 4.25 (br. s., 2H). 13C NMR (100 MHz, 
CDCl3) δ (ppm): 169.1, 134.2, 131.9, 123.5, 81.4, 79.2, 51.0, 27.2. HRMS–ESI (m/z): [M + H]+ calcd for 
C12H10NO3 216.0665; found, 216.0653. The achieved product (0.66 g, 3.1 mmol) was added to a solution 
of PPh3 (0.78 g, 3.1 mmol), and 1,3-bis(tert-butoxycarbonyl)guanidine in dry THF (5.0 mL). DIAD (0.5 
mL, 3.1 mmol) was added to ice-cooled above solution in a dropwise manner. The reaction stirred for 16 
h at room temperature under inert atmosphere. The colorless title product was isolated by column 
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chromatography with EtOAc/hexanes as eluent (0.87 g, 63%). 1H NMR (400 MHz, CDCl3) δ (ppm): 9.36 
(br. s., 1H), 9.14 (br. s., 1H), 7.88 (dd, J = 5.4, 3.0 Hz, 2H), 7.74 (dd, J = 5.4, 3.0 Hz, 2H), 4.74 (s, 2H), 
4.44 (s, 2H), 1.48 (s, 9H), 1.47 (s, 9H). 13C NMR (100 MHz, CDCl3) δ (ppm): 167.0, 163.4,159.7, 154.2, 
134.1, 132.0, 123.4, 84.5, 79.3, 79.0, 75.6, 34.4, 28.2, 27.8, 27.2. IR (neat) ν (cm-1): 3381, 3279, 3246, 
3029, 2978, 2941, 2358 (weak), 1728, 1686, 1604. HRMS–ESI (m/z): [M + H]+ calcd. for C23H29N4O6 
457.2082; found 457.2068. 
N-(4-Amino-but-2-ynyl)-N',N''-1,3-bis(tert-butyloxycarbonyl)guanidine (18). 
Compound 17 (0.71 g, 1.6 mmol) was dissolved in MeOH (12.0 mL) and CHCl3 (9.5 mL), then hydrazine 
monohydrate 64-65% (1.0 mL) was added to the solution and stirred for 4 h. The white solid byproduct 
was filtered off. The filtrate was evaporated and diluted with more CHCl3 and then washed with 1 M 
sodium hydroxide. The organic phase was dried with magnesium sulfate, filtered and concentrated to 
give the desired product as a brownish yellow solid (0.41 g, 78%). 1H NMR (400 MHz, CDCl3) δ (ppm): 
9.36 (br. s., 1H), 9.14 (br. s., 1H), 4.73 (s, 2H), 3.39 (s, 2H), 1.52 (s, 9H), 1.47 (s, 9H). 13C NMR (100 
MHz, CDCl3) δ (ppm): 163.4, 159.7, 154.3, 84.26, 79.3, 78.9, 34.6, 31.5, 28.2, 27.9. IR (neat) ν (cm-1): 
3380, 2977, 2933, 2370 (weak), 1717, 1610. HRMS–ESI (m/z): [M + H]+ calcd. for C15H27N4O4 
327.2027; found 327.2048. 
2-Fluoroterephthalonitrile (20).  
The yellow slurry of 4-bromo-2-flouro-benzonitrile 19 (1.00 g, 5.0 mmol), Pd(PPh3)4 (0.29 g, 0.25 mmol, 
0.05 equiv) and Zn(CN)2 (0.35 g, 3.0 mmol, 0.6 equiv) in deoxygenated dry DMF (6.5 mL) was heated 
at 80 oC for 6 h. The resulting solution was diluted with EtOAc and washed twice with 2 M ammonium 
hydroxide and brine. A yellow solid was obtained after flash chromatography with 15-20% EtOAc in 
hexanes (0.70 g, 95% yield). The spectroscopic data are in accordance with literatures.221 1H NMR (400 
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MHz, CDCl3) δ (ppm): 7.62 (dd, J = 1.4, 0.6 Hz, 1H), 7.60 (dd, J = 1.4, 0.6 Hz, 1H), 7.56 (dd, J = 1.4, 
0.6 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ (ppm): 162.9 (d, J = 260.0 Hz) 134.5, 128.5, 120.2 (d, J = 
23.0 Hz) 118.4 (d, J = 10.0 Hz) 115.8 (d, J = 3.0 Hz) 112.1, 106.37 (d, J = 15.0 Hz). HRMS–ESI (m/z): 
[M + H]+ calcd. for C8H4FN2 147.0353; found 147.0351. 
6-(Aminomethyl)benzo[d]isoxazol-3-amine (21).  
Acetyl-hydroxamic acid (0.68 g, 9.0 mmol) was dissolved in DMF (12.0 mL). K2CO3 (2.21 g, 16.0 mmol) 
was added, followed by a few drops of H2O. The mixture was stirred at room temperature for 30 min, 
then compound 20 (0.58 g, 4.0 mmol) was added. The stirring was continued for 12 h, and then diluted 
with EtOAc and H2O. The phases were separated, and aqueous phase extracted twice with EtOAc. The 
combined organic phases were dried over MgSO4, filtered and evaporated under vacuum to give a 
colorless solid which was dissolved in dry THF (5.0 mL). A 1 M solution of BH3-THF in THF (12.0 mL, 
12.0 mmol) was added dropwise to the ice-cooled above solution. The stirring was continued for 6 h. 
Then, 6 M HCl (15.0 mL) solution was added to the resulting white slurry and stirred for 2 h. The obtained 
solution was evaporated to dryness and purified by reverse phase HPLC to give the product as a colorless 
solid (0.48 g, 73% for two steps) 1H NMR (300 MHz, D2O) δ (ppm): 7.67 (d, J = 8.1 Hz, 1H), 7.42 (s, 
1H), 7.26 (d, J = 8.1 Hz, 1H), 4.23 (s, 2H). 13C NMR (75 MHz, D2O) δ (ppm): 162.2, 159.0, 135.8, 123.5, 
122.2, 116.3, 110.1, 42.9. HRMS–ESI (m/z): [M + H]+ calcd. for C8H10N3O 164.08184; found 164.0819. 
6-(Aminomethyl)-1H-indazol-3-amine (22).  
A mixture of bis-nitril 20 (0.60 g, 4.1 mmol) and hydrazine hydrate (0.6 mL, 12.3 mmol) in n-butanol 
(16.0 mL) was heated at reflux under inert atmosphere for 16 h. After completion of the reaction, the 
mixture was dried under vacuum and purified by flash chromatography (66−100% EtOAc in hexane as 
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eluent) to yield brown crystalline needles (0.60 g, 93%). 1H NMR (400 MHz, CDCl3): δ (ppm) 11.96 (br 
s, 1H) 7.88 (dd, J = 8.3, 1.0 Hz, 1H) 7.78 (t, J = 1.0 Hz, 1H) 7.21 (dd, J = 8.3, 1.0 Hz, 1H) 5.63 (s, 2H). 
13C NMR (100 MHz, CDCl3): δ (ppm) 149.6, 139.7, 121.9, 119.8, 119.3, 115.7, 114.8, 108.1. This 
compound was treated with BH3−THF, as was mentioned for compound 21’s synthesis, to get 22 as a 
brownish solid (0.58 g, 60%). 1H NMR (300 MHz, D2O): δ (ppm) 4.27 (s, 2H), 7.22 (d, J = 8.4 Hz, 1H), 
7.47 (s, 1H), 7.81 (d, J = 8.4 Hz, 1H). 13C NMR (75 MHz, D2O): δ (ppm) 145.8, 142.5, 137.0, 122.3, 
122.2, 112.1, 111.6, 43.0. HRMS-ESI (m/ z): [M + H]+ calcd. for C8H11N4, 163.0978; found, 163.0966.  
(E)-4-(2-Nitrovinyl)benzonitrile (24).  
A solution of NaOH (0.84 g, 21.0 mmol) in ice-cold water (40.0 mL) was added dropwise to a solution 
of 4-formylbenzonitrile 23 (2.60 g, 20.0 mmol) and nitromethane (1.1 mL, 20.0 mmol) in MeOH (40.0 
mL). The reaction temperature was kept below 10−15 °C during the addition of the NaOH solution. After 
stirring for 15 min, the whole reaction mixture was transferred to a separating funnel and slowly added to 
5 M HCl (100.0 mL). A yellow solid was obtained almost instantly; it was filtered, washed with cold 
water, dried, and recrystallized from hot EtOH to furnish the pure product 24 as yellow needles (1.66 g, 
48%). The spectroscopic data are in accordance with literatures.222 1H NMR (400 MHz, CDCl3): δ (ppm) 
8.00 (d, J = 13.7 Hz, 1H), 7.77 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 7.62 (d, J = 13.7 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ (ppm) 139.5, 136.5, 134.4, 133.0, 129.4, 117.8, 115.3. 
tert-Butyl (4-cyanophenethyl)carbamate (25).  
n-Bu3SnH (2.4 mL, 8.9 mmol) was added to a solution of 24 (1.29 g, 7.4 mmol) in dry DCM (19.0 mL) 
under inert atmosphere, and the reaction mixture was stirred for 16 h. The solvent was evaporated under 
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reduced pressure, and the residue was partitioned between MeCN (100.0 mL) and hexane (30.0 mL). The 
MeCN phase was washed two times with hexane to remove the remained tin by-products and concentrated 
under reduced pressure. The residue was dissolved in MeOH (110.0 mL) and 2 M HCl (110.0 mL). Zinc 
powder (6.00 g, 90.0 mmol) was added slowly to the solution. After stirring for 1 h at 65 °C, the reaction 
mixture was cooled and basified to pH = 8 using sodium carbonate. The solid was filtered off, and the 
filtrate was concentrated to half of its volume. (Boc)2O (1.62 g, 7.4 mmol) in THF (50.0 mL) was added 
to the above solution and stirred for 16 h. THF was evaporated, and the resulting aqueous phase was 
extracted three times with EtOAc. The combined organic phases were washed with brine, dried over 
magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by flash chromatography 
(20% EtOAc in hexane as eluent) to furnish the title compound as a colorless crystalline solid (1.13 g, 
57% yield for three steps). The spectroscopic data are in accordance with literatures.223 1H NMR (300 
MHz, CDCl3): δ (ppm) 7.59 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 4.60 (br s, 1H), 3.38 (q, J = 6.5 
Hz, 2H), 2.86 (t, J = 6.5 Hz, 2H), 1.42 (s, 9H). 13C NMR (75 MHz, CDCl3): δ (ppm) 155.7, 144.7, 132.3, 
129.6, 118.8, 110.3, 79.5, 41.3, 36.4, 28.3. HRMS-ESI(m/z): calcd. for C14H19N2O2 [M + H]
+, 247.1441; 
found, 247.1415. 
4-(2-Aminoethyl)benzimidamide (26).  
To a solution of carbamte 25 (0.27 g, 1.07 mmol) in MeOH (20.0 mL) were added hydroxylammonium 
chloride (0.11 g, 1.60 mmol) and DIPEA (0.28 mL, 1.60 mmol), and the reaction was stirred at 60 °C for 
16 h. Then, the solvent was evaporated, and the residue was dissolved in EtOAc, washed with water and 
brine, and dried over MgSO4. The solvent was removed, and the residue was dissolved in THF (10.0 mL). 
DIPEA (0.28 mL, 1.60 mmol) and acetic anhydride (0.15 mL, 1.60 mmol) were added to the solution. 
The amidoxime intermediate was acetylated within 30 min as monitored by TLC. The excess of acetic 
anhydride was quenched by addition of H2O (0.50 mL). Stirring was continued for 30 min. Then, the 
solvent was evaporated, and the residue was dissolved in MeOH/AcOH (50:50), and 10% Pd/C (0.05 g) 
was added. The hydrogenation was conducted under 35 psi pressure of H2 in a Parr hydrogenator reactor 
for 12 h. Upon completion of the reaction (HPLC-MS), the mixture was filtered through a pad of 
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diatomaceous earth and purified by preparative HPLC (gradient of 0−30% MeCN in water) to yield a 
colorless solid which was dissolved in MeOH (3.0 mL). Concentrated HCl (1.0 mL) was added slowly at 
0 °C. After stirring for 1 h, the volatiles were removed using an air stream overnight. The residue was 
triturated using MeOH/Et2O to furnish 26 as a white solid (55% for three steps). 
1H NMR (400 MHz, 
DMSO-d6): δ (ppm) 9.34 (s, 2H), 8.40 (br. s, 2H), 7.87 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 
3.00−3.09 (m, 4H). 13C NMR (100 MHz, DMSO-d6): δ (ppm) 165.3, 144.0, 129.3, 128.4, 126.1, 39.2, 
32.7. HRMS (ESI) calcd. for C9H14N3 m/z [M + H]
+, 164.1182; found, 164.1181. 
2,3,5,6-Tetrafluoro-4-(nitromethyl)benzonitrile (28).  
Nitromethane (2.8 mL, 51.30 mmol) was placed in a flask that was flushed with nitrogen for about 10 
min then treated with 1,1,3,3-tetramethylguanidine (0.5 mL, 4.27 mmol), was stirred for 20 min, cooled 
to -35°C and treated slowly with pentafluorobenzonitrile (0.5 mL, 4.30 mmol). The reaction was stirred 
for 5 min and quickly quenched with a 1 M aq. solution of HCl saturated with NaCl (10.0 mL). The 
solution was then extracted with EtOAc three times. The combined organic layers were washed with 0.1 
M HCl then dried with magnesium sulfate, filtered and volatiles were removed in vacuum to give the 
desired product, a yellowish powder (0.80 g, 80%). The spectroscopic data are in accordance with 
literatures.224 1H NMR (400 MHz, CDCl3) δ (ppm): 5.69 (s, 2H). 13C NMR (100 MHz, CDCl3) δ (ppm): 
147.2 (m), 145.5 (m), 114.5 (t, J = 16.9 Hz), 106.6 (t, J = 3.7 Hz), 96.9 (t, J = 2.9 Hz), 65.5. 19F NMR 
(377 MHz, CDCl3) δ ppm: -137.2 (m, 2F), -130.5(m, 2F). HRMS (ESI) calcd. for C8H3N2O2F4 m/z 
[M+H]+ 235.0125; found 235.0143. 
4-(Aminomethyl)-2,3,5,6-tetrafluorobenzimidamide (29).  
Compound 28 (0.60 g, 2.56 mmol) and hydroxylamine hydrochloride (0.27 g, 3.85 mmol) were added 
to a solution of DIPEA (0.7 mL, 3.85 mmol) in MeOH (40.0 mL), which was stirred gently overnight at 
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room temperature. The mixture was extracted with ethyl acetate, and the organic layer was washed three 
times with saturated aqueous NaHCO3 followed by brine, then dried with magnesium sulfate, filtered, and 
evaporated in vacuo. The obtained crude product (0.25 g, 0.95 mmol) and acetic anhydride (0.3 mL, 2.8 
mmol) were added to a solution of acetic acid (5.0 mL), and the mixture was stirred for 1 h. Water (0.5 
mL) was then added to the solution that was stirred for 1 h before addition of 10% Pd/C (0.08 g). After 
48 h of stirring under hydrogen (balloon), the palladium was removed by filtration on diatomaceous earth, 
and the solvents were evaporated in vacuo. The product was purified by flash chromatography with 15% 
MeOH in DCM as eluent to furnish the title compound as a yellowish-brown oil (0.09 g, 15%). 1H NMR 
(400 MHz, D2O): δ (ppm) 5.69 (s, 2H). 13C NMR (100 MHz, D2O): δ (ppm) 156.8 (m), 144.6 (m), 142.7 
(m) 122.2 (m), 113.1 (m), 32.7 (s). 19F NMR (377 MHz, D2O): δ (ppm) −141.0 (br. m, 2F), −139.8 (br. 
m, 2F). IR (neat) ν (cm−1): 3566−2323 (br.), 1736, 1647, 1474. HRMS (ESI) calcd. for C8H8N3F4 m/z [M 
+ H]+, 222.0649; found, 222.0661. 
4-(Hydroxymethyl)-2-nitrobenzonitrile (31).  
To a solution of H5IO6 (17.00 g, 75.0 mmol) in MeCN (300.0 mL) was stirred vigorously and treated 
CrO3 (0.30 g, 3.0 mmol). Upon the addition of 4-methyl-2-nitro-benzonitrile 30 (4.90 g, 30.0 mmol) to 
the above solution, a white precipitate formed immediately. After 3 h of stirring, the liquid was decanted 
from the precipitate and evaporated. The obtained product (2.70 g, 13.9 mmol) was dissolved in dry THF. 
The solution was cooled to 0 oC, and treated sequentially with isobutyl chloroformate (1.8 mL, 13.9 
mmol) and NMM (1.5 mL, 13.9 mmol). After 2 min, a solution of NaBH4 (1.60 g, 41.7 mmol) in water 
(2.0 mL) was added to the above solution in one portion. The reaction mixture was stirred until the gas 
evolution ceased (30 min) then it was quenched with a saturated NH4Cl aqueous solution. The volatiles 
were removed under vacuum, and the residue was extracted three times with EtOAc. Combined organic 
phases were dried over MgSO4, filtered and the solvent was removed in vaccuo. Column chromatography 
(40 to 50% EtOAc in hexanes) furnished a white solid as product (2.0 g, 37% for two steps). The 
spectroscopic data are in accordance with literatures.225 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.32 (s, 
1H), 8.13 (d, J = 7.8 Hz, 1H), 7.89 (d, J = 7.8 Hz, 1H), 5.75 (br. s, 1H), 4.70 (d, J = 4.9 Hz, 2H). 13C 
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NMR (100 MHz, DMSO-d6) δ (ppm): 150.5, 148.2, 135.6, 131.9, 122.6, 115.7, 104.7, 61.41. HRMS–
ESI (m/z): [M + H]+ calcd. for C8H7N2O3 179.0451; found 179.0444. 
tert-Butyl (4-cyano-3-nitrobenzyl)carbamate (32). 
DMAP (0.06 g, 0.5 mmol) and triethylamine (1.7 mL, 12.0 mmol) were added to an ice-cooled solution 
of tosyl chloride (1.05 g, 5.5 mmol) and 31 (0.85 g, 4.8 mmol) in MeCN (10.0 mL). The reaction mixture 
was stirred for 1 h prior to evaporation of solvent. The residue was taken into EtOAc and washed with 
0.5 M HCl and brine. The organic phase was then dried over MgSO4, filtered, and evaporated to dryness. 
The resulting solid was dissolved in DMF (10.0 mL). NaN3 (0.94 g, 14.4 mmol) and NaI (0.36 g, 2.4 
mmol) were added to the reaction mixture, which was stirred at room temperature for 1 h. The reaction 
was quenched by addition of water, and the product was extracted with Et2O (3×). The combined organic 
phases were dried over MgSO4 and evaporated to dryness. The residue was purified by column 
chromatography, using 20% EtOAc in hexane as eluent, to give a pale yellow oil (0.58 g, 60% for two 
steps). 1H NMR (400 MHz, CDCl3): δ (ppm) 8.31 (s, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 
1H), 4.65 (s, 2H). 13C NMR (100 MHz, CDCl3): δ (ppm) 142.9, 135.9, 132.9, 124.4, 114.6, 107.5, 53.1. 
HRMS-ESI (m/z): [M + H]+ calcd for C8H7N5O2, 204.0516; found, 204.0513. The obtained 4-
(azidomethyl)-2-nitrobenzonitrile (0.58 g, 2.9 mmol) was dissolved in a mixture of THF (10.0 mL) and 
H2O (4.0 mL), and PPh3 (0.76 g, 2.9 mmol) was added slowly to the solution. The mixture was stirred for 
16 h and its volume was reduced to one-third of the original by evaporation. 2 M HCl was added to the 
residual aqueous solution, which was washed with EtOAc. The pH of the combined aqueous phases was 
adjusted to 8−9 by addition of solid K2CO3. A solution of (Boc)2O (0.62 g, 2.9 mmol) in THF (10.0 mL) 
was added to the above solution that was stirred for a further 16 h. THF was evaporated from the reaction 
mixture, and the resulting aqueous phase was extracted with EtOAc (three times). The organic extract 
was dried (MgSO4), the volatiles were removed, and the residue was purified by column chromatography 
with 30% EtOAc in hexanes. Evaporation of the collected fractions gave a yellow oil which was solidified 
at ambient temperature (0.36 g, 45%) was achieved. 1H NMR (400 MHz, CDCl3) δ (ppm): 8.25 (s, 1H), 
7.88 (d, J = 7.9 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 4.48 (d, J = 6.1 Hz, 2H), 1.47 (s, 10H). 13C NMR (100 
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MHz, CDCl3) δ (ppm): 155.8, 148.8, 146.9, 135.7, 132.5, 123.8, 114.9, 106.6, 80.7, 43.7, 28.3. IR (neat) 
ν (cm-1): 3370, 3083, 2978, 2232, 1682, 1516, 1341, 1281. HRMS–ESI (m/z): [M + H]+ calcd. for 
C13H16N3O4 278.1135; found 278.1119. 
2-Amino-4-(aminomethyl)benzimidamide (33).  
This compound was prepared from 32 as a yellow solid with the same procedure that was used to get 
compound 26 from 25 (0.18 g, 50% yield for three steps). 1H NMR (400 MHz, D2O) δ (ppm): 7.39 (d, J 
= 8.0 Hz, 1H), 6.92 (d, J = 1.0 Hz, 1H), 6.87 (dd, J = 8.0, 1.0 Hz, 1H), 4.10 (s, 2H). 13C NMR (100 MHz, 
D2O) δ (ppm): 165.7, 145.3, 138.4, 130.1, 118.2, 117.4, 114.4, 42.5. IR (neat) ν (cm-1): 3403-2602 (br.), 
1738, 1637. HRMS–ESI (m/z): [M + H]+ calcd. for C8H13N4 165.1135; found 165.1126. 
5-(Hydroxymethyl)picolinonitrile (35).  
The cyanation of methyl 6-bromonicotinate 34 (1.30 g, 6.0 mmol) was accomplished as noted in the 
preparation of 20 except the reaction mixture was heated at 100 oC for 16 h. The residue was purified by 
column chromatography (15% EtOAc in hexane) to give the intermediate cyanoester as a colorless solid 
(0.70 g, 64%).1H NMR (400 MHz, CDCl3) δ (ppm): 9.30 (d, J = 1.0 Hz, 1H), 8.45 (dd, J = 8.0, 1.0 Hz, 
1H), 7.81 (dd, J = 8.0, 1.0 Hz, 1H), 4.02 (s, 3H). 13C NMR (100 MHz, CDCl3) δ (ppm): 164.1, 151.8, 
138.1, 137.0, 128.5, 128.1, 116.5, 53.1. HRMS–ESI (m/z): [M + H]+ calcd. for C8H7N2O2 163.0502; 
found 163.0489. The obtained solid (0.62 g, 3.8 mmol) was dissolved in MeOH (2.5 mL) prior to addition 
of LiCl (0.32 g, 7.7 mmol). Then, NaBH4 (0.29 g, 7.7 mmol) was slowly added, and the reaction mixture 
was stirred for 2 h. The volatiles were removed by evaporation. The residue was treated with sat. aqueous 
NH4Cl and extracted three times using EtOAc. The combined organic phases were dried over MgSO4 and 
the solvent was removed in vacuum. The residue was purified by column chromatography (50% EtOAc 
in hexane) to furnish the title compound as a white solid (0.34 g, 73%). The spectroscopic data are in 
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accordance with literatures.226 1H NMR (400 MHz, CDCl3) δ (ppm): 8.71 (s, 1H), 7.89 (d, J = 7.9 Hz, 
1H), 7.71 (d, J = 7.9 Hz, 1H), 4.86 (d, J = 5.2 Hz, 2H), 2.22 (t, J = 5.2 Hz, 1H). 13C NMR (100 MHz, 
CDCl3) δ (ppm): 149.5, 140.2, 135.0, 132.7, 128.3, 117.2, 61.9. HRMS–ESI (m/z): [M + H]+ calcd. for 
C7H7N2O 135.0553; found 135.0538. 
tert-Butyl((6-cyanopyridin-3-yl)methyl)carbamate (36).  
5(Hydroxymethyl)picolinonitrile 35 (0.34 g, 2.5 mmol), PPh3 (1.00 g, 3.8 mmol), and phthalimide (0.56 
g, 3.8 mmol) were dissolved in dry THF (5.0 mL) under inert conditions and cooled to 0 °C in an ice bath. 
DIAD (0.75 mL, 3.8 mmol) was added by small portions over 30 min. The reaction mixture was stirred 
for 16 h at ambient temperature after which the solvent was removed in vacuo. The crude product was 
purified by column chromatography. 1H NMR (400 MHz, CDCl3): δ (ppm) 8.81 (d, J = 2.0 Hz, 1H), 7.92 
(dd, J = 8.0, 2.0 Hz, 1H), 7.89 (dd, J = 5.5, 3.0 Hz, 2H), 7.77 (dd, J = 5.5, 3.0 Hz, 2H), 7.67 (d, J = 8.0 Hz, 
1H), 4.93 (s, 2H). 13C NMR (100 MHz, CDCl3): δ (ppm) 168.1, 151.9, 137.7, 136.2, 135.0, 133.8, 132.2, 
128.5, 124.3, 117.4, 39.2. The phthalimide-protecting group was removed using the same procedure 
described for the preparation of 18 from 17. The obtained solid was dissolved in H2O (60.0 mL), and the 
pH was adjusted to 8−9 using K2CO3. A solution of (Boc)2O (0.83 g, 3.8 mmol) in THF (30.0 mL) was 
added to the mixture that was stirred for 18 h. After reducing to one-third of the original volume by 
evaporation of the volatiles, the mixture was extracted three times with EtOAc. The volatiles were 
evaporated, and the residue purified by column chromatography using 30% EtOAc in hexane to yield the 
title compound as a white solid. (0.30 g, 51% for three steps). 1H NMR (400 MHz, CDCl3) δ (ppm): 8.65 
(d, J = 1.4 Hz, 1H), 7.78 (dd, J = 7.9, 1.4 Hz, 1H), 7.68 (d, J = 7.9 Hz, 1H), 5.07 (br. s., 1H), 4.40 (d, J = 
5.8 Hz, 2H), 1.46 (s, 9H). 13C NMR (100 MHz, CDCl3) δ (ppm): 155.8, 150.2, 138.9, 135.8, 132.6, 128.3, 
117.1, 80.5, 41.9, 28.3. IR (neat) ν (cm-1): 3380, 2997, 2981, 2970, 2931, 2240, 1738, 1679, 1513. 
HRMS–ESI (m/z): [M + H]+ calcd. for C12H16N3O2 234.1237; found 234.1217. 
5-(Aminomethyl)picolinimidamide (37).  
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This compound was prepared using the same procedure as described for the preparation of amine 26 as a 
yellow solid (0.12 g, 61% for three steps). 1H NMR (300 MHz, D2O) δ (ppm): 4.39 (s, 2H), 8.14 (d, J = 
8.1 Hz, 1H), 8.20 (dd, J = 8.1, 1.0 Hz, 1H), 8.83 (d, J = 1.0 Hz, 1H). 13C NMR (75 MHz, D2O) δ (ppm): 
162.3, 150.3, 144.3, 139.2, 133.8, 123.4, 40.1. IR (neat) ν (cm-1): 3587-2629 (br.), 1672, 1650. HRMS–
ESI (m/z): calcd. for C7H11N4 [M+H]
+ 151.0987; found 151.0951. 
2.6.2. Molecular modeling 
DFT calculations. High-level DFT calculations (M06-2X/6.31Gdp)227-229 were performed in water as 
solvent using GAMESS software (version R1, May 1st, 2013).230 
Docking studies. Calculations were performed with the Molecular Operating Environment (MOE),231 
using a homology model of PACE4 developed based on the furin crystal structure (PDB code; 1P8J).74, 
87 The Ac-RVKR-NH2 was modified with the “builder” tool to the desired ligand and then minimized 
using the OPLS-AA force field. The general docking protocol of MOE (receptor: receptor + solvent; site: 
ligand atoms; ligand: ligand atoms) was used for docking, and the Triangle Matcher routine (timeout: 300 
s; returned poses: 1000) was employed as the placement method and the acquired poses were scored with 
the “London dG” algorithm (30 retained poses). The different poses were refined with the induced fit 
protocol (refinement > induced fit; cutoff: 15 Å; side chains: free; termination criterion: gradient 0.01; 
iterations: 500; pharmacophore restraint: force constant 100; radius offset: 0.4) and rescored with the 
“GBVI/WSA dG” algorithm (5 retained poses). The docking score and the presence of vital interactions 
were used to select the best poses. 
2.6.3. Biology 
Enzyme kinetics. As reported earlier,212 the PACE4 and furin inhibitory constants of compounds 5-13 
were calculated using Cheng and Prusoff’s equation123 and the SoftMaxPro5 program, except for 
compound 13’s PACE4 affinity which was calculated by Morrison’s equation232 and Prism 6.0 (GraphPad 
Software). All measurements were performed on a Gemini EM 96-well spectrofluorometer (Molecular 
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Devices Sunnyvale, CA, USA) (λex = 370 nm; λem = 460 nm; cutoff, 435 nm). The recombinant human 
furin ([E0] = 0.54 nM, Km = 5.040 µM) and recombinant human PACE4 ([E0] = 20.18 nM, Km = 4.035 
µM) were prepared and purified as described before.80 The competitive substrate was pyroGlu-Arg-Thr-
Lys-Arg-AMC peptide (Bachem, Switzerland) for both furin and PACE4 with a concentration of 100 μM 
per well. 
Cell proliferation assay. Cell lines were purchased from the American Type Culture Collection (ATCC) 
and maintained in RPMI-1640 and supplemented with 5% fetal bovine serum (FBS) for DU145 and 10% 
FBS for LNCaP. The antiproliferative activity of compounds 5-13 was evaluated as reported earlier.167 
The IC50 values were calculated using Prism 6.0 (GraphPad Software). 
Cell permeability. The DU145 cells were plated (200000 cells per 100 mm petri dish) and incubated for 
48 h at 37 oC. After addition of a 1 µM solution of FITC-labeled analogs and further incubation for 1 h 
at 37 oC, cells were collected by treatment with 0.05% trypsin and subsequently was inactivated with 
FBS-containing media. Cell pellets were washed with PBS, centrifuged and resuspended in 200 µL of 
fresh PBS prior to addition of propidium iodide (final concentration of 10 µg/mL) just before fluorescence 
acquisition. In another set of tubes, trypan blue (final concentration of 0.04%) was used to quench the 
non-penetrated fluorophore. Fluorescence analysis (at least 10000 events) was performed in a CytoFLEX 
15 flow cytometer (Beckman Coulter, Brea, CA, USA) with the following diode lasers: 488 nm and 638 
nm, 50 mW each. The resulting fluorescence was divided into four channels and detected through band 
pass filters (Forward scatter area, side scattered area and side scattered width signals) to discriminate the 
live gates from exclude debris and cell clumps. Dead cells (PI-positive) were omitted with gating in the 
red channel. 
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2.8. Supporting information 
Analytical data of peptide inhibitors and the FITC-labeled analogue is presented in the Table S1. 
 
Table S1. The analytical data for all peptide inhibitors and the FITC-labeled analogue. 
 
Compound 
Exact Mass 
HPLC retention time 
Calculated for Found 
5 [M+2]2+ 502.8582 502.8687 29.77a 
6 [M+2]2+ 519.8791 519.8777 8.47b 
7 [M+2]2+ 521.3684 521.3770 29.36a 
8 [M+3]3+ 367.2302 367.2260 12.95b 
9 [M+2]2+ 521.3502 521.3488 11.49b 
10 [M+2]2+ 520.8582 520.8664 10.57b 
11 [M+2]2+ 523.3659 523.3609 28.67a 
12 [M+2]2+ 514.8582 514.8667 28.50a 
13 [M+2]2+ 521.8660 521.8744 28.41a 
15 [M+3]3+ 482.9287 482.9315 31.75a 
a50 min and b16 min gradient of 10 to 70% of CH3CN and H2O containing 0.1% TFA 
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CHAPTER 3 : INCREASING C-TERMINAL HYDROPHOBICITY IMPROVES THE CELL 
PERMEABILITY AND ANTIPROLIFERATIVE ACTIVITY OF PACE4 INHIBITORS AGAINST 
PROSTATE CANCER CELL LINES 
The current chapter is published as a full article in J. Med. Chem., 2018, 61 (18), pp 8457–8467 (DOI: 
10.1021/acs.jmedchem.8b01144) with the following title, authors and affiliations; 
Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative 
Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines 
 
Vahid Dianati,† Anna Kwiatkowska,‡  Frédéric Couture,‡ Roxane Desjardins,‡ Yves L. Dory†* and 
Robert Day‡* 
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Université de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, Québec J1H 5N4 (Canada) 
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This work was done in the Institut de Pharmacologie de Sherbrooke of Université de Sherbrooke under 
supervision of Pr. Robert Day and Pr. Yves L. Dory. The original research article by Vahid Dianati, 
Pauline Navals, Frédéric Couture, Roxane Desjardins, Anthony Dame, Anna Kwiatkowska, Robert Day, 
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21), Frédéric Couture (compounds 28-32) and Roxane Desjardins (compound 33). Roxane Desjardins 
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performed the cell toxicity and cell permeability studies as well. Vahid Dianati, Robert Day and Yves L. 
Dory analyzed the data. Vahid Dianati wrote the manuscript with revisions from Frédéric Couture, Anna 
Kwiatkowska, Robert Day and Yves L. Dory. 
3.2. Abstract 
The serine protease, PACE4, is a proprotein convertase which plays a substantial role in malignancy of 
prostate cancer. Our initial selective PACE4 inhibitor (Ac-LLLLRVKR-NH2) has evolved to the current 
lead compound C23 (Ac-dLeu-LLLRVK-Amba), which is active both in-vitro and in-vivo. By screening 
natural residues, except Cys, in C-terminal P1' position, it was established that increasing hydrophobicity 
was improving cell permeability, which was directly translated into PCa cells antiproliferative activity. 
This cell antiproliferation enhancement seems independent from effect of P1' residue on PACE4 affinity. 
Replacement of P1-Amba of C23 by Acpa ((S)-2-amino-3-(4-carbamimidoylphenyl)propanoic acid) 
followed by addition of tryptamine in P1' resulted in compound 32 exhibiting superior PCa cells 
antiproliferative activity over the reference compound C23 (3-fold). This study sheds light on key factors 
that improve cell penetrating property and antiproliferative activity of PACE4 inhibitors. 
3.3. Introduction 
PACE4 is an enzyme in the family of proprotein convertases (PCs) that activates secretory protein 
precursors through peptide bond cleavage at paired basic amino acids (i.e., consensus cleavage site R-X-
R/K-R↓). PACE4 transits within the secretory pathway and is secreted.210, 233 Our studies were the first 
to demonstrate the role of PACE4 in prostate cancer (PCa).114 We showed an overexpression of PACE4 
in PCa tissues obtained from patients who underwent radical prostatectomy for clinically localized tumor, 
while no other PC showed any significant changes. Using mouse PCa xenograft models, we also showed 
that only PACE4 inhibition blocks PCa progression, and not the inhibition of other PCs.117 Recently, we 
discovered that PCa cells utilize an alternative splicing mechanism to generate a cancer-specific C-
terminally modified PACE4 isoform (named PACE4-altCT), which is retained in the cell.91 RNA 
interference silencing studies targeting PACE4-altCT demonstrate that this isoform is responsible for 
PACE4-associated cancer progression. PACE4 is also overexpressed and involved in other malignancy 
including non-small cell lung carcinoma, ovarian, and breast cancer.108, 111-112, 114, 117 The sum of our data 
provides the proof of concept and the justification to proceed with a development plan for PACE4 
inhibitors for a novel cancer therapy. 
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In this regard, we developed a specific PACE4 inhibitor named the Multi-Leu peptide (ML-peptide).166-
167 In enzyme kinetic assays, the ML-peptide (sequence: Ac-LLLLRVKR-NH2) 1 is potent (Ki = 22 ± 6 
nM) and selective for PACE4 (e.g., 20-fold over furin). In cell-based assays, the compound 1 blocks the 
proliferation of PCa cell lines (LNCaP, DU145 and 22Rv1) and induces G0/G1 cell cycle arrest. We also 
discovered that the target of the compound 1 is intracellular since a cell impermeable analog (i.e., PEG8-
ML-peptide) has no effect on cell proliferation.166 We believe compound 1 exerts its anti-proliferative 
effects by reaching PACE4-altCT (i.e., cell retained PACE4 isoform). While potent in cell-based assays, 
the compound 1 displays poor stability in vivo, so we developed a stable version named C23 (compound 
2; Figure 38).170 Among the modifications in compound 2, the replacement of the P1 Arg by 4-
amidinobenzylamide (Amba) gives this PACE4 inhibitor with higher potency than the compound 1 and 
antiproliferative activity against PCa cell lines and improved stability and pharmacokinetic profile.167-169 
The additional change of P8-Leu to its d-isomer, raised the plasma stability up to 1.7 hours with almost 
no loss of potency and anti-proliferative activity.168,234 In LNCaP xenografted mice, compound 2 (2 
mg/kg/day iv) diminished tumor volumes by 60% over 18 days with a 47% reduction in plasma PSA 
levels, as well as a significant decrease in cells progressing through the cell cycle, increased apoptosis 
and impaired neovascularization.170 
Figure 38. Structure of lead compound 2 (C23). 
While compound 2 represents a significant improvement for PACE4 inhibition in vivo, further 
refinements may be needed. Indeed, a systematic scan of positions P5 to P8 of compound 2 revealed that 
these four residues have to be hydrophobic. It was even shown that charged residues at those positions 
reduce antiproliferative activity on PCa cell lines. This may be due to the disruption of the amphipathic 
nature of the inhibitor, which affects its cell penetrating properties.171 Parallel studies on the compound 
1 indicated that introduction of a β-branched basic residue, (2S)-amino-(3S)-guanidinobutyryl (S-i-Agb), 
in the P3 position led to a compound with unprecedented high potency and selectivity towards PACE4.212 
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However, further antiproliferative PCa cells analysis of this compound and related analogs showed very 
poor activity. 
The analysis of PC homology models based on furin crystal structure suggests that the S1 to S4 pockets 
are strongly conserved among PCs.87 However, these models also highlight noticeable differences in the 
P' region of PC catalytic pockets. Despite few reports, no comprehensive investigation has been done on 
the significance of the P' region of the catalytic site for PACE4 inhibitors.80, 138 Accordingly, a screening 
was conducted with natural residues at the P1' position of the compound 1. The impact of these 
modifications was evaluated on the inhibition of PACE4 and PCa cell lines antiproliferative activity of 
new compounds. Additional molecules were further designed based on the obtained results to evaluate 
any potential gain in terms of PACE4 inhibition and cellular activity. 
3.4. Results and discussion 
3.4.1. Screening of DNA-encoded residues in P1' 
So far, the most potent PACE4 inhibitors including our lead compound 2 have been armed with Amba at 
their P1 C-terminal. For synthetic feasibility reasons in the investigation of the P1' position, Amba was 
replaced by Arg-NH2. The 20 natural amino acids, except Cys, have been incorporated in the P1' position 
of compound 1. The inhibitory constants (Ki) of each peptide have been determined for PACE4 and furin 
using a fluorometric assay to compare the binding affinities. The efficacy of compounds was further 
assessed ex vivo using DU145 and LNCaP PCa cell lines using an MTT cell proliferation assay. 
The PACE4 and furin affinities (Table 3) of the new compounds 3−21, compared to the control 
compounds 1 and 2, reveal that P1'-Lys (10) and P1'-Arg (16) are the least-favored residues for the S1' 
pocket of both enzyme which is in accordance with what has been observed for affinity of PC’s 
substrates.87 However, only compounds 10 and 16 remain as selective as compound 1 (17 and 16 times 
more selective toward PACE4, respectively). As illustrated in Figure 40, other P1'-modified peptides, 
except Pro (14) and Leu (11), inhibit PACE4 in the range of compound 1 (20-64 nM). Compounds 6, 20 
and 21 with aromatic residues (Phe, Trp and Tyr) in P1' are among the best PACE4 inhibitors in this 
series, with compound 6 displaying a Ki value as low as 20 ± 2 nM for PACE4. In general, most of the 
inhibitors were showing enhanced affinity for furin and diminished inhibition of PACE4, in comparison 
to compound 1. As a result, no gain in selectivity was ever observed with the introduction of residues in 
position P1'. The PACE4 inhibition profile of compounds 3−21 suggests that no natural residue could 
introduce a favorable interaction with PACE4 in the S1' pocket. 
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Table 3. Inhibition profiles and cellular antiproliferative activities of compounds 3−21 with general 
structure of Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Xaa-NH2 compared to control compounds 1 and 2. 
aKi and IC50 values are based on at least two independent experiments. Errors reported as SEM for Ki and 
IC50. For more details of inhibitor concentrations used in the MTT antiproliferative assay see 
experimental section. bData were adapted from references.166, 168 cN.D.: Not determined. dN.C.: Not 
calculable as the curves did not converge to 50% with doses up to 300 µM. 
 
MTT cell proliferation was then investigated to assess the cell activity of inhibitors on PCa cell lines 
(Table 3). The compounds 3−21 were first monitored on DU145 cells. Thereafter, the most active 
compounds were also examined on LNCaP cells. Clearly, the introduction of hydrophobic residues in P1' 
position enhances the antiproliferative activity of peptides. For instance, compounds with P1' residues 
Entry Structure 
Ki (nM) ± SEMa Selectivity 
for PACE4 
IC50 (μM) ± SEMa 
PACE4 Furin DU145 LNCaP 
1 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-NH2b 22 ± 6 430 ± 10 20 100 ± 10 180 ± 60 
2 Ac-dLeu-Leu-Leu-Leu-Arg-Val-Lys-Ambab 4.9 ± 0.9 9.8 ± 2 2 25 ± 10 45 ± 10 
3 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Ala-NH2 37 ± 5 210±10 6 160 ± 10 N.D.c 
4 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Asp-NH2 30 ± 2 74 ± 8 2 230 ± 20 N.D. 
5 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Glu-NH2 58 ± 4 260 ± 30 4 N.C.d N.D. 
6 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Phe-NH2 20 ± 2 74 ± 9 4 70 ± 8 170 ± 40 
7 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Gly-NH2 44 ± 5 500 ± 30 11 N.C. N.D. 
8 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-His-NH2 33 ± 7 140 ± 10 4 N.C. N.D. 
9 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Ile-NH2 64 ± 4 290 ± 10 5 72 ± 8 N.C. 
10 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Lys-NH2 150 ± 20 2600 ± 100 17 130 ± 10 N.D. 
11 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Leu-NH2 170 ± 30 990 ± 30 6 90 ± 10 N.D. 
12 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Met-NH2 32 ± 2 170 ± 10 5 130 ± 20 N.D. 
13 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Asn-NH2 28 ± 3 130 ± 20 5 N.C. N.D. 
14 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Pro-NH2 250 ± 10 990 ± 30 4 210 ± 30 N.D. 
15 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Gln-NH2 43 ± 3 190 ± 10 5 210 ± 20 N.D. 
16 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Arg-NH2 160 ± 5 2500 ± 400 16 71 ± 7 N.C. 
17 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Ser-NH2 64 ± 2 330 ± 20 5 240 ± 50 N.D. 
18 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Thr-NH2 22 ± 2 100 ± 10 5 170 ± 10 N.D. 
19 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Val-NH2 38 ± 4 200 ± 10 5 170 ± 10 N.D. 
20 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Trp-NH2 29 ± 1 110 ± 10 4 25 ± 2 31 ± 3 
21 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Tyr-NH2 29 ± 1 64 ± 5 2 100 ± 20 N.D. 
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Phe (6), Ile (9), Leu (11) and Trp (20) led to the IC50 values of 70 ± 8, 72 ± 8, 90 ± 10 and 24 ± 2 μM, for 
DU145 PCa cells, respectively. As exceptions for polar residues, we were at first very surprised by the 
P1'-Lys (10) and P1'-Arg (16) peptides with their respective antiproliferative IC50 values of 130 ± 20 and 
71 ± 7 μM while they are very weak PACE4 inhibitors. Based on these results, it was then uncovered that 
positive charge and hydrophobicity in P1' residue are the main factors for enhancing the antiproliferative 
activity. 
3.4.2. SAR studies based on the screening. 
Following the encouraging data collected for peptides 6, 16 and 20 (Table 3), the next logical move was 
to combine the basic nature of Arg and the aromatic nature of Phe at position P1'. This is how the new 
residues 4-aminophenylalanine (Apa) 22, 4-guanidinophenylalanine (Gpa) 23 and 4-(2-
aminoethyl)benzimidamide (Aeba) 24 were designed (Figure 39-a). Hence, the corresponding 
compounds 28−30 were synthesized on solid support, then tested (Figure 39-b). Only compound 29 
inhibited PACE4 with an improved Ki of 11 ± 2 nM but once again, this increased affinity didn’t translate 
to antiproliferative activity. The reduced polarity in Aeba 24 with no C-terminal −CONH2 group, 
contributed to the antiproliferative properties of compound 30 (41 ± 9 and 67 ± 7 μM for DU145 and 
LNCaP cells, respectively) which is no better than lead compound 2. 
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Figure 39. a) The PACE4 affinity and antiproliferative activity of compounds 28−33. Ki and IC50 values 
are means of at least two independent experiments. Errors reported as SEM for Ki and IC50. For more 
details on the concentration of inhibitors in the MTT antiproliferative assay see experimental section. b) 
The IC50 values of selected compounds for DU145 and LNCaP PCa cell lines. 
Since the decarboxylated compound 30 (residue 24 at P1') showed better IC50 values than compounds 28 
and 29, P1'-Trp in compound 20 was replaced with tryptamine (Tryp) 25 increasing the C-terminal 
hydrophobicity. As expected, compound 31 showed promising IC50 values (14 ± 2 μM for DU145 and 
18 ± 5 μM for LNCaP cells). To further increase the cell efficacy, compound 31 was modified in P1 
position by substituting Arg with (S)-2-amino-3-(4-carbamimidoylphenyl)propanoic acid (Acpa) 26 and 
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(S)-2-amino-3-(4-carbamimidoylphenyl)acetic acid (Aca) 27 which have the 4-amidinophenyl side chain 
similar to Amba in compound 2. Those modifications led to the compounds 32 (PACE4 Ki of 41 ± 7 nM) 
and 33 (PACE4 Ki of 248 ± 6 nM). The PACE4 affinity comparison of these compounds with compound 
31 indicates a 2-fold preference for Acpa (32) over Arg (31) in P1 position while Aca (33) is 6 times 
disfavored. The diminished PACE4 affinity of compound 33 is most likely due to the steric hindrance 
around the opening of P1 pocket. Overall, there seems to be no correlation between affinity and 
antiproliferative activity linked to the nature of the P1' residues (Figure 40-a). On the other hand, 
observations indicate that such a correlation may exist at the P1 position, since PACE4 affinity is well 
translated into PCa cell antiproliferative activity in both compounds 32 and 33. Compound 32, displaying 
unprecedented IC50 values (7.5 ± 0.8 and 13 ± 1 μM for DU145 and LNCaP cells, respectively) for PCa 
cell lines, is a good candidate for further in vivo studies (Figure 39-b). 
Figure 40. a) Linear relation of IC50 values for MTT antiproliferative assay on DU145 PCa cell line with 
Wimley-White bilayer scale for hydrophobicity of P1' residues and b) weak correlation to PACE4 affinity 
of compounds 3−21. 
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3.4.3. Cell permeability studies. 
The relationship between Ki and IC50 is clearly not linear. It is obvious that PACE4 affinity of inhibitors 
translates poorly into antiproliferative activity with introduction of the P1' residue (Figure 40-a). On the 
other hand, there is a linear relation between hydrophobicity of P1' residues and antiproliferative activity 
of compounds (Figure 40-b). The IC50 values are in respectable agreement with Wimley-White bilayer 
scale for hydrophobicity of amino acids.235 In this scale, the ΔG(water to bilayer), is calculated for the 
partitioning of peptides Ac-WL-X-LL-OH (X: natural amino acid) between water and a POPC lipid 
bilayer.236 The ΔG(water to bilayer) value of each amino acid can be used to evaluate its contribution to 
membrane penetration. 
We, thus, suggest that the preeminent cytostatic activity of compounds with a hydrophobic P1'-residue 
originated from enhancement in penetration of such peptides through cell membrane. Thus, the 
compounds 35−38 which were FITC-labeled in their N-terminal. After an hour of incubation of the 
labeled compounds with DU145 cells, the emitted fluorescence from cells was analyzed using 
fluorescence-activated cell sorting (FACS) and compared to compound 34 as control. The signal of 
membrane absorbed peptides was eliminated by treatment of cells with trypan blue prior to analysis. The 
depicted results in Figure 41 revealed that the higher permeability achieved with increased P1' 
hydrophobicity. In comparison to control compound 34, uptake of compounds 37 and 38 enhanced by 2 
and 3.5-fold, respectively, which totally correlate with IC50 values for compounds 20 and 31. The better 
penetration of compounds with Arg (35) and Lys (36) in P1' position, compared to control, also suggests 
that lower PACE4 affinity of compounds 16 and 10 were compensated by their amended cell penetration.  
Figure 41. Quantitative cell penetration assessment of FITC-labeled compounds 35−38 compared to 
control compound 34. 
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The direct relation between cell penetration and antiproliferative activity has been constantly observed 
for compound 1 and its derivatives.167-168 The cell permeability is required to reach the intracellular 
PACE4-altCT isoform which is responsible for PACE4-associated cell growth of prostate malignant 
cells.91 This is consistent with our previous observations with N-terminal PEGylated derivatives of 
compound 1 displayed no cell permeability and thus no antiproliferative activity.166 The amphipathic 
nature of peptide inhibitors with the charged warhead and four hydrophobic residues in N-terminal has 
been considered crucial for cell derivatives of compound 2.171 Arg residues play the key role in cell 
permeability of poly-arginine cell penetrating peptides (CPPs), including compound 1 derivatives, 
through bidentate electrostatic and hydrogen bonds with negatively charged groups of membrane.237 
Hydrophobic residues, when present in a CPP, increase the interactions with lipid bilayer and thus 
increasing translocation of peptides through membrane.238 Among hydrophobic residues, inclusion of Trp 
within basic peptides is a molecular determinant for enhancement of cell uptake efficiency.239-242  For 
instance, more abundancy of Trp residues in amphiphilic helical CPPs increased their uptake in A549 cell 
lines.243  The exclusive role of tryptophan in cell penetration of polyarginine peptides is ascribed to the 
interaction with sulfated glycosaminoglycans possibly through hydrophobic and π–anion interactions in 
addition to its important hydrophobic interactions with lipid bilayer.244-245 
3.4.4. DU145 cell toxicity studies 
The toxicity of compounds 10, 16, 20, 31 and 32 on DU145 cells was evaluated to ascertain the fact that 
observed fluorescence in the permeability assay is related to pure cell penetration of peptides and not to 
cell lysis. Hence, DU145 cells treated with peptides for 1.5 h and the number of live cells was assessed 
by addition of PI (propidium iodide) followed by FACS measurement of fluorescence. The compounds 
10 and 16, displayed no toxicity to doses up to 100 µM. The results for compounds 20, 31, and 32 revealed 
that toxicity for these compounds occurred at concentrations above 10 µM which is more than 10-fold 
higher than the tested concentration for FITC-labeled peptides (1µM) in permeability assays (Figure S1). 
For compound 32, a few more concentrations were tested to obtain a dose-response curve for cellular 
toxicity (DU145 IC50 (PI) = 28 ± 2 µM; Figure 43). In comparison, this compound inhibited metabolic 
activity of DU145 cells in 4-fold lower doses (DU145 IC50 (MTT) = 7.5 ± 0.8 µM). The fact that 4-fold 
more concentration of compound 32 is necessary for DU145 cytotoxicity, suggests that this compound is 
likely mediating its effects through mechanisms other than killing the cells in one-digit µM 
concentrations. 
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3.4.5. Plasma stability studies 
Despite rapid tumor uptake of PACE4-inhibitor, which permits in vivo efficacy, the half-lives of all-
natural residue peptide inhibitors of PACE4 in human plasma is quite short.170 Accordingly, increasing 
the peptide stability in biological matrices is essential. Half-life (t1/2) of compound 31 with dLeu in P8 
and Tryp in P1' (0.8 h) was less than half of compound 2 (1.7 h). Statistically, addition of a residue in P1' 
increased the number of breakable amide bonds thus making the modified peptides more prone to the 
plasma proteases than their 8-mer counterparts. It is well known that replacement of natural residues with 
the unnatural one, is a way that could potentially increase the stability of peptides.246 As a result, 
modification of P1-Arg in 31 with Acpa in 32 increased the plasma half-life up to 2.0 h (Figure 42). 
Figure 42. Stability of compounds 28, 31 and 32 in human plasma comparing to lead compounds 1 and 
2. 
3.4.6. Acute toxicity studies 
To assess the safety profile of compound 32, the acute toxicity of this compound was studied on healthy 
mice. The experiment included a single intravenous or intraperitoneal administration dose of compound 
32 into healthy mice (CD1 mice as standard for toxicological and safety evaluations) at various doses to 
find the toxicity threshold (maximum tolerated dose, MTD). The results indicated that this compound has 
an MTD of at least 5 mg/kg for intravenous administration (Figure 43-b).  
In a previous study, we showed that a 2 mg/kg/day dose of compound 2 is sufficient for therapeutic 
activity in a LNCaP xenografted model of prostate cancer170 while it displayed safe profile in acute 
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toxicity studies (MTDs of 10 mg/kg in healthy mice).168 The in vivo therapeutic activity for compound 
32 is yet to be evaluated in LNCaP xenografted models. 
Figure 43. The toxicity profile of compound 32. a) The dose-response curve for DU145 cellular toxicity 
was performed using PI as a staining reagent. The errors are reported as SEM. For more details on 
concentration of inhibitors in this assay see experimental section. b) Table showing IC50(PI) and MTD 
values of compound 32 in healthy CD1 mice. Data are representative of at least two independent 
experiments. 
3.4.7. Synthesis 
Compounds 3−21, 28 and 29 with amino acid residues in P1' were prepared with conventional 9-
fluorenylmethyloxycarbonyl (Fmoc)-based solid phase peptide synthesis (SPPS) on TentaGel® S RAM 
resin (Scheme S1). The decarboxylated analogues 30, 31, 32 and 33 were synthesized using a 
combination of solid and solution phase peptide synthesis (Schemes 5 and 6). At first crude protected 
peptide were obtained from Fmoc-SPPS on 2-chlorotrityl chloride resin, and then the free C-terminal was 
coupled with the corresponding amines in solution. The global deprotection with a TFA cocktail 
(composed of TFA/TIPS/H2O 95:5:5) yielded the desired peptides. 
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Scheme 5. Synthesis of P1 residue of compound 30, and P1-P1' adduct of compounds 32 and 33. Reagents 
and conditions: (a) CH3NO2, NaOH, MeOH/H2O, <10-15 
oC, 15 min then 5 M HCl; (b) Bu3SnH, DCM, 
rt, 16 h; (c) Zn, HCl(aq), 65 oC, 1 h; (d) (Boc)2O, K2CO3, THF/H2O, 16 h; (e) NH2OH.HCl, DIPEA, 
MeOH, 60 oC, 16 h; (f) Ac2O, DIPEA, THF then 5% Pd/C, AcOH/MeOH 35 atm H2, 16 h; (g) Conc. 
HCl(aq), MeOH, 0 oC to rt, 1 h; (h) tryptamine hydrochloride, EDCI, 6-Cl-HOBt, DIPEA, DCM, 0 oC to 
rt, 16 h; (i) i-BuOCOCl, DIPEA, tryptamine hydrochloride, THF,   ̶ 20 oC, 2 h; (j) Pd(PPh3)4, Zn(CN)2, 
DMF, 100 oC, 16 h.  
For obtaining Aeba 24, aldehyde 39 condensed with nitromethane to give (E)-4-(2-nitrovinyl)benzonitrile 
40 (Scheme 5). The double bond and nitro moiety were reduced using tributyltin hydride and Zn/HCl, 
respectively. The resulting amine was protected with t-butyl carbamate (Boc) group for more convenient 
purification in the following steps. Transformation of nitrile 41 to amidine in compound 24 was 
performed as previously reported for Amba.167 Boc-Phe(4-CN)-OH 42 was coupled with tryptamine 25 
using EDCI coupling reagent. Compound 45‘s amino group was protected with Boc and then coupled 
with tryptamine 25 at low temperature using acyl chloride strategy. An additional cyanation step was 
necessary to obtain compound 46. The conversion of nitrile groups in compounds 43 and 46 to the 
corresponding amidines in 44 and 47 was performed with a similar procedure as was used for AEBA 24. 
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Scheme 6. Synthesis of compounds 30−33. Reagents and conditions: (a) Fmoc-Arg(Pbf)-OH, DIPEA, 
DMF/DCM (1:1); (b) Pip/DMF (1:4); (c) Fmoc-aa-OH, HATU, DIPEA, DMF; (d) Ac-dLeu-OH, HATU, 
DIPEA, DMF; (e) HFIP/DCM (1:4); (f) PyBOP, 6-Cl-HOBt, DIPEA, DMF, 24, 0 oC to rt, 16 h; (g) 
PyBOP, 6-Cl-HOBt, DIPEA, DMF, tryptamine hydrochloride, 0 oC to rt, 16 h; (h) TFA/TIPS/H2O 
(38:1:1); (i) Fmoc-Lys(Boc)-OH, DIPEA, DMF/DCM (1:1); (j) PyBOP, 6-Cl-HOBt, DIPEA, DMF, 44, 
0 oC to rt, 16 h; (k) PyBOP, 6-Cl-HOBt, DIPEA, DMF, 47, 0 oC to rt, 16 h. 
3.5. Conclusion 
In conclusion, we developed PACE4 inhibitors by SAR studies in P1 and P1' using ML-peptide 1 as 
template. By performing a systematic screening of natural amino acids in P1' position of peptide 1, 
compound 20 (Trp in P1') was identified as having improved antiproliferative effect on PCa cell lines. 
Further modification of this Trp residue to Tryp (31) increased the hydrophobicity in the C-terminal 
region of the resulting peptide. Despite its diminished affinity for recombinant PACE4, Trp to Tryp 
replacement improved plasma stability and cell efficacy. In an attempt to further increase the in vitro cell 
activity of compound 31, P1-Arg was replaced with an Acpa residue. This change contributed to the 
plasma stability and antiproliferative effect of compound 32 which possesses the best cell efficacy of 
peptide 1 derivatives reported to date. The enhancement of antiproliferative activity with the 
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incorporation of Trp or Tryp in the C-terminal region was found to be related to the improved cell 
penetration properties of such inhibitors. The cell permeability is the main obstacle in the development 
of multi-basic inhibitors of PACE4 as well as similar targets such as furin and some other flaviviral 
proteases.247-249 The present study constitutes a significant step forward to address such cell penetration 
issues. 
3.6. Experimental 
3.6.1. Chemistry 
General Experimental Methods. All chemical reagents and solvents were obtained from commercial 
resources and used without further purification. Fmoc-protected amino acids and Boc-protected amino 
acid 42 and coupling reagents, were purchased from ChemPep (Miami, FL, USA) or Chem-Impex 
International (Wood Dale, IL, USA). Tryptamine and most of other reagents were bought from Sigma 
Aldrich (St. Louis, MO, USA). TentaGel® S RAM resin and 2-chlorotrityl-chloride resin were received 
from Rapp Polymer (Tübingen, Germany). Peptide synthesis (Fmoc/tBu strategy) was accomplished 
either manually or automatically on a Pioneer peptide synthesizer (Applied Biosystems). The purification 
and purity check of peptide inhibitors were performed using reverse phase high-performance liquid 
chromatography (RP-HPLC) on an Agilent Technologies 1100 system (analytical and semi-prep) 
equipped with a diode array detector (λ = 210, 214, 230, and 254 nm). Preparative HPLC were done using 
either a Varian ProStar preparative system equipped with a UV-Vis detector (λ = 214 nm) or a Waters 
preparative HPLC system (Autosampler 2707, Quaternary gradient module 2535, UV detector 2489 (λ = 
214 and 230 nm), fraction collector WFCIII) equipped with an ACE5 C18 column (250 × 21.2 mm, 5 μm 
spherical particle size). A gradient of 0.1% TFA in water and acetonitrile was used as eluent. Analytical 
HPLC was carried out using C18 columns, either Agilent Eclipse XDB (5 mm, 4.6 μm, 250 mm) or a 
Phenomenex Jupiter (5 mm, 4.6 μm, 250 mm). ESI-HRMS (TripleTOF 5600, ABSciex; Foster City, CA, 
USA) was used to confirm the identity of the pure products. Water H Class Acquity UPLC coupled with 
an SQ Detector 2 and a PDA eλ detector paired with an Acquity UPLC CSH C18 column (1.7 μm×2.1 
mm×50 mm) was also used for synthesis check and plasma stability assessment (linear gradient from 5 
to 95% of ACN containing 0.1% formic acid in 0.1% aqueous formic acid was used for 1.3 min, flow 
rate 0.8 mL/min). NMR experiment were performed on either AV300 Bruker (300 MHz for 1H and 75 
MHz for 13C) or an Avance III hd 400 Bruker (400 MHz for 1H and 100 MHz for 13C). 13C NMR 
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experiments were done with complete decoupling of protons. Infrared (IR) spectra were recorded using 
Alpha-Platinum ATR Bruker, diamond crystal. 
Peptide Synthesis. A sequence of washes including DMF 3×, a cycle of MeOH/DCM 3× and DCM 3× 
was applied, after every reaction on resin except stated otherwise. TentaGel® S RAM resin was used for 
the synthesis of compounds 3−21, 28 and 29. The chain length growth was performed by standard Fmoc-
SPPS. Fmoc group was removed with 20% piperidine in DMF. Fmoc protected amino acids were coupled 
using 5 equiv of protected amino acids, 5 equiv of HATU and 15 equiv of DIPEA in DMF. The cleavage 
from resin and side chain deprotection was carried out in one step with a cocktail of TFA/TIPS/H2O 
95:2.5:2.5 for 2 h. The crude peptides were triturated with Et2O after evaporation of 50% of cleaving 
cocktail, centrifuged and the supernatant was discarded. For compounds 30−33 the peptide cores were 
synthesized on 2-chlorotrtiyl chloride resin as following. 1.2 equiv of first amino acid was loaded on resin 
in the presence of 4 equiv DIPEA in DMF for 3 h. The unreacted groups were capped with a mixture of 
DCM/MeOH/DIPEA 85:10:5, and the resin was washed by a sequence of DCM 3×, a cycle of 
MeOH/DCM 3× and DCM 5×. The protected peptides were cleaved from resin with 20% hexafluoro-2-
propanol in DCM. The solvent was evaporated in vacuo and the residue was dissolved in a mixture of t-
BuOH/H2O (1:1) and lyophilized. A mixture of protected peptide, 2.5 equiv of corresponding P1' or P1-
P1' amine, 2.2 equiv of PyBOP, 7.5 equiv of 6-Cl-HOBt was dissolved in DMF and cooled in an ice bath, 
then 7.5 equiv of DIPEA was added to the solution and the reaction was stirred overnight. Solvent was 
removed with an air stream and the crude protected peptide was deprotected with the same TFA cocktail 
as compounds 3−21. FITC-labeled peptides were prepared as reported elsewhere.167 The crude of 
compounds 3−21, 28−33 and 35−38 were purified using preparative HPLC. Analytical HPLC was used 
for confirmation of purity (>95%) of fractions. These compounds were characterized by high-resolution 
mass spectroscopy (HRMS). The HPLC chromatograms and HRMS details of these compounds are 
provided in supplementary material. 
4-(2-Aminoethyl)benzimidamide (Aeba, 24).  
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Aeba 24 was prepared as previously reported in chapter 2. 
tert-Butyl (S)-(1-((2-(1H-indol-2-yl)ethyl)amino)-3-(4-cyanophenyl)-1-oxopropan-2-yl)-carbamate 
(43).  
To a suspension of Boc-Phe(4-CN)-OH 42 (1.45 g, 5.00 mmol), tryptamine hydrochloride (0.98 g, 5.00 
mmol) and 6-Cl-HOBt (0.93 g, 5.50 mmol) in DCM (15 mL) DIPEA (2.61 mL, 15.00 mmol) was added 
maintaining the temperature between 0-5 oC. Once a clear solution was obtained, EDCI (1.05 g, 5.50 
mmol) was added at the same temperature. The resulting solution was stirred for 16 h at room temperature. 
The volatiles were evaporated, and the residue was taken into EtOAc and washed with 10% citric acid, 
saturated NaHCO3 and brine, dried over MgSO4 and evaporated to a residue that was triturated with DCM 
and hexanes to obtain the title compound as a white solid (1.96 g, 90% yield). 1H NMR (400 MHz, 
DMSO-d6) δ (ppm) 10.81 (br. s., 1H), 8.05 (br. s., 1H), 7.72 (d, J = 7.7 Hz, 2H), 7.54 (d, J = 7.8 Hz, 1H), 
7.42 (d, J = 7.7 Hz, 2H), 7.34 (d, J = 7.8 Hz, 1H), 7.15 (s, 1H), 7.07 (t, J = 7.8 Hz, 1H), 6.91 - 7.02 
(overlapped, 2H), 4.18 (m, 1H), 3.35 (m, 2H), 3.00 (dd, J = 13.0, 3.1 Hz, 1H), 2.80 (overlapped, 3H), 
1.28 (s, 9H). 13C NMR (100 MHz, DMSO-d6) δ (ppm) 171.0, 155.2, 144.5, 136.3, 131.9, 130.4 
(overlapped 2C), 127.2, 122.7, 121.0, 119.1, 118.3, 111.7, 111.4, 109.1, 78.1, 55.3, 41.2, 37.9, 28.1, 25.1. 
IR (neat) ν (cm-1) 1651, 1682, 2228, 2918, 2956, 3327, 3348, 3407, 3412. HRMS (ESI) calculated for 
C25H29N4O3 m/z [M+H]
+ 433.2234 found 433.2306. Mp; 174-176 oC. 
(S)-N-(2-(1H-indol-2-yl)ethyl)-2-amino-3-(4-cyanophenyl)propanamide (44). 
The amidine 44 was prepared from 43 (0.4 g, 9.2 mmol) using the previously reported protocol for the 
preparation of amidine 24. 1H NMR (400 MHz, D2O) δ (ppm) 7.68 (d, J = 8.5 Hz, 2H), 7.56 (d, J = 7.9 
Hz, 1H), 7.42 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 7.9 Hz, 1H), 7.08 - 7.12 (m, 1H), 7.06 (s, 1H), 6.97-7.03 
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(m, 1H), 4.30 (dd, J = 9.0, 5.6 Hz, 1H), 3.42 - 3.57 (m, 2H), 3.13 (dd, J = 13.5, 5.6 Hz, 1H), 2.92 (t, J = 
7.0 Hz, 2H), 2.86 (dd, J = 13.5, 9.0 Hz, 1H). 13C NMR (100 MHz, D2O) δ (ppm) 168.3, 157.6, 146.3, 
138.3, 131.6, 129.0, 127.9, 123.6, 122.5, 119.8, 119.4, 116.9, 113.2, 112.4, 57.2, 41.4, 39.4, 26.3. IR 
(neat) ν (cm-1) 1666, 1678, 2905, 2943, 2989, 3296, 3393, 3413 HRMS (ESI) calculated for C20H23N5O 
m/z [M+H]+ 350.1975 found 350.1995. Mp; decomposed at >300 oC. 
tert-Butyl (S)-(2-((2-(1H-indol-3-yl)ethyl)amino)-1-(4-cyanophenyl)-2-oxoethyl)carbamate (46). 
4-bromo-phenylglycine 45 (0.92 g, 4.00 mmol) and K2CO3 (0.55 g, 4.00 mmol) were dissolved in H2O 
(50 mL), treated with (Boc)2O (1.05 g, 4.80 mmol) in THF (25 mL), stirred overnight, and the mixture 
was evaporated under reduced pressure. The resulting aqueous phase was neutralized with solid citric 
acid and extracted with EtOAc (3x). The combined organic phases were washed with brine, dried over 
magnesium sulfate and evaporated to dryness to give Boc-Phg(4-Br)-OH in quantitative yield. This white 
solid (1.38 g, 4.00 mmol) and i-butyl chloroformate (0.52 mL, 4.00 mmol) were dissolved in THF (20 
mL), cooled to -20 oC prior and treated with precooled (-20 oC) DIPEA (0.70 mL, 4.00 mmol, precooled 
to -20 oC). The suspension was agitated for 10 min before the addition of a mixture of tryptamine 
hydrochloride (0.94 g, 4.80 mmol) and DIPEA (0.84 mL, 4.8 mmol) in THF (5 mL). After stirring for 24 
h at -20 oC, the volatiles were removed, and the residue was partitioned between EtOAc and water. The 
phases were separated, and the organic phase was washed with saturated NaHCO3, water, 10% citric acid 
and brine solutions. The volatiles were evaporated in vacuum and the residue was purified by column 
chromatography to yield Boc-Phg(4-Br)-Tryp as a white solid (1.13 g, 60 %) 1H NMR (400 MHz, CDCl3) 
δ (ppm) 8.19 (br. s, 1H), 7.49 (d, J = 8.00 Hz, 1H), 7.38 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 8.0 Hz, 1H), 
7.20 (t, J = 8.0 Hz, 1H), 7.06-7.15 (overlapped, 3H), 6.68 (d, J = 2.2 Hz, 1H), 5.93 (overlapped, 2H), 5.02 
(br. s, 1H), 3.58 (dt, J = 13.0, 6.5 Hz, 1H), 3.49 (dt, J = 13.0, 6.5 Hz, 1H), 2.80 - 2.96 (m, 2H), 1.40 (s, 
9H). 13C NMR (100 MHz, CDCl3) δ (ppm) 169.4, 155.1, 137.7, 136.3, 131.9, 128.7 (overlapped 2C), 
127.0, 122.2, 122.1, 119.4, 118.4, 112.1, 111.3, 80.2, 57.9, 39.9, 28.2, 24.9. HRMS (ESI) calculated for 
C23H27BrN3O3 m/z [M+H]
+ 472.1230 found 472.1217. The obtained solid plus Zn(CN)2 (0.16 g, 1.40 
mmol) and Pd(PPh3)4 (0.13 g, 0.11 mmol) were suspended in deoxygenated dry DMF (3 mL) under inert 
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condition. The yellow slurry was heated to 100 oC for 16 h, then taken into EtOAc and washed three times 
with 20% NH4OH, dried over MgSO4, and purified by column chromatography to yield the title 
compound as a white solid (0.39 g, 40%) 1H NMR (400 MHz, CDCl3) δ (ppm) 8.07 (br. s, 1H), 7.46 - 
7.57 (overlapped, 3H), 7.38 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.0 Hz, 2H), 7.23 (t, J = 8.0 Hz, 1H), 7.12 
(t, J = 8.0 Hz, 1 H), 6.79 (d, J = 2.0 Hz, 1H), 5.94 (br. s, 1H), 5.76 (br. s, 1H), 5.05 (br. s, 1H), 3.57-3.67 
(m, 2H), 2.84 - 2.98 (m, 2H), 1.40 (br. s., 9H). 13C NMR (100 MHz, CDCl3) δ (ppm) 168.5, 164.8, 143.8, 
136.3, 132.6, 127.7, 127.0, 122.4, 122.0, 119.7, 118.4, 118.4, 112.1, 112.0, 111.4, 80.5, 60.4, 40.1, 28.2, 
24.8. IR (neat) ν (cm-1) 1659, 1699, 2235, 2939, 2983, 3234, 3290, 3421. HRMS (ESI) calculated for 
C24H27N4O3 m/z [M+H]
+ 419.2077 found 419.2137. Mp; 98-101 oC. 
(S)-N-(2-(1H-Indol-3-yl)ethyl)-2-amino-2-(4-carbamimidoylphenyl)acetamide 47. 
The amidine 47 was synthesized from 46 (0.3 g, 7.2 mmol) using the protocol previously described for 
the preparation of 24. 1H NMR (400 MHz, D2O) δ (ppm) 7.54 (d, J = 8.54 Hz, 2H), 7.44 (d, J = 7.86 Hz, 
1H), 7.39 (d, J = 8.20 Hz, 1H), 7.26 - 7.33 (m, 2H), 7.16 (t, J = 7.2 Hz, 1H), 7.02 (t, J = 7.2 Hz, 1H), 6.89 
(s, 1H), 5.00 (s, 1H), 3.89 (ddd, J = 13.6, 8.7, 5.1 Hz, 1H), 3.39 (dt, J = 13.6, 5.1 Hz, 1H), 2.94 (dt, J = 
13.6, 5.1 Hz, 1H), 2.83 (ddd, J = 13.6, 8.7, 5.1 Hz, 1H). 13C NMR (100 MHz, D2O) δ (ppm) 165.6, 
162.8,137.5, 135.9, 128.5, 128.1, 126.9, 123.1, 121.6,118.9, 118.2, 114.9, 111.5, 111.0, 55.8, 39.5, 23.5. 
IR (neat) ν (cm-1) 1622, 1682, 2914, 2970, 3010, 3265, 3292. HRMS (ESI) calculated for C19H22N5O m/z 
[M+H]+ 336.1819 found 336.1872. Mp; decomposed at >300 oC. 
3.6.2. Enzyme kinetics 
The fluorometric Ki measurements of PC enzymes was performed using a Gemini EM 96-well 
spectrofluorometer (Molecular Devices; Sunnyvale, CA, USA) (λEX., 370 nm; λEM., 460 nm; Cut Off, 435 
nm). Both PACE4 and furin are human recombinant proteins produced from S2 insect cells and purified 
as described earlier.80 All the experiments were done in duplicate or triplicate. Furin inhibition 
measurements were performed in 100 mM of HEPES buffer (pH = 7.5), 1 mM CaCl2, 1 mM β-
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mercaptoethanol, and 1.8 g/L BSA, while PACE4 inhibition assays were done in a 20 mM Bis-Tris buffer 
(pH = 6.5), 1 mM CaCl2, and 1.8 g/L BSA. The competitive substrate was pyroGlu-Arg-Thr-Lys-Arg-
AMC peptide (Bachem, Switzerland) for both furin and PACE4 with the concentration of 100 μM in each 
well. Inhibitors were added at various concentrations in the range of 0-10 μM. Enzyme (final 
concentration 100 μL) was added in each well, and the real-time fluorescence was measured during 1 h 
of experiments. The Ki values were calculated using the Cheng and Prusoff’s equation and the 
SoftMaxPro5 program.36 
3.6.3. Cell proliferation 
MTT antiproliferative assays were performed on DU145 and LNCaP PCa cell lines as reported earlier.166 
The 96 well plates were seeded with an approximate density of 1500 cells for DU145 or 2500 cells for 
LNCaP. The media was changed after 24 h and the cells were subsequently treated with different 
concentrations of peptide inhibitor (peptides 3−19, 21 and 28 were used at a concentration range of 300, 
200, 100, 50, 25, 10 and 1 μM; peptides 20 and 29−33 were employed at a concentration range of 150, 
100, 75, 50, 25, 10 and 1 μM). After incubation continued for 72 h, the MTT reagent was added (with 
final concentration per well of 1 g/L). Incubation was continued for 4 h, when the media was removed, 
and the cells were treated with 0.10 mL of 2-propanol/HCl (24:1 N) to solubilize the formazan produced 
in the mitochondria. Cell metabolic activity assessed relative to vehicle treated cells (Sterile bi-distilled 
water 0.1% DMSO). The maintenance of cells and all the assay steps were performed in RPMI 1640 5% 
FBS for DU145 and 10% FBS for LNCaP cells. The IC50 values were calculated using Prism 6.0 
(GraphPad software). 
3.6.4. Cell permeability 
The DU145 cells were plated at a density of 200000 cells per 100 mm petri dish and incubated for 48 h 
at 37 oC. Cells were treated with 1 µM of FITC analogs for 1 h at 37 oC prior to collection using 0.05% 
trypsin and subsequent inactivation using FBS-containing media. Cell pellets were washed one more time 
with PBS and were resuspended in 200 µL of fresh PBS after centrifugation. PI was added at a final 
concentration of 10 µg/mL just before doing the acquisition. In another set of tubes, fluorophore was 
quenched using trypan blue at a final concentration of 0.04%. Cells were analyzed (at least 10000 events) 
by CytoFLEX 15 flow cytometer (Beckman Coulter, Brea, CA, USA) with the following diode lasers: 
488 nm and 638 nm, 50 mW each. The emitted fluorescence was split into four channels and detected 
through band pass filters (forward scatter area, side scattered area and side scattered width signals) to 
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establish the live gates and exclude debris and cell clumps. Dead cells (PI-positive) were excluded by the 
gating in the red channel. 
3.6.5. Cell toxicity 
200 000 cellules were plated in a 6-well plate and treated respectively with 1, 10, 50 and 100 µM 
concentrations of compounds 10, 16, 20 and 31 in serum free media for 1.5 h (for compound 32 the 
concentrations were 1, 10, 15, 20, 30, 50, 100 µM). Cells were collected using trypsin prior to washing 
and then resuspension in PBS. PI at a final concentration of 10 µg/mL was added just prior to acquisition 
of fluorescence by a CytoFLEX 15 flow cytometer as described above. The IC50(PI) value for compound 
32 was calculated using Prism 6.0 (GraphPad software). 
3.6.6. Plasma stability 
Peptide samples for determination of t1/2 half-lives were prepared as follows. The total concentration of 
50 μM peptide in human serum (from male AB plasma; Sigma Aldrich) was incubated at 37 oC. At each 
indicated timepoint and just following peptide addition, 25 μL of plasma were precipitated with 100 μL 
of MeOH containing 20 μM Fmoc-Leu-OH as internal standard. Samples, were centrifuged at 12000 ×g 
for 10 min at room temperature to remove precipitated proteins and clear supernatants were filtered on 
0.2 μM PVDF centrifugal filters (Canadian Life Science) prior to analysis. Quantitative analysis was 
performed based on the peptide/standard ratio of integrated area under the curve in the total ion 
chromatogram and reported from 0 h incubation. The one-phase decay curve-fit of GraphPad Prism was 
used to determine t1/2 values.  
3.6.7. In vivo acute toxicity 
All experimental procedures were performed as reported earlier in accordance with regulations of the 
Canadian Council on Animal Care.168 
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3.8. Supporting information 
3.8.1. The synthesis of compounds 3-21, 28 and 29 
Scheme S1. Synthesis of compound 3-21, 28 and 29 using conventional Fmoc-solid phase peptide 
synthesis (Xaa: Apa, Gpa and natural amino acids except Cys)  
 
3.8.2. Details of enzyme kinetic assays 
Both PACE4 and furin are human recombinant enzymes and were produced from S2 insect cells and 
purified by a method described earlier.80 
Table S1. Substrate concentration and enzymes properties used in assays. 
Enzyme [E0] (nM) [Substrate] (µM) Km (µM) 
Furin 20.18 100 5.04 
PACE4 0.545 100 4.035 
 
3.8.3. Cell toxicity experiments 
Figure S1. DU145 cell toxicity of selected peptides. 
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3.8.4. Analytical data of peptide inhibitors and their FITC-labeled analogues. 
Table S2. The analytical data for all peptide inhibitors and FITC-labeled analogues. 
Compound Structure 
Exact Mass HPLC 
rt Calculated for Found 
3 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Ala-NH2 [M+2]2+ 561.8953 561.8923 29.78[a] 
4 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Asp-NH2 [M+2]2+ 583.89.02 583.8775 29.61[a] 
5 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Glu-NH2 [M+2]2+ 590.8981 590.8262 29.66[a] 
6 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Phe-NH2 [M+2]2+ 599.9110 599.9123 32.23[a] 
7 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Gly-NH2 [M+2]2+ 554.8875 554.8856 29.58[a] 
8 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-His-NH2 [M+2]2+ 594.9062 594.9053 28.66[a] 
9 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Ile-NH2 [M+2]2+ 582.9188 582.9190 31.66[a] 
10 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Lys-NH2 [M+2]2+ 590.4242 590.4243 28.54[a] 
11 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Leu-NH2 [M+2]2+ 582.9188 582.9162 22.47[b] 
12 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Met-NH2 [M+2]2+ 591.8970 591.8972 31.47[a] 
13 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Asn-NH2 [M+2]2+ 583.3982 583.3988 29.37[a] 
14 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Pro-NH2 [M+2]2+ 574.9031 574.9015 21.66[b] 
15 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Gln-NH2 [M+2]2+ 590.4061 590.4063 29.33[a] 
16 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Arg-NH2 [M+3]3+ 403.2873 403.2831 28.82[a] 
17 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Ser-NH2 [M+2]2+ 569.8928 569.8940 21.29[b] 
18 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Thr-NH2 [M+2]2+ 576.9006 576.9011 29.74[a] 
19 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Val-NH2 [M+2]2+ 575.9110 575.9110 22.05[b] 
20 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Trp-NH2 [M+2]2+ 619.4164 619.4143 32.88[a] 
21 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Tyr-NH2 [M+2]2+ 607.9084 607.9086 30.85[a] 
28 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Apa-NH2 [M+2]2+ 607.4239 607.4164 29.20[a] 
29 Ac-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Gpa-NH2 [M+2]2+ 628.4273 628.4314 26.74[a] 
30 Ac-DLeu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Aeba [M+2]2+ 599.4190 599.4163 27.64[a] 
31 Ac-DLeu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Tryp [M+3]3+ 348.9183 348.9135 32.43[a] 
32 Ac-DLeu-Leu-Leu-Leu-Arg-Val-Lys-Acpa-Tryp [M+2]2+ 614.4080 614.4150 19.46[c] 
33 Ac-DLeu-Leu-Leu-Leu-Arg-Val-Lys-Aca-Tryp [M+2]2+ 607.4002 607.4071 31.68[a] 
35 FITC-βAla-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Arg-NH2 [M+3]3+ 542.6414 542.6483 18.34[c] 
36 FITC-βAla-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Lys-NH2 [M+3]3+ 533.3060 533.3094 18.22[c] 
37 FITC-βAla-Leu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Trp-NH2 [M+3]3+ 552.6341 552.6426 19.72[c] 
38 FITC-βAla-DLeu-Leu-Leu-Leu-Arg-Val-Lys-Arg-Tryp [M+3]3+ 543.6305 543.6361 34.82[a] 
[a] 50 min, [b] 25 min and [c] 20 min gradient of 10 to 70% of CH3CN and H2O containing 0.1% TFA 
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CHAPTER 4: GENERAL DISCUSSION AND PERSPECTIVE 
4.1. General discussions 
PACE4, a proprotein convertase, has been recognized as a validated target in prostate cancer. The 
inhibition of PACE4 using substrate-like inhibitors (peptides and peptidomimetics) has shown effective 
in vitro antiproliferative effects on PCa cell lines (both LNCaP and DU145 cells). Such inhibitors also 
reduced the growth of xenografted prostate tumors in mice. In light of their promising activity in vitro 
and in vivo, lead compounds ML peptide (Ac-LLLLRVKR-NH2) and C23 (Ac-DLeu-LLLRVK-Amba) 
merit further development. The primary objective of the current dissertation was to increase the selectivity 
and affinity of these inhibitors towards PACE4 over furin. In this regard, three approaches were applied 
to enhance the selectivity of PACE4 inhibitors using structure activity relationship studies on ML and 
C23 compounds. These approaches included modifications in the P3, P1 and P1' positions of the lead 
compounds.  
Benefiting from a structural difference of the S3 sub-pocket between PACE4 and furin, the inhibitor P3 
Val of ML has been modified to target PACE4 Asp160 vs furin Glu256. The other main interaction in S3 
is the β-sheet-like hydrogen bonding of P3 Val with Gly158 of PACE4. This is a general attribute of 
proteases substrates to form a β-sheet with the active site residues. The β-branched amino acids like Val 
and Ile are known to enhance this interaction in β-sheets. The β-sheet-like interaction in S3 is vital to 
optimizing the inhibitor’s conformation in the active site and drives all P1 to P4 residues into their 
respective sub-pockets. In order to sum up both mentioned interactions in S3, some β-branched basic 
amino acids were designed and synthesized. 
With the objective of optimizing the length of the side chain, different basic amino acids were examined. 
These residues were introduced at the P3 position of the ML peptide and the PACE4 and furin inhibitions 
of the resulting compounds were measured. The inhibitors with P3-Dap ((S)-2,3-diaminopropionyl) and 
P3-Apg ((S)-2-amino-3-guanidinopropionyl) residues were found to be the most potent compounds in the 
series. The corresponding methyl β-branched analogues were synthesized based on them. With S-i-Abg 
((S)3-guanidino- (S)-2-aminobutyric acid) at the P3 position, the selectivity was improved compared to 
ML (40-fold vs 20-fold), while the potency was enhanced by 7-folds (PACE4 Ki = 2.7 vs 22 nM). The 
hydrogen bonds between Ala or Val backbones of the ligand and Gly158 of PACE4 in the S3 subsite 
were analyzed using molecular dynamic simulations of Ac-RXKR-NH2 (X = Val and Ala). 
107 
 
Computational analysis indicated, the β-sheet-like hydrogen bonds were tighter for β-branched Val 
compared to Ala. Moreover, the geometry of the tetrapeptide Ac-RVKR-NH2 matched closely that of an 
antiparallel β-sheet. Such was not the case for Ac-RAKR-NH2. 
The introduction of a basic β-branched residue (S-i-Abg) instead of Val at the P3 position of ML resulted 
in better selectivity and increased potency. In addition, it was shown that β-branching at the P3 position 
is important for the formation of the necessary β-sheet conformation of peptide substrates and inhibitors 
in the active site.  
Despite the superior profile of C23 over ML in terms of PACE4 affinity and cellular antiproliferative 
activity, C23 is not as selective as ML (2 times selective vs 20 times for PACE4 over furin). Considering 
that the most important difference between the two inhibitors was the replacement of Arg in P1 by Amba, 
the structural impact of this modification was further explored. Therefore, P1-modified inhibitors were 
designed based on the lead compound C23 (PACE4 Ki = 4.9 nM) to increase the PACE4 selectivity and 
potency. Two sets of aliphatic residues based on Arg and aromatic residues derived from Amba were 
investigated at this position. Although the aliphatic modifications were not successful in improving the 
potency nor selectivity, replacement of Amba with 5-(aminomethyl)picolinimidamide (Ampa) as a P1 
residue increased the PACE4 selectivity and binding affinity by 8-fold and 2-fold, respectively (Ki = 2.6 
nM). DFT calculations and molecular docking suggested that the flatter geometry of Ampa comparing to 
Amba may be a responsible factor for the observed improvement in potency and selectivity for PACE4. 
This flat geometry is the result of an intramolecular hydrogen bonding between the pyridine N (acting as 
the acceptor) and the suitable amidinium NH (acting as the donor) in Ampa. However, despite 
improvements in PACE4 affinity and selectivity, the Ac-DLeu-Leu-Leu-Leu-Arg-Val-Lys-Ampa peptide 
displayed moderate antiproliferative activity. The cell permeability was not the reason for this 
phenomenon because penetration into the DU145 cells was observed using the Ampa analog in amounts 
similar to that of C23. Further studies are necessary to provide better insight into this issue.  
In another study aimed at exploring the P1' position to optimize the selectivity profile of the ML-derived 
PACE4 inhibitors, a biased library of peptides with the general sequence Ac-LLLLRVKRX-NH2 (X is a 
natural amino acid apart for Cys) was synthesized and their inhibitory potency was examined. Although 
the resulting analogues showed no improvement for PACE4 affinity and selectivity, their antiproliferative 
activity against prostate cancer cell lines illustrated that hydrophobic residues like tryptophan increased 
the antiproliferative effect in a dose-dependent manner. Replacement of tryptophan with the even more 
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hydrophobic tryptamine (Tryp) in the P1' position further improved the antiproliferative activity. To 
duplicate the C23 P1 features in a new inhibitor, P1-Arg was modified to Acpa (2-amino-3-(4-
carbamimidoylphenyl)propanoic acid). The resulting inhibitor with the structure Ac-DLeu-Leu-Leu-Leu-
Arg-Val-Lys-Acpa-Tryp displayed a 3-fold improvement in the IC50 values for PCa cells compared to 
C23 (7.5 ± 0.8 and 13 ± 1 μM for DU145 and LNCaP cells, respectively). The observed cellular potency 
was the consequence of improved cell permeability of the P1'-modified inhibitors (evaluated using N-
terminally FITC-labeled compounds). Additionally, this inhibitor was slightly more stable than C23 with 
t1/2 of 2 h vs 1.74 h. By comparing the PI cell toxicity and MTT metabolic activity in DU145 cells, 
antiproliferative activity was shown to be due to the factors other than cell death in low micromolar 
concentrations of the inhibitor. 
In summary, the SAR exploration of the P1 and P3 positions of the ML and C23 compounds resulted in 
more selective and potent inhibitors, and additional modifications in the P1' position led to inhibitors that 
are more permeable to PCa cells and with enhanced antiproliferative activity. 
4.2. Future studies 
Diminished cellular activity was found to be the main issue for the inhibitors Ac-LLLLR-[S-i-Agb]-KR-
NH2 and Ac-DLeu-LLLRVK-Ampa despite their improved PACE4 affinity and selectivity. One of the 
possible reasons behind the reduced cellular activity of P3-modified inhibitors could be the increased 
number of positively charged residues. Hence, some compounds may be investigated to solve this 
problem. One of the charges could be removed by replacing the least important P2-Lys residue of the P4–
P1 warhead by a hydrophobic residue (e.g. Trp). The expected loss of affinity might be compensated by 
the concurrent introduction of an S-i-Abg residue in P3 (Figure 44). The resulting inhibitor could then 
benefit from increased cell permeability by having an additional Trp residue as discussed in section 3.4.4. 
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Figure 44. Reducing the total charge by replacing P2-Lys with Trp 
Another strategy is to use the most potent cellular antiproliferative compound Ac-DLeu-Leu-Leu-Leu-
Arg-Val-Lys-Acpa-Tryp as the basis for the design of PACE4 inhibitors with improved affinity and 
selectivity. In this regard, replacing concomitantly P3-Val with S-i-Abg and P2-Lys with Trp could be 
helpful to find the right combination of modifications (Figure 45, top molecule).  
Figure 45. Combining modifications at P1' and P3 of lead inhibitor 32 (Chapter 3). 
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The final design strategy is to combine the best P1 modifications discussed in chapter 2 and 3 in a new 
unusual amino acid. This modified P1 residue should have a picolinimidamide side chain similar to Ampa 
(Figure 45, bottom molecule).  
The synthesis pathway for the new unusual amino acid is outlined in Scheme 7, it begins with a Horner-
Wadsworth-Emmons type reaction followed by the reduction of the double bond and cyanation of the 
resulting amino acid as described in the literature.250-251 The conversion of the pyridine N to its N-oxide 
during the synthesis was shown to be necessary for increasing the enantioselectivity of the 
hydrogenation.241 
 
Scheme 7. The proposed synthesis for the novel P1-P1' dipeptide. UHP: Urea-hydrogen peroxide adduct. 
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CONCLUSION 
In the first chapter, a new basic β-branched amino acid (S-i-Agb) was used in the P3 position of ML, 
which led to the discovery of a PACE4 inhibitor with enhanced potency and selectivity for PACE4. The 
inclusion of this residue in the P3 position introduced additional stabilizing electrostatic interactions with 
Asp160. As a β-branched residue, S-i-Agb increased the β-sheet propensity of the peptide inhibitor. To 
the best of our knowledge, the correlation between β-sheet propensity of inhibitor residues and protease 
inhibition had not been studied before. This β-sheet propensity improvement coupled with other side 
chain stabilizing interactions could be used as a principle for targeting other proteases as well. 
In the second chapter, PACE4 inhibitors were modified at their P1 position and their SAR was studied. 
The results indicated structural differences in the S1 pocket that could be used to discriminate between 
furin and PACE4 and open new frontiers for achieving higher selectivity. The most potent and selective 
inhibitor in the series displayed a Ki value of 2.6 nM for PACE4 (2-fold more potent and 4-fold more 
selective than C23). Using Ampa as the P1 residue was associated with the same stabilizing van der Waals 
contacts as Amba in C23. It was found that Ampa is held rigidly (intramolecular hydrogen bond) in a flat 
conformation. It was suggested that the gain in affinity for PACE4 could arise from this rigidifying 
process. Surprisingly, the compound with P1-Ampa displayed lower efficiency in PCa cell 
antiproliferative assays compared to C23. Further studies may provide the knowledge necessary to 
explain this impairment. However, this significant improvement at the P1 position can now be used in 
combination with other modifications at other positions. 
In the third chapter, SAR studies were performed on P1 and P1' of the ML peptide to yield potent PACE4 
inhibitors. By screening natural amino acids in the P1' position of ML, it was discovered that Trp 
improved the antiproliferative effect on PCa cell lines. Further modification of this Trp residue to Tryp 
enhanced the hydrophobicity in the C-terminal region of the resulting peptide. This Trp-to-Tryp 
replacement also improved plasma stability and cell efficacy although the affinity of the resulting 
inhibitor to recombinant PACE4 had been reduced. Since P1-Amba in C23 had resulted in better PACE4 
affinity and cellular activity, a new related unnatural residue, Acpa (4-amidinophenyl as side chain), was 
designed and synthesized to replace P1-Arg in the former inhibitor (with Tryp). This additional change 
contributed to improve the plasma stability and the antiproliferative effect of the resulting compound. 
The antiproliferative activity enhancement introduced by C-terminal Trp or Tryp was related to the 
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improved cell permeability of these inhibitors. This study sets a good example for addressing the impact 
of cell penetration on the cell efficacy and overall activity of PACE4 inhibitors. 
In conclusion, rational design of PACE4 inhibitors by modifications in P3 (chapter 1) and P1 (chapters 2 
and 3) resulted in more selective and potent compounds. Although the cellular activity of both P3 and 
P1-modified inhibitors was less than that in the parent compounds ML and C23, we believe that the 
combination of these modifications with others could lead to an improvement in cellular antiproliferative 
activity. Although the original objective of selectivity improvement was not achieved in chapter 3, 
increased cell permeability led to enhanced antiproliferative activity by using hydrophobic residues in the 
P1' position. 
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APPENDIX I 
Table of the copyright reference numbers for figures adapted from literatures in the chapter of 
introduction 
 
Graphic content 
Reference number  
(Copyright clearance center) 
Date of receiving the 
permission 
Figure 4 4432470429691 Jun 15, 2011 
Figure 10 4396660786195 Jul 26, 2018 
Figure 11 4396660786195 Jul 26, 2018 
Figure 12 4397170444644 Jul 27, 2018 
Figure 13 4398970264683 Jul 30, 2018 
Figure 15 4404271138682 Aug 8, 2018 
Figure 20 2234402 Sep 19, 2018 
Figure 21 2234402 Sep 19, 2018 
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APPENDIX II  
All the HPLC chromatograms of inhibitors and NMR spectra for small molecule intermediates 
synthesized in chapter 1 is presented in this appendix. 
HPLC chromatograms: 
 
Inhibitor 11: 
 
Inhibitor 12: 
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Inhibitor 13: 
 
Inhibitor 14:
 
Inhibitor 15:
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Inhibitor 16:
 
Inhibitor 17:
 
Inhibitor 18: 
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Inhibitor 19:
 
Inhibitor 20:
 
Inhibitor 21:
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1H NMR and 13C NMR spectra: 
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APPENDIX III 
All the HPLC chromatograms of peptides and NMR spectra for small molecule intermediates synthesized 
in chapter 2 is presented in this appendix. 
HPLC chromatograms: 
 
Compound 5: 
 
Compound 6: 
 
Compound 7: 
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Compound 8: 
 
Compound 9: 
 
Compound 10: 
 
Compound 11: 
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Compound 12: 
 
Compound 13: 
 
Compound 15: 
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1H NMR and 13C NMR and 19F NMR spectra: 
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APPENDIX IV 
All the HPLC chromatograms of peptides and NMR spectra for small molecule intermediates synthesized 
in chapter 3 is presented in this appendix. 
HPLC chromatograms: 
Compound 3: 
 
Compound 4: 
 
Compound 5: 
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Compound 6: 
 
Compound 7: 
 
Compound 8: 
 
Compound 9: 
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Compound 10: 
 
Compound 11: 
 
Compound 12: 
 
Compound 13: 
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Compound 14: 
 
Compound 15: 
 
Compound 16: 
 
Compound 17: 
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Compound 18: 
 
Compound 19: 
 
Compound 20: 
 
Compound 21: 
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Compound 28: 
 
Compound 29: 
 
Compound 30: 
 
Compound 31: 
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Compound 32: 
 
Compound 33: 
 
Compound 35: 
 
Compound 36: 
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Compound 37: 
 
Compound 38: 
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1H NMR and 13C NMR spectra: 
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